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4Abstract
SUNCT (Short-lasting Unilateral Neuralgiform headache attacks with Conjunctival 
injection and Tearing) and SUNA (Short-lasting Unilateral Neuralgiform headache 
attacks with cranial Autonomic symptoms) are rare primary headache syndromes, 
classified with the Trigeminal Autonomic Cephalgias (TACs). Hypothalamic 
involvement in SUNCT and other TACs has been suggested by functional imaging data 
and clinically with successful deep brain stimulation.
This thesis studies 52 patients (43 SUNCT, 9 SUNA). It addresses the clinical phenotype 
of these conditions and response to medications. A functional imaging study explores 
activation of the posterior hypothalamus in attacks of SUNCT and SUNA, and looks for 
structural changes in this region on voxel-based morphometry.
The clinical study characterises SUNCT and SUNA in terms of epidemiology of the 
syndromes, phenotype and clinical characteristics.
A double-blind trial of topiramate in SUNCT showed a 40% response rate, although a 
similar trial in lamotrigine was less successful. Indomethacin is ineffective in these 
conditions on single-blind testing. Intravenous lidocaine was effective in all cases. Open- 
label trials showed the effectiveness of lamotrigine, topiramate and gabapentin.
On functional imaging there was activation bilaterally in the posterior hypothalamus in 
5/9 SUNCT patients, and contralaterally in two patients. Two SUNCT patients had 
ipsilateral negative activation. In SUNA the activation was bilaterally negative. Group 
analysis showed bilateral activation, although there was no such activation on whole 
brain analysis. There was no structural change in this region on voxel-based 
morphometry.
The thesis concludes that there should be revised classification for SUNCT and SUNA, 
with an increased range of attack duration and frequency, cutaneous triggering of attacks,
5and a lack of refractory period. The concept of ‘attack load’ is introduced. The lack of 
response to indomethacin, and the response to intravenous lidocaine, are useful in 
diagnostic and therapeutic measures respectively. Preventive treatments include 
lamotrigine, gabapentin and topiramate. Hypothalamic activation is discussed in light of 
the imaging and methodological issues. Finally the role of hypothalamic involvement in 
SUNCT and SUNA as TACs is considered.
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PART I. INTRODUCTION 
Chapter 1 
Primary Headache Syndromes and Trigeminal Autonomic Cephalgias
1.1 Primary Headaches
Headache is one of the commonest symptoms for which patients present to doctors in 
general, and to neurologists more specifically (Linet et al., 1991; Pascual et al., 1995; 
Tepper et al., 2004). Primaiy headache syndromes are those for which there is no 
underlying structural abnormality or other disorder which is closely temporally related 
and known to cause headaches (Headache Classification Committee of The International 
Headache Society, 2004). Common causes for secondary headaches include those 
attributed to head or neck trauma, cranial or cervical intravascular disorder, non-vascular 
intracranial disorders such as intracranial hypertension, low cerebrospinal fluid pressure, 
infection, neoplasm, hypothalamic or pituitary hypo-or hyper-secretion, headaches 
attributable to a substance or its withdrawal, infection, disorders of homeostasis, 
disorders of cranium or facial mouth or cranial disorders, and headaches attributable to 
psychiatric disorder (Headache Classification Committee of The International Headache 
Society, 2004).
The commonest primary headache syndrome is tension-type headache, which in its 
episodic form affects 78% of the population, and as chronic tension-type headache affects 
3% of the population (Jensen, 2003). Other primary headache syndromes include 
migraine; the Trigeminal Autonomic Cephalgias (TACs) comprising cluster headache, 
paroxysmal hemicrania, and SUNCT (Short-lasting Unilateral Neuralgiform headache 
attacks with Conjunctival injection and Tearing); and other primary headache syndromes 
such as primary stabbing headache, primary cough headache, primary exertional 
headache, primary headache associated with sexual activity, hypnic headache, primary
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thunderclap headache, hemicrania continua, and new daily persistent headache (Headache 
Classification Committee of The International Headache Society, 2004).
Migraine is a common primary headache syndrome with an overall 1-year prevalence in 
Europe and North America of 10-12%, and a female:male ratio of 2:1 to 3:1 (Breslau and 
Rasmussen, 2001). The pain and associated symptoms of migraine attacks carry 
considerable morbidity. Indeed the World Headache Organisation ranks chronic 
migraine as one of the leading causes of disability worldwide (World Health 
Organization, 2001).
Migraine usually manifests as recurrent attacks lasting 4-72 hours, characterised typically 
by pain of unilateral location, pulsating quality, moderate or severe intensity, and 
aggravation by routine physical activity; as well as nausea, photophobia or phonophobia. 
There may be an aura of reversible focal neurological symptoms developing over 5-20 
minutes and lasting usually for less than 60 minutes. Chronic migraine occurs on 15 or 
more days per month for more than 3 months, in the absence of medication overuse 
(Headache Classification Committee of The International Headache Society, 2004).
1.2 Trigeminal Autonomic Cephalgias (TACs)
Trigeminal Autonomic Cephalgias are relatively rare stereotypical primary headache 
syndromes which share the following characteristics: they are usually unilateral, the pain 
is typically peri- or retro-orbital and temporal, and they have associated cranial 
autonomic symptoms, including conjunctival injection, lacrimation, nasal blockage, 
rhinorrhoea, eyelid oedema and ptosis. They may be accompanied by agitation. Cluster 
Headache (CH), Paroxysmal Hemicrania (PH), and SUNCT, are all classified as TACs. 
Appendix 1 lists the International Headache Society criteria for TACs (Headache 
Classification Committee of The International Headache Society, 2004).
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1.2.1 Cluster headache
Cluster headache (CH) is the commonest of the TACs and therefore the one for which we 
have the most information. It is a stereotypical primary headache syndrome, characterised 
by attacks of unilateral excruciating pain usually in the eye, periorbital region and temple, 
with associated cranial autonomic symptoms. Restlessness and agitation also feature 
prominently. Attacks can last for 15-180 minutes untreated, and have a frequency of one 
every other day up to 8 a day (Headache Classification Committee of The International 
Headache Society, 2004). They can be triggered by alcohol (Bahra et al., 2002), usually 
in under an hour. This is in contrast to migraine for which alcohol typically has a longer 
timecourse to triggering an attack.
Attacks usually occur in clusters (bouts) lasting for weeks or months, separated by 
remissions lasting months or years. Episodic cluster headache (ECH) is defined as bouts 
of attacks lasting 7 days up to one year, with breaks of one month or more between bouts. 
Bouts are usually circannual, with a mean bout duration of 8-9 weeks (Bahra et al., 2002). 
Chronic cluster headache (CCH) is defined as occurring for more than one year with no 
remission, or with remissions lasting less than one month. CH attacks may also occur 
with clocklike regularity during the day, and may be precipitated by sleep (Dexter and 
Weitzman, 1970), usually occurring 90 minutes after the onset of sleep.
With a prevalence of 0.3% in the general population (Sjaastad and Bakketeig, 2003), 
cluster headache is not as rare as was previously thought. It affects slightly more men 
than women, with a male: female ratio of 2.5:1 in a recent study (Bahra et al., 2002).
CH is probably the most severe pain known to humans, with most female patients 
describing each attack as worse than childbirth. Health-related quality of life is 
significantly impaired in cluster headache sufferers (D'Amico et al., 2002; Ertsey et al.,
2004). Even though it is under-recognised and often suboptimally managed in primary 
care (Geweke, 2002), an early diagnosis and prompt treatment are essential to alleviate 
the devastating morbidity of these attacks (van Vliet et al., 2003b).
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Diagnosis
The diagnosis is usually clear on taking a thorough history. The presence of autonomic 
symptoms, restlessness, and the length of the attacks usually distinguishes this from 
migraine, although a proportion of migraine patients may exhibit cranial autonomic 
features (Barbanti et al., 2002; Dora, 2003), and migraine can coexist with CH (Evans 
and Bahra, 2004). The differential diagnosis for CH includes the other (TACs), although 
these differ from CH in that the attack lengths are shorter (Headache Classification 
Committee of The International Headache Society, 2004), and that PH responds to 
indomethacin (Antonaci et al., 1998).
The clinical examination is usually entirely normal, although relevant clinical signs may 
alert the physician to secondary causes of cluster-like headache, including tumors, 
infections, vascular abnormalities and head trauma (Carter, 2004). These cases may 
warrant neuroimaging investigations such as CT or MRI, as may cases of new onset CH 
in older patients, as the mean age of onset of primary CH is 28-37 years, with incidence 
diminishing with age (Bahra et al., 2002).
Management o f CH
The management of CH is threefold; first to avoid the precipitating factors which may 
trigger an attack during a cluster bout, such as alcohol and afternoon naps; the second is 
abortive therapy for individual attacks, and the third is preventive medication, which is 
taken on a daily basis during the cluster bout and long-term in chronic CH, in order to 
prevent the attacks from occurring.
Abortive therapy
The most effective choice to abort an acute CH attack is serotonin (5-hydroxytryptamine; 
5-HTib/d agonists, (triptans) in parenteral form. Sumatriptan as 6mg subcutaneous 
injections has been shown to be efficient in terminating attacks within a few minutes 
(Diener, 2001; Ekbom et al., 1993; Hardebo, 1993). Sumatriptan nasal spray is also 
effective, albeit with a slower onset of efficacy (Hardebo and Dahlof, 1998; Schuh-Hofer 
et al., 2002), is better tolerated than the subcutaneous route (van Vliet et al., 2003a). Oral
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zolmitriptan lOmg has been effective in terminating attacks in episodic cluster headache 
(ECH) but not in chronic cluster headache (CCH) (Bahra et al., 2000). Intranasal 
zolmitriptan at 5mg and lOmg is effective in patients with ECH or CCH (Cittadini et al.,
2005).
The drawbacks of the triptans include limitations of daily usage. Current practice is to 
limit sumatriptan usage to 2 subcutaneous injections or 3 nasal sprays a day, in order to 
prevent tachyphylaxis and rebound. At this dosage, there was no tachyphylaxis even in 
long-term use (Ekbom et al., 1992). Triptans are also contraindicated in patients for 
whom there is a vascular risk such as ischaemic heart disease.
The other first-choice abortive treatment for acute CH attacks is the inhalation of high- 
dose, high-flow oxygen at 100% for 15 minutes at the start of the attack, which is safe 
and effective in aborting a CH attack (Kudrow, 1981), and this has been confirmed in a 
small controlled study (Fogan, 1985). However good controlled evidence in a large-scale 
trial for the effectiveness of oxygen therapy in acute cluster attacks is lacking. Hyperbaric 
oxygen has been shown to be effective, but no more so than hyperbaric air in a recent 
study (Nilsson Remahl et al., 2002).
Other abortive therapies include topical agents such as intranasal lidocaine which has 
been reported as successful (Hardebo and Elner, 1987; Kittrelle et al., 1985). A placebo- 
controlled trial of intranasal capsaicin showed reduced severity of attacks, especially in 
ECH (Marks et al., 1993), but is used less often in clinical practice because of local side 
effects.
Preventive treatment
The importance of an effective preventive treatment is paramount. When optimally 
managed, the patient’s attacks can often be suppressed entirely on prophylactic therapy 
for the duration of the bout in ECH, or longer-term in CCH, with a minimal side-effect 
profile and without the need for acute abortive agents.
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Short-term prophylaxis
Many of the preventive drugs for longer-term prophylaxis require several weeks of dose 
escalation, thus making them unsuitable for patients with shorter bouts. Short-term 
preventives may be appropriate in these cases, or in patients whose headaches are 
uncontrolled and who require rapid control of their attack frequency.
Corticosteroids are very effective and fast-acting in the prevention of CH attacks (Couch 
and Ziegler, 1978; Kudrow, 1980). However the CH attacks usually recur shortly after 
the steroid treatment has been stopped. Steroids may therefore be used in conjunction 
with other preventives during their phase of dose escalation, until they are effective. 
There has been one open-label study documenting the effectiveness of intravenous 
methylprednisolone followed by a reducing dose of oral steroids in ECH (Mir et al., 
2003).
Until recently, triptans were thought not to be useful in prophylaxis of CH due to their 
short half-lives. However longer acting agents such as naratriptan (Mulder and Spierings,
2002), eletriptan (Zebenholzer et al., 2004) and frovatriptan (Siow et al., 2004) have been 
used as add-on therapy to verapamil in the short-term management of CH.
Longer-term prophylaxis
The first choice is verapamil, which has been shown to be effective in episodic and 
chronic cluster headache (Bussone et al., 1990; Gabai and Spierings, 1989; Leone et al., 
2000a), and to cause fewer side effects and have a shorter latency period when compared 
to lithium (Bussone et al., 1990). Two randomised controlled trials used verapamil at a 
dose of 360 mg daily (Bussone et al., 1990; Leone et al., 2000a), and an open trial used 
an increasing regime of doses up to 1200mg daily (Gabai and Spierings, 1989). Side 
effects of verapamil were reported as constipation, vertigo, nausea, asthenia, ankle 
swelling, bradycardia, and stomach cramps. Interestingly the patients who had to 
discontinue the drug because of side effects were at the lower dose (240 mg daily).
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Clinical experience has shown that higher doses of verapamil than those used in 
cardiological indications are needed in cluster headache (Olesen, 1999). Excessive 
concentrations of verapamil have been shown to cause atrio-ventricular block (Frishman 
et al., 1982; Seipel and Breithardt, 1982). The incidence of arrhythmias was reported at 
18% in a recent series, with bradycardia in 37% of patients (Cohen et al., 2005).
The second choice for preventive treatment is lithium, which has been proven effective in 
both ECH and CCH (Bussone et al., 1990; Ekbom, 1981; Steiner et al., 1997b). Renal and 
thyroid functions should be checked before and during treatment, and the serum levels of 
lithium determined at regular intervals (Ekbom, 1995).
Methysergide has been used in cluster headache since the 1950s (Ekbom, 1995). It is an 
ideal choice in patients with short bouts of up to 4-5 months. Prolonged treatment has 
been associated with fibrotic reactions (pleural, pericardial, retroperitoneal and 
pulmonary), but these are rare (Graham et al., 1966), and can be avoided by using 
methysergide for less than six months at a time.
Another treatment which is emerging as being useful in CH is topiramate at doses of 75- 
200mg daily (Forderreuther et al., 2002) in ECH and CCH (Lainez et al., 2003). However 
there is some conflicting evidence (Leone et al., 2003a), and care must be taken to avoid 
potential side-effects which include dyspepsia, distal limb paraesthesiae, ataxia, 
dizziness, weight loss in 10% of patients, exacerbation of renal stones in those 
predisposed to them, and cognitive impairment ranging from mild memory slowing to 
frank psychosis in a small number of patients. However, if side effects are minimal or 
tolerable, topiramate remains a valuable and feasible treatment option in cluster 
headache. One approach is to start with a dose of 12.5mg daily and increase every week 
by 12.5 or 25mg to a maximum daily dose of 200-400mg. Both the therapeutic and 
unwanted effects may not occur in a strictly dose-dependent fashion.
Other anti-epileptic therapies such as sodium valproate (El Amrani et al., 2002b; 
Gallagher et al., 2002) and gabapentin (Leandri et al., 2001) have been used in CH but
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without good controlled evidence. Given the diurnal nature of many CH attacks, 
melatonin has been tried in order to combat the reduced nocturnal melatonin in CH 
patients. A double-blind study of melatonin treatment significantly reduced headache 
frequency in episodic, but interestingly not chronic, CH sufferers (Leone et al., 1996; 
Pringsheim et al., 2002), although an open-label trial of melatonin as add-on therapy in 
two chronic CH patients was successful (Peres and Rozen, 2001).
As for the use of botulinum toxin in CH, there have been positive and negative case 
reports, but no randomised controlled trials have been done yet (Sycha et al., 2004).
Neuromodulatory Procedures
There is a subset of patients with CH which appears to be refractory to current medical 
treatment options, or for whom side effects and contraindications preclude the use of 
effective therapeutics. In these cases, and also in patients who require rapid control of 
attack frequency, a subcutaneous injection of lidocaine and depomedrone in the region of 
the Greater Occipital Nerve (GON) is an option as transitional therapy to be started at the 
same time as preventive medications (Peres et al., 2002). An acute local anaesthetic 
injection into the region of the GON has been shown to abort a CH attack (Anthony, 
1987). A placebo-controlled study of betamethasone could suppress attacks in more than 
80% of CH patients, with the effect maintained for at least 4 weeks in the majority of 
them (Ambrosini et al., 2005). This blockade could interfere in the trigeminal activity in 
cluster headache and potentially interrupt the trigeminal autonomic reflex pathway 
(Goadsby et al., 1999). Being a non-systemic treatment, the side-effects are rare and 
limited to mild paraesthesiae and a small area of hair loss at the site of injection (Shields 
et al., 2004).
Surgery
Surgery is a last-resort measure for patients with CH which is resistant to all other 
treatments. Procedures such as radiofrequency blockade of the sphenopalatine ganglion in 
a series including 10 patients with CH (Sanders and Zuurmond, 1997), and percutaneous 
radiofrequency rhizotomy in seven patients (Taha and Tew, 1995), have had variable
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effects ranging from no relief to pain free at 20 years’ followup. Trigeminal nerve 
section has also had variable results, ranging in two series from no effect to pain free at 
19 years (Jarrar et al., 2003; Kirkpatrick et al., 1993). Occasionally complete trigeminal 
anaesthesia is achieved, with subsequent risk of comeal injury (Jarrar et al., 2003; 
Kirkpatrick et al., 1993). Gamma knife radiosurgery has also been used in CH (Ford et 
al., 1998), although a prospective study found that the high morbidity and low efficacy 
precluded its use in mainstream CH treatment (Donnet et al., 2005). Destructive surgery 
in order to block trigeminal sensory or autonomic pathways should only be considered in 
patients with strictly unilateral attacks, as those whose attacks alternate sides may find an 
upsurgence of attacks on the side contralateral to surgery (Jarrar et al., 2003). In one 
devastating case the CH attacks persisted even after complete destruction of the 
trigeminal sensory pathway (Matharu and Goadsby, 2002a). This provides further 
evidence that CH is a central nervous system disorder as opposed to being a peripheral 
nerve or vascular headache.
Functional imaging data has suggested the hypothalamus to be the origin for cluster 
headache (reviewed (Cohen and Goadsby, 2004)). There have been recent successes with 
abolition of attacks by the insertion of deep brain stimulators to the posterior 
hypothalamus in CH (Franzini et al., 2003; Leone et al., 2003b; Schoenen et al., 2005), 
and this clearly may prove a viable option in the future, for patients with otherwise 
refractory CCH. A less invasive procedure involves inserting a stimulator subcutaneously 
in the region of the GON, as it is known that pain afferents from the trigeminal and 
occipital nerves converge at the trigeminocervical complex (Bartsch and Goadsby, 
2003b), and in animal models stimulation of the greater occipital nerve alters metabolic 
activity in the trigeminal nucleus caudalis and cervical dorsal hom (Goadsby et al., 1997), 
and increases excitability from afferents from the first trigeminal nerve (Bartsch and 
Goadsby, 2002). Occipital nerve stimulation has been reported as effective in patients 
with migraine (Matharu et al., 2004a), occipital neuralgia (Kapural et al., 2005), cluster 
headache (Dodick et al., 2003; Peres et al., 2002) and in one case each of CH and 
hemicrania continua (Schwedt et al., 2006), although with persistence of autonomic
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symptoms in the latter two cases, indicating a central cause for the autonomic symptoms 
which was not altered by modulation of the trigeminocervical pain system.
1.2.2 Paroxysmal Hemicrania
Paroxysmal Hemicrania (PH) is a severe, strictly unilateral headache centred on the 
orbital, supra-orbital or temporal regions, lasting two to 30 minutes and occurring with an 
attack frequency above five daily for more than half of the time, although periods with lower 
frequency may occur. The attacks are associated with one or more of the following cranial 
autonomic features: conjunctival injection, lacrimation, nasal congestion, rhinorrhoea, 
eyelid oedema, forehead and facial sweating, miosis, and ptosis. A complete response to 
indomethacin is a prerequisite for diagnosis by the classification criteria of the 
International Headache Society (Headache Classification Committee of The International 
Headache Society, 2004).
PH was first described by Sjaastad and Dale in 1974 (Sjaastad and Dale, 1974) when they 
reported a case they rather aptly named "a new treatable headache entity". They 
subsequently coined the term “chronic paroxysmal hemicrania” to describe these patients 
(Sjaastad and Dale, 1976). Later, a remitting form of the disease was recognized and 
termed “episodic paroxysmal hemicrania” (Kudrow et al., 1987). The release of the 
second edition of the IHS Classification resulted in the introduction of the umbrella term 
“paroxysmal hemicrania” that is recognized to have both an episodic and a chronic form 
(Headache Classification Committee of The International Headache Society, 2004). The 
episodic form occurs during a period that lasts seven days to one year and is separated by 
pain-free periods that last one month or more. The chronic form has attacks that occur for 
more than one year without remission or with remissions lasting less than one month.
A requirement of PH is that it is absolutely responsive to indomethacin, whereas CH and 
SUNCT are not (Antonaci et al., 2003; Antonaci et al., 1998; Cohen et al., 2005c;
Matharu et al., 2004b). There are some reports of CH responsive to indomethacin (Buzzi 
and Formisano, 2003; Geaney, 1983; Klimek, 1984), although these are rare and not
28
placebo controlled. Hemicrania continua, although not a TAC, is another primary 
headache syndrome with some cranial autonomic features which responds absolutely to 
indomethacin (Headache Classification Committee of The International Headache 
Society, 2004).
Side-effects of indomethacin include gastric irritation in 23% of patients (Pareja et al.,
2001), which has necessitated the withdrawal of indomethacin in PH, and using 
alternatives such as cyclo-oxygenase 2 (COX-2) inhibitors (rofecoxib, valdecoxib and 
celecoxib) (Lisotto et al., 2003; Mathew et al., 2000; Siow, 2004), and calcium channel 
blockers (Coria et al., 1992). Topiramate is a neuromodulator which is effective in the 
prevention of migraine (Brandes et al., 2004; Diener et al., 2004; Silberstein et al., 2004), 
and probably effective in cluster headache (Forderreuther et al., 2002; Lainez et al., 2003; 
Mathew et al., 2002; Wheeler and Carrazana, 1999), and SUNCT (Cohen et al., 2005c; 
Matharu et al., 2002; Matharu et al., 2004b; Rossi et al., 2003). There is a case report of 
the effectiveness of topiramate in paroxysmal hemicrania-tic syndrome (Boes et al.,
2003), and one in post traumatic PH (Cohen and Goadsby 2006, Paroxysmal hemicrania 
responding to topiramate; accepted for publication in Journal of Neurology Neurosurgery 
and Psychiatry, Appendix 2).
1.3 SUNCT and SUNA
SUNCT (Short-lasting Unilateral Neuralgiform headache attacks with Conjunctival 
injection and Tearing) is a rare primary headache syndrome first described in 1978 
(Sjaastad, 1978). The syndrome has been described more fully over subsequent years 
(Pareja and Sjaastad, 1997; Sjaastad et al., 1989), although in small series. It has been 
suggested that it be grouped together with cluster headache and paroxysmal hemicrania 
as a Trigeminal Autonomic Cephalalgia (TAC) (Goadsby and Lipton, 1997) based on the 
now classical clinical combination of head pain and activation of cranial autonomic 
efferents (May and Goadsby, 1999). The syndrome was included in the second edition of 
the International Headache Classification (Headache Classification Committee of The
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International Headache Society, 2004), as was the syndrome of SUNA: Short-lasting 
Unilateral Neuralgiform Headache attacks with cranial Autonomic symptoms.
SUNCT is defined by the International Headache Society as being characterised by 
unilateral orbital or temporal pain which is stabbing or throbbing in quality and of 
moderate severity. There should be at least 20 attacks, lasting for 5-240 seconds and 
ipsilateral conjunctival injection and lacrimation should be present (Headache 
Classification Committee of The International Headache Society, 2004). In recognition of 
the possibility that all patients with generically the same condition might not have both 
conjunctival injection and tearing, the classification committee considered that SUNCT 
syndrome may be a subset of SUNA, Short-lasting Unilateral Neuralgiform headache 
attacks with cranial Autonomic features. In SUNA there may be cranial autonomic 
symptoms other than conjunctival injection and lacrimation, or indeed only one of those 
symptoms may be present. Since publication of that classification there has been little by 
way of case reports of SUNA (Volcy et al., 2005).
A comprehensive review of 50 cases of SUNCT from the worldwide literature was 
published in 2003 (Matharu et al., 2003a), and there have been further case reports since 
then (Black et al., 2005; Calvo et al., 2004; Cohen et al., 2004; Malik et al., 2002;
Matharu et al., 2004b; Matharu et al., 2003c; Prakash and Lo, 2004; Ramirez-Moreno et 
al., 2004; Rossi et al., 2003; Sekhara et al., 2005; Vikelis et al., 2005). The typical age of 
onset is between 35 and 65 (68% of primary SUNCT cases) (Matharu et al., 2003a), but 
ranges from 5 (Sekhara et al., 2005) to 88 years (Vikelis et al., 2005). SUNCT appears to 
have a male predominance, with one review of 15 men and 4 women stating the 
malerfemale ratio of 3.75:1 (Pareja and Sjaastad, 1997), and a subsequent review of 28 
men and 22 women stating the male:female ratio at 1.3:1 (Matharu et al., 2003a). The 
trend towards increasing female preponderance over time, and the emergence of new 
cases at the extremes of age of onset, reflect an increasing recognition of these conditions 
in the general population.
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SUNCT is usually a primary headache syndrome. However there are a number of cases 
which are secondary to intracranial lesions,typically either in the posterior fossa or in the 
pituitary gland. Case reports of SUNCT secondary to a posterior fossa abnormality 
include the following: ipsilateral cerebellopontine arteriovenous malformations in two 
patients (Bussone et al., 1991; Morales et al., 1994), a brainstem cavernous haemangioma 
(De Benedittis, 1996), a posterior fossa lesion associated with HIV/AIDS (Goadsby and 
Lipton, 1997), severe basilar impression causing pontomedullary compression in a patient 
with osteogenesis imperfecta (ter Berg and Goadsby, 2001), craniostosis resulting in a 
foreshortened posterior fossa (Moris et al., 2001), ischaemic brainstem infarction (Penart 
et al., 2001), a pilocytic astrocytoma expanding to the trigeminal root entry zone (Blattler 
et al., 2003) and a plaque of multiple sclerosis in the anterior pons, ipsilateral cerebral 
peduncle, and medulla (Vilisaar and Constantinescu, 2006). There has also been a recent 
report of SUNCT secondary to intraorbital metastatic bronchial carcinoid, which although 
not in the posterior fossa, would meet criteria proposed by Trucco et al to identify causal 
links in secondary SUNCT (Trucco et al., 2004).
As for pituitary lesions, a patient with a pituitary macroadenoma had reported symptoms 
of SUNCT which were labeled as trigeminal neuralgia (Ferrari et al., 1988). SUNCT has 
been described in patients both with microprolactinomas (Levy et al., 2003) and 
macroprolactinomas (Massiou et al., 2002; Matharu et al., 2003c), with attacks occurring 
on the side ipsilateral to the side of the tumour, suggesting a role for a direct or 
mechanical mode of action in macroadenomas, but this would not account satisfactorily 
for microadenomas. It has therefore been suggested that the attacks were predominantly 
neurohormonally mediated rather than by the size or invasiveness of the tumour (Matharu 
et al., 2003c). It is also interesting to note that headache symptoms can precede pituitary 
symptoms by 3-10 years (Ferrari et al., 1988; Massiou et al., 2002).
A difficulty in defining the clinical characteristics of a rare syndrome is to obtain 
sufficient experience in one place and case histories to make comparisons and see 
common themes. This has not been hitherto possible with SUNCT/SUNA. This thesis 
presents a case series of 52 patients with SUNCT or SUNA, which is a substantial
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enough cohort to compare and contrast the clinical presentation. The clinical and 
epidemiologic characteristics of a large clinic-based population of persons with SUNCT 
and SUNA were prospectively studied. This study addresses the clinical characteristics of 
the syndrome and the management strategies used. The phenotype of the attacks is 
reported in more detail than has been previously described. The work was initially 
reported at the 12th Congress of the International Headache Society (Cohen et al., 2005b).
1.4 SUNCT and Trigeminal Neuralgia
The diagnosis of SUNCT is often confused with trigeminal neuralgia (TN), which is 
categorised by the International Headache Society classification as one of the cranial 
Neuralgias and central causes of facial pain (Headache Classification Committee of The 
International Headache Society, 2004). It is a unilateral disorder affecting 4.3 per 100 000 
people annually (Wilkins, 2002). Attacks are characterised by brief electric-shock-like 
pains, abrupt in onset and termination, in one or more distributions of the trigeminal 
nerve (Headache Classification Committee of The International Headache Society, 2004), 
usually the maxillary (V2) or mandibular (V3) divisions, and rarely in the ophthalmic 
division (V,). It can be precipitated by trivial stimuli such as washing, shaving, smoking, 
talking and brushing the teeth, although attacks can occur spontaneously. The pains 
usually remit for variable periods.
Neurovascular compression in the root entry zone of the trigeminal nerve in the 
cerebellopontine angle cistern of the trigeminal nerve is widely believed to be the 
essential mechanism for the pathogenesis of TN (Dandy, 1934; Gardner and Miklos,
1959; Jannetta, 1980), with 10% (Adams et al., 1982) to 100% of patients (Jannetta, 
1985) having operatively confirmed vascular compression. Magnetic resonance (MR) 
imaging (Majoie et al., 1997) and magnetic resonance angiographic techniques (Boecher- 
Schwarz et al., 1998; Meaney et al., 1995) are useful to detect neurovascular 
compression in TN. Microvascular decompression (the Jannetta procedure) is a useful 
method to treat trigeminal neuralgia (Barker et al., 1996), as are gamma-knife 
radiosurgery and glycerol rhizotomy (Henson et al., 2005). From a medical treatment
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perspective, the gold standard is treatment with carbamazepine (Campbell, 1966; Killian 
and Fromm, 1968; Nicol, 1969; RocklifF and Davis, 1966). Other neuromodulators such 
as gabapentin (Serpell, 2002), and lamotrigine as an add-on therapy (Zakrzewska et al., 
1997), and topiramate (Gilron et al., 2001) have shown benefit, as have the muscle 
relaxants baclofen (Fromm et al., 1984) and tizanidine (Fromm et al., 1993), and the anti- 
arrhythmic tocainamide (Backonja, 2000; Lindstrom and Lindblom, 1987).
Given the short, stabbing nature of the attacks, the cutaneous triggering, and the 
association of cranial autonomic symptoms with V! pain, the differentiation between TN 
and SUNCT has often been difficult (Sesso, 2001), especially in the elderly (Cohen et al.,
2004). SUNCT and TN were thought to coexist as two separate headache entities in a 
patient with neurovascular compression at the ipsilateral trigeminal root entry zone 
(Zidverc-Trajkovic et al., 2005). Indeed SUNCT has been reported in a case with 
ipsilateral neurovascular compression, although it is not clear in this case whether 
surgical intervention would have relieved the symptoms (Koseoglu et al., 2005).
SUNCT has previously been thought to be a form of transformed TN based on the shared 
phenomenology in a case report (Bouhassira et al., 1994). TN with lacrimation has been 
reported in six cases, and in the same series in 16 cases without lacrimation (Benoliel and 
Sharav, 1998). It is also discussed in older texts from as early as 1888 (Collier, 1922; 
Gowers, 1888; Kinnier Wilson, 1940). A series of 19 patients with V, TN suggested that 
although 8 of them had autonomic phenomena, these were likely to be relatively ‘mild’ 
compared to autonomic symptoms in SUNCT (Sjaastad et al., 1997).
Cranial autonomic symptoms such as conjunctival injection and lacrimation are thought 
to result, in part, from activation of the trigeminal-autonomic reflex (May and Goadsby,
1999), and are recognised in other forms of head pain, including experimental head pain 
with capsaicin injection (May et al., 1999) and other headache syndromes such as 
migraine (Barbanti et al., 2002; Benoliel and Sharav, 1998). In fact, some degree of 
cranial autonomic symptomatology is a normal physiologic response to cranial 
nociceptive input (Frese et al., 2003; May et al., 2001). The distinction between TACs
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(such as SUNCT) and other headache syndromes (such as TN) appears to be the degree 
of cranial autonomic activation (Goadsby et al., 2001), as was borne out in an objective 
assessment of autonomic signs during attacks of triggered Vi TN, where mild lacrimation 
was observed, even in relatively long attacks, in clear contradiction with SUNCT where 
conjunctival injection and lacrimation are dramatic on the ipsilateral side (Pareja et al,
2002). It has been suggested that the cranial autonomic symptoms may be prominent in 
TACs due to a central disinhibition of the trigeminal-autonomic reflex by the 
hypothalamus (Benjamin et al., 2004).
1.5 Treatments for SUNCT
SUNCT has until recently been considered refractory to treatment. However it has now 
been shown in open-label trials that neuromodulatory treatments such as lamotrigine 
(D'Andrea et al., 1999a; D’Andrea et al., 2001; Gutierrez-Garcia, 2002; Leone et al., 
2000b; Malik et al., 2002), carbamazepine (Matharu et al., 2003a; Matharu et al., 2004b), 
topiramate (Matharu et al., 2002; Matharu et al., 2004b; Rossi et al., 2003), and 
gabapentin (Graff-Radford, 2000; Hunt et al., 2002; Porta-Etessam et al., 2002) have 
been successful in the preventive treatment of some cases of SUNCT.
Drug therapies
Several categories of drugs used in headache and other pain syndromes have been tried in 
SUNCT, a large number of which have been reviewed extensively (Matharu et al., 
2003a). Most of them have been reported to be ineffectual, and until recently SUNCT 
was thought to be highly refractory to treatment.
Serotonergic agonists and antagonists
Sumatriptan, either in oral form (100-300mg daily), or subcutaneously (6mg), has been 
reported with little or no response in SUNCT (Matharu et al., 2003a). Oral or intravenous 
dihydroergotamine was also ineffectual. Methysergide and pizotifen have also had no 
reported effect (Goadsby and Lipton, 1997; Matharu et al., 2004b; Pareja et al., 1995).
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Selective serotonin reuptake inhibitors (SSRIs) have been used in SUNCT, including 
sertraline (lOOmg/day) (Koseoglu et al., 2005)and fluoxetine (20mg/day) (Matharu et al., 
2004b), with no effect.
Oxygen
High-dose high-flow oxygen has been used to good effect in cluster headache (Fogan, 
1985; Kudrow, 1981), but has had little or no effect in SUNCT (Matharu et al., 2003a; 
Matharu et al., 2004b). It is arguable that any benefit seen in SUNCT patients may be due 
to the spontaneous resolution of each attack over seconds to a few minutes, rather than 
any beneficial therapeutic effect.
Indomethacin, non-steroidal anti-inflammatory drugs and cyclo-oxygenase inhibitors 
Non-steroidal anti-inflammatory drugs (NSAIDs), including ibuprofen, piroxicam, 
naproxen, ketoprofen, aspirin and mefenamic acid, are ineffective in the treatment of 
SUNCT and SUNA (Matharu et al., 2003a; Matharu et al., 2004b; Rossi et al., 2003; 
Volcy et al., 2005). Oral indomethacin in doses up to 300mg a day has also been found to 
be mainly ineffective (Gardella et al., 2001; Hunt et al., 2002; Koseoglu et al., 2005; 
Matharu et al., 2004b; Narbone et al., 2005; Prakash and Lo, 2004; Rossi et al., 2003; 
Volcy et al., 2005).
Lidocaine
Intravenous lidocaine has been reported previously in 4 patients with SUNCT, providing 
them with pain free times of up to 12 hours (Matharu et al., 2004b), and in a further case 
with pain relief for an unknown time (Shiiba et al., 2005).
Preventive Medications
Lamotrigine
Recently, lamotrigine given in an open-label manner at doses up to 300mg daily was 
reported as highly efficacious in 10 patients (D'Andrea et al., 1999a; D'Andrea et al., 
2001; Gutierrez-Garcia, 2002; Leone et al., 2000b; Malik et al., 2002), although it was 
ineffective in 4 patients (Black and Dodick, 2002; Matharu et al., 2004b; Sprenger et al.,
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2005), and ineffective at 400mg daily in a patient with SUNCT related to trigeminal 
nerve compression (Koseoglu et al., 2005).
Problems with lamotrigine include a skin reaction which may progress to Stevens- 
Johnson syndrome, and this necessitated the cessation of lamotrigine in at least 1 patient 
in the literature (Rossi et al., 2003).
Topiramate
Topiramate has been reported to be effective in 5 patients at doses up to 300mg daily 
(Matharu et al., 2002; Matharu et al., 2004b; Rossi et al., 2003), and ineffective in three 
patients (Black and Dodick, 2002; Koseoglu et al., 2005). Problems with topiramate 
include side effects, which sometimes necessitated the cessation of the drug. Two patients 
reported mild hypersomnolence at doses of 75 and 300mg a day respectively, but as they 
were rendered pain free and the headaches recurred on reducing the dose, they 
maintained the topiramate treatment (Matharu et al., 2004b; Rossi et al., 2003).
Carbamazepine
Carbamazepine has been a mainstay of treatment in trigeminal neuralgia (Backonja and 
Serra, 2004), and has also been reported as having a good or partial effect in SUNCT at 
doses up to 900mg a day (Matharu et al., 2003a; Matharu et al., 2004b), especially when 
used in combination with naloxone, verapamil and lithium (Sabatowski et al., 2001); 
prednisolone (Calvo et al., 2004; Gardella et al., 2001; Montes et al., 2001), topiramate 
(Matharu et al., 2004b), and indomethacin (Prakash and Lo, 2004). However there are 
some reports of carbamazepine having no effect at doses of 100-1200mg a day (Cohen et 
al., 2004; Koseoglu et al., 2005; Rossi et al., 2003), and only a mild effect at 1600mg a 
day (Gantenbein and Goadsby, 2005).
Gabapentin
SUNCT has been shown to respond to gabapentin, with complete suppression of attacks 
in three of nine patients treated with 800 to 2700 mg daily (Graff-Radford, 2000; Hunt et 
al., 2002; Porta-Etessam et al., 2002), and minimally effective in 1 patient with SUNA at
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an unknown dose (Volcy et al., 2005). However it has been reported as completely 
ineffective in 9 patients (Koseoglu et al., 2005; Malik et al., 2002; Matharu et al., 2003a; 
Matharu et al., 2004b), although in 1 patient this was SUNCT secondary to compression 
of the trigeminal nerve (Koseoglu et al., 2005).
Valproate
Valproate, which is used commonly in migraine (Hering and Steiner, 1994; Jensen et al.,
1994), has been ineffective in doses up to 2000 mg a day in 8 patients with SUNCT, was 
partially effective in one, and transiently had a good effect when combined with 
nortriptyline and prednisolone in another patient (Matharu et al., 2004b; Pareja et al., 
1995; Sesso, 2001). It was ineffective in a patient with SUNA at 15mg/kg/day 
(375mg/day) (Volcy et al., 2005).
Verapamil and Lithium
Verapamil at high doses (up to 960mg/day), and lithium (to a therapeutic range of 0.8-1.1 
pmol/lt) are usually used in cluster headache (Bussone et al., 1990; Ekbom, 1981; Leone 
et al., 2000a), and have had little or no reported effect in SUNCT (Gardella et al., 2001; 
Matharu et al., 2003a; Rossi et al., 2003), or verapamil has made the attacks worse 
(Jimenez-Huete et al., 2002; May et al., 1999b), except in one recent case where 
verapamil at doses of 480-960mg a day abolished attacks in a patient with SUNCT and an 
ischaemic lesion in the posterior fossa (Narbone et al., 2005). Lithium and verapamil are 
both known to accumulate in the hypothalamus (Bussone, 2003; Dodick et al., 2003), 
which plays an important role in the generation of both CH and SUNCT attacks, so it 
would be intuitive that they may both have some beneficial effect in SUNCT.
Corticosteroids
Corticosteroids, particularly prednisolone, are used in the treatment of cluster headache 
(Antonaci et al., 2005; Couch and Ziegler, 1978; Kudrow, 1980). There have been some 
benefits reported in SUNCT with steroid monotherapy (Matharu et al., 2003a), although 
there is another report showing no benefit of 60mg prednisolone for 1 month (Rossi et al.,
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2003). Steroids have also been used in combination with carbamazepine at doses of 40- 
60mg/day (Calvo et al., 2004; Gardella et al., 2001; Montes et al., 2001).
Adrenoreceptor blockers
Beta-blockers such as propranolol, and alpha-blockers such as clonidine, have been 
shown to be ineffective in SUNCT (Matharu et al., 2003a).
Amitriptyline and tricyclic antidepressants
Amitriptyline and other tricyclic antidepressants are commonly used in the treatment of 
migraine (Couch et al., 1976; Punay and Couch, 2003; Ziegler et al., 1987), neuropathic 
pain (McQuay et al., 1996; Sindrup and Jensen, 1999) and atypical facial pain (Lascelles, 
1966), but there are no randomised controlled trials of amitriptyline in trigeminal 
neuralgia or SUNCT.
Phenytoin
Phenytoin has been tried in 10 patients and was reported to be ineffective in all except 
one in whom a possible slight improvement was noted (Malik et al., 2002; Pareja et al.,
1995). It has been used in combination with carbamazepine, which had no beneficial 
effect but caused ataxia (Matharu et al., 2004b).
Other anticonvulsants
Other drugs used with little or no effect include oxcarbazepine (2400mg/day (Sprenger et 
al., 2005)) (1800mg/day in the patient with SUNCT associated with compression of the 
trigeminal nerve) (Koseoglu et al., 2005), baclofen, both alone and in combination with 
carbamazepine (Calvo et al., 2004), and clonazepam (Matharu et al., 2004b).
Analgesics
Simple analgesics (paracetamol, aspirin) opiates (morphine, tramadol, buprenorphine, 
dihydrocodeine), and combination analgesics (paracetamol/codeine, 
hydrocodone/acetaminophen), have all been reported as ineffective (Malik et al., 2002; 
Matharu et al., 2003a; Matharu et al., 2004b; Putzki et al., 2005).
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Surgery
Several surgical approaches have been attempted for the treatment of SUNCT syndrome. 
These take the form either of local blockades, invasive procedures involving the 
trigeminal nerve, and neuromodulatory procedures using superficial nerve and deep brain 
stimulation.
Local Blockades
Local blockades of pericranial nerves with anaesthetics, alcohol, phenol, or opioids, have 
generally been reported as ineffectual. Supraorbital blockades using lidocaine, 
bupivacaine or alcohol, were ineffective in suppressing spontaneous attacks in nine 
patients, but made triggering of attacks more difficult by touching the anaesthetised area 
(Hannerz and Linderoth, 2002; Pareja et al., 1995). Infraorbital blockades were 
ineffective in 8 of nine patients (Hannerz and Linderoth, 2002), and lidocaine blockades 
of lacrimal nerve, orbicularis oculi muscles, and the retrobulbar region also had no effect, 
as did a stellate ganglion block with bupivacaine (Pareja et al., 1995). A pterygopalatine 
ganglion blockade with phenol produced a variable effect in one patient (Hannerz and 
Linderoth, 2002), and one had a partial response with opioid blockade of the superior 
cervical ganglion (Sabatowski et al., 2001).
Invasive surgical procedures involving the trigeminal nerve 
Two patients have been treated with the Jannetta procedure (microvascular 
decompression of the trigeminal nerve) with good effect (Gardella et al., 2001; Lenaerts, 
1997), although in one patient it made the symptoms worse (Matharu et al., 2004b), and 
in 2 further patients it was unhelpful, as were glycerol rhizotomy and y knife 
radiosurgery, and in fact the patients suffered post surgical side effects which were 
anaesthesia dolorosa, unilateral deafness, chronic vertigo and disequilibrium (Black and 
Dodick, 2002). One patient underwent a right trigeminal radiofrequency 
thermocoagulation, after which she was pain free for 3 years, but with marked 
hypoanaesthesia over the second and third trigeminal distributions on that side (Matharu 
et al., 2004b). Some authorities recommend that trigeminal surgery be considered only as 
a last resort, and then with extreme caution, given its uncertain outcomes and the
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potential for debilitating side effects. Others suggest that it has no place in current 
therapy.
Hypothalamic deep brain stimulation
Functional imaging work has shown that activation of the posterior hypothalamus is 
linked to attacks of cluster headache (May et al., 1998a; Sprenger et al., 2004), and 
SUNCT (Cohen et al., 2004a; May et al., 1999b; Sprenger et al., 2005). Sixteen patients 
with intractable chronic cluster headache and one patient with intractable SUNCT have 
undergone deep brain electrical stimulation to the posterior hypothalamus, with good 
results (Leone et al., 2004a; Leone, 2004). In another series of six patients, 2 were 
painffee with a third patient with much reduced frequency of attacks. However the side 
effect of diplopia limited the increase of the voltage, and one patient died of an 
intracerebral haemorrhage (Schoenen et al., 2005). Therefore the referral of patients for 
these procedures is done with great caution, and currently is reserved for those patients 
who are refractory to all other types of treatment.
Greater occipital nerve injections
Two patients with SUNCT and 6 patients with PH underwent lidocaine blockades of the 
greater occipital nerve with no benefit (Antonaci et al., 1997; Pareja et al., 1995).
Other non-pharmacological procedures
One patient tried a transcutaneous electrical nerve stimulation (TENS) machine, 
acupuncture, and a maxillary bite appliance, all with no effect (Matharu et al., 2004b).
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Chapter 2
Functional imaging in primary headaches
2.1 Introduction
Primary headache disorders, such as migraine and cluster headache, have until recently 
been described as vascular headaches. However there is now considerable imaging and 
clinical evidence to suggest that they are primarily driven from the brain (Goadsby, 
2002b; Goadsby et al., 2002). Early functional imaging work using positron emission 
tomography (PET) has shed light on the genesis of these syndromes, documenting 
activation in the midbrain and pons in migraine, and in the posterior hypothalamic grey in 
cluster headache and other trigeminal autonomic cephalgias. PET has also been used to 
show both hypothalamic and brainstem activation in hemicrania continua, a syndrome 
which shares features both with migraine and the trigeminal autonomic cephalgias.
These areas are involved not simply as a response to first division nociceptive pain 
impulses but specifically in each syndrome, probably in a permissive or dysfunctional 
role. Further studies using functional magnetic resonance imaging techniques, voxel- 
based morphometry and magnetic resonance spectroscopy, all add evidence that these 
primary headache syndromes are primarily brain disorders.
2.2 Techniques
The concept of ‘intrinsic mechanisms’ responsible for coupling neural activity with 
cerebral blood flow was introduced in 1890 (Roy, 1890), although for a decade earlier 
there were studies investigating the change in cerebral blood flow in humans according to 
different psychological states (Iadecola, 2002). There is considerable evidence that under 
normal circumstances the brain utilizes glucose as its only source of energy (Jueptner and 
Weiller, 1995), and as there are only minimal glycogen stores in the brain, a permanent
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supply of glucose by the blood is necessary (Clarke, 1994). The evidence is presented 
that glucose utilization reflects neuronal activity, especially at the synapses (Jueptner and 
Weiller, 1995), and that regional changes in cerebral blood flow reflect variations in local 
synaptic activity, as measured using positron emission tomography (PET) (Frackowiak 
and Friston, 1994; SokolofF et al., 1977).
PET is a tomographic nuclear imaging procedure using positron emitters, such as 
positron-labelled water 15H20, which is injected intravenously into the patient, in order to 
detect changes in regional cerebral blood flow (Herscovitch et al., 1983; Raichle et al., 
1983).
Functional magnetic resonance imaging (fMRI) also detects the change in cerebral blood 
flow, but uses the changing ratio of oxyhaemoglobin to deoxyhaemoglobin (Ogawa et al., 
1990; Rosen et al., 1998). Oxyhaemoglobin has no magnetic properties, but 
deoxyhaemoglobin is strongly paramagnetic and can serve as an intrinsic paramagnetic 
contrast agent (termed the blood oxygenation level dependent (BOLD) contrast), when a 
strong magnetic field is applied in MRI. As the local cerebral blood flow increases, but 
without increasing the local oxygen consumption, the venous oxyhaemoglobin 
concentration will increase and the deoxyhaemoglobin concentration with decrease. As a 
result there is less paramagnetic influence on the spin of nuclei generated by an externally 
applied magnetic field, and thus there is less disturbance, and an increase of intensity of 
the signal (Matthews, 2001).
Voxel Based Morphometry (VBM) was developed as a novel technique for characterising 
regional cerebral grey and white matter differences in structural magnetic resonance 
images by the application of methods derived from functional imaging (Wright et al.,
1995). It is an automated nan-biased whole brain technique which analyses changes in 
brain structure, involving a voxel-wise comparison of the local concentration of grey 
matter between two groups of subjects. Specifically in VBM, the structural MR images 
are spatially normalised to the same stereotactic space, then the grey matter is extracted 
from the normalised images (segmentation), and then smoothed with an isotropic
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Gaussian kernel, in order to make them comparable for specific anatomical differences on 
a voxel-by voxel basis (Ashbumer and Friston, 2000; Mechelli, 2005). VBM has been 
useful in characterising subtle changes in brain structure in a variety of diseases 
associated with neurological and psychiatric dysfunction, such as schizophrenia, 
developmental and congenital disorders, autism, bipolar disorders, temporal lobe 
epilepsy, supranuclear palsy (Mechelli et al., 2005), cluster headache (May et al., 1999a) 
and chronic tension type headache (Schmidt-Wilcke et al., 2005).
Statistical parametric mapping refers to the construction and assessment of spatially 
extended statistical processes used to test hypotheses about functional imaging data, 
(Friston, 2003) (www.fil.ion.ucl.ac.uk/spmV It is a voxel-based approach, employing 
classical inference, and was developed to make some comment about regionally specific 
responses to experimental factors (Friston et al., 1991). The images are pre-processed 
using realignment, normalisation, and smoothing. The realignment transformation aims to 
reduce unwanted variance components in the voxel time-series that are induced by 
movement or shape differences among a series of scans. After realigning the data, a mean 
image of the series is used to estimate some warping parameters that map it onto a 
template conforming to a standard anatomical space e.g. (Talairach and Toumoux, 1988). 
The data are then smoothed using a Gaussian smoothing kernel corresponding to the size 
of the anticipated effect. The spatial scale of haemodynamic responses is, according to 
high-resolution optical imaging experiments, about 2 to 5mm. Despite the potentially 
high resolution afforded by fMRI, an equivalent smoothing is suggested for most 
applications. In the context of inter-subject averaging it is often necessary to smooth 
more (e.g. 8 mm in fMRI) to project the data onto a spatial scale where homologies in 
functional anatomy are expressed among subjects.
Statistical parametric maps (SPMs) are generated by testing a null hypothesis at each 
voxel, using a univariate Student’s t or F  test, and the resulting statistical parameters are 
assembled into an image which is the SPM. The general linear model is employed to 
construct a design matrix whereby each voxel is tested for a response Y in terms of a 
linear combination of explanatory variables X  plus a well behaved error term e:
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Y = Xp + 8 (Friston et al., 1995b).
Variables may be tested with parametric modulation; that is the test is performed on each 
voxel for the variable as it changes with time, or severity of pain, and this can be done 
either in a linear fashion (polynomial order = 1), or a nonlinear fashion (polynomial order 
> 1). Each column of the design matrix corresponds to an effect, also known as a 
parameter, which may be part of the experiment, or which may be an unwanted effect 
such as movement of the hand to press the keypad, and will confound the results unless it 
is accounted for in the design matrix and ‘modelled out’ of the results of interest. An 
example is shown in Figure 11.1. The relative contribution of each of these columns is 
assessed using standard least squares and inferences about these contributions are made 
using t or F  statistics, depending upon whether one is looking at a particular linear 
combination (e.g. a subtraction), or all of them together. When assessing a particular 
effect, a contrast vector is set up; so in this example the contrast vector [0 1 000]  
assesses the second column, which corresponds to headache as parametrically assessed 
with the intensity of the pain.
The significance of each contrast is assessed with a statistic that has Student’s t 
distribution under the null hypothesis. For each contrast or difference in parameter 
estimates, a SPM {/} statistic is generated for each voxel in the brain. This is transformed 
into a SPM {Z}. Statistical inferences are then made about local excursions of the SPM 
{Z}, using the Gaussian field theory (Worsley et al., 1992). The resulting P values and 
the SPM {Zj scores are the endpoint of the analysis.
2.3 Functional Imaging in Primary Headache Syndromes
2.3.1 Migraine
Migraine with aura
Migraine aura is the complex of reversible neurological symptoms that occur just before 
or at the onset of the headache. Aura usually involves visual, sensory or speech
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symptoms, and develops gradually over 5-20 minutes and lasts less than 60 minutes 
(Headache Classification Committee of The International Headache Society, 2004). 
Cortical spreading depression of Leao (Leao, 1944) has been suggested to underlie 
migraine visual aura, based on the slow spread of clinical and electrophysiological events 
in animal experiments (Lauritzen, 1987; Mraovitch et al., 1992). The advent of functional 
imaging has allowed the testing of this hypothesis in humans.
Using intra-arterial 133Xenon blood flow studies, Olesen and colleagues (Friberg et al., 
1994; Olesen, 1991; Olesen et al., 1981) showed a focal reduction of regional cerebral 
blood flow (rCBF) during aura- like symptoms, usually in the posterior parts of one 
hemisphere. These changes were produced by carotid angiography, but similar changes 
have been seen in spontaneous attacks with single photon emission computer tomography 
(SPECT) (Lauritzen, 1994) and perfusion-weighted magnetic resonance imaging (Cutrer 
et al., 1998). Areas of hypoperfusion in the frontal cortex have also been observed, both 
with and without simultaneous reductions in posterior parietal and occipital blood flow 
(Friberg et al., 1987; Lauritzen et al., 1983). However symptomatic patients with no 
disturbance in rCBF have been observed in some series (Lauritzen et al., 1983).
A recent study using high-field functional MRI during visual aura in three subjects 
demonstrated BOLD signal changes which were time-locked to precept/onset of the aura, 
and which progressed slowly over the occipital cortex in line with the retinotopy of the 
visual percept of the aura (Hadjikhani et al., 2001). A recent PET study has demonstrated 
activation in the primary visual area of the occipital cortex in migraine aura which was 
reproducibly triggered by nitroglycerin (Afridi et al., 2005a).
Hemiplegic Migraine
A case of sporadic hemiplegic migraine showed SPECT evidence of increased cerebral 
blood flow in the contralateral hemisphere, consistent with hyperperfusion (Barbour et 
al., 2001). Hyperperfusion has also been demonstrated in a patient with familial 
hemiplegic migraine (FHM), using multimodal MRI including diffusion-weighted (DWI) 
and perfusion-weighted (PWI) imaging, and FADS (factor analysis of dynamic studies)
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(Lindahl et al., 2002). A PET investigation in a patient with FHM revealed glucose- 
hypometabolism in the fronto-basal cortex, caudate nucleus and thalamus on the side 
contralateral to the hemiplegia (Gutschalk et al., 2002). However, MRI including PWI 
and DWI were normal in the same patient.
Migraine without aura
In 1994, Woods and colleagues published the first report of PET measurements in a 
patient from the start of a spontaneous migraine attack of unilateral headache without 
aura but with visual blurring, whilst lying in the PET scanner for another purpose (Woods 
et al., 1994). There was bilateral reduction in rCBF in the visual association cortex, and 
this decrease spread contiguously across the cortical surface at a relatively constant rate, 
sparing the cerebellum, basal ganglia and thalamus. Most of the changes were relatively 
short-lasting, with substantial recovery by the time of the next scan (12-15 minutes). 
These findings are in contrast with SPECT studies (Lauritzen and Olesen, 1984; Olesen, 
1991; Olesen et al., 1982) in which no changes in rCBF in migraine attacks without aura 
were demonstrated. However given the difficulties of reporting the visual changes in a 
PET scanner environment, it is not clear whether or not the subject experienced true aura.
Migraine without aura and CBF
In contrast to migraine with aura, blood flow is usually normal and symmetrical both 
ictally and interictally in migraine without aura (Olesen et al., 1990; Olesen et al., 1982). 
However a SPECT study by Friberg et al demonstrated abnormal interhemispherical 
asymmetries in rCBF interictally in almost 50% or patients (Friberg et al., 1994a). The 
authors concluded that, at least interictally, a cerebrovascular dysregulation existed. This 
has been corroborated by other groups (Mirza et al., 1998). In a study combining rCBF 
and blood flow velocity in the middle cerebral arteries using transcranial Doppler 
sonography, it was found that middle cerebral artery (MCA) velocity on the headache 
side was significantly lower than that on the non-headache side, returning to normal 
values after treatment with sumatriptan (Friberg et al., 1991). It was concluded at the time 
that the headache phase was associated with a dilation of the MCA on the headache side 
which was reversed by the vasoconstrictor action of the 5HTiB/id agonist sumatriptan.
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However, as the cerebral blood flow was unaffected, no evidence for an important 
vascular role was established (Goadsby, 2001b). Consistent with the lack of a correlation 
are transcranial Doppler findings that the vasoconstrictor effect of sumatriptan is not 
temporally related to headache relief (Limmroth et al., 1996). Moreover it has been 
recently shown that sildenafil can induce migraine via a cGMP-dependent mechanism, 
without initial dilation of the MCA (Kruuse et al., 2003); thus refuting the theory that 
migraine is primarily a vascular headache.
Migraine and PET
Animal studies indicating that dysfunction in brainstem nuclei involved in sensory 
modulation, including antinociception and craniovascular control, may account for the 
pathophysiology of migraine (Goadsby et al., 1991; Lance et al., 1983). It has been 
postulated that the brainstem plays a central role in the pathogenesis of migraine 
(Goadsby et al., 1991; Welch et al., 2001).
Weiller at al (Weiller et al., 1995) studied patients with migraine without aura using PET, 
and found significantly higher rCBF values during an attack compared to the headache- 
free state in brainstem structures over several planes. These structures were towards the 
midline but contralateral to the headache side, and have since been refined in their 
localisation to the dorsal pons (Bahra et al., 2001). It has been speculated that the 
contralateral changes may represent rostral, rather than caudal, control systems (Goadsby 
and Fields, 1998). There was also activation in the anterocaudal cingulate cortex and in 
visual and auditory association cortices; these activations were abolished with abortion of 
the attack by subcutaneous sumatriptan, but the activation in the medial brainstem 
persisted (Weiller et al., 1995). It can therefore be deduced that the observed activation in 
the brainstem was unlikely to be just the result to pain perception or increased activity of 
the endogenous anti-nociceptive systems (May, 2003), and that the brainstem may indeed 
be the ‘generator’ of the attacks.
A PET scan in a patient with both migraine and CH during a migraine attack, while he 
was in an active cluster period, showed brainstem activation in the dorsal rostral pons
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(Bahra et al., 2001), and dorsal rostral pontine activation at virtually the same locus has 
been demonstrated in a PET study in chronic migraine (Matharu et al., 2004a). This was 
reinforced in a group of patients with episodic migraine where activation of the 
dorsolateral pons on the left side was noticed during acute migraine, and associated 
deactivation of the contralateral pons (Afridi et al., 2005b), as well as the ‘pain matrix’ 
such as the anterior cingulate, prefrontal cortex, and insula, which were consistent with 
areas seen during studies involving acute pain, and the thalamus contralateral to the side 
of pain, which is consistent with known anatomy (Bingel et al., 2003). Furthermore, a 
PET study in spontaneous migraine showed activation in the ipsilateral cingulate cortex, 
bilateral insulae, cerebellum, brainstem (including midline and contralateral midbrain, 
and dorsal midline pons), and also in the ipsilateral hypothalamus when comparing the 
attack to the painffee state; and after pain relief with subcutaneous sumatriptan, the 
hypothalamic, brainstem and ipsilateral cerebellar activations persisted (Denuelle et al.,
2004), thus strengthening the evidence that these structures are involved in the migraine 
attack and are not just activated in response to pain.
Experimental evidence has emerged that supports a role for the brainstem in the 
pathogenesis of migraine. The brainstem, specifically the periaqueductal grey matter 
(PAG), is involved in the inhibition of trigeminovascular specific nociception traffic. 
Stimulation of the ventrolateral PAG produces inhibition of nociceptive signals (Knight 
and Goadsby, 2001), while blockade of P/Q type voltage gated calcium channels (Ophoff 
et al., 1996), known to be involved in familial hemiplegic migraine, is pronociceptive 
(Knight et al., 2002). The L- and T-type calcium channel blocker flunarizine has been 
reported as beneficial in migraine without aura (Ciancarelli et al., 2004) and hemiplegic 
migraine (Silver and Andermann, 1993; Tobita et al., 1987) and the L-type calcium 
channel antagonist verapamil had a good effect in hemiplegic migraine (Yu and 
Horowitz, 2003).
Further evidence for the importance of the brainstem in the initiation of migraine is 
provided by the presence in the brainstem of binding sites for specific anti-migraine 
compounds such as dihydroergotamine (Goadsby and Gundlach, 1991) and zolmitriptan
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(Goadsby and Knight, 1997). There is clinical evidence from a report of non-migraine 
patients who developed migraine-like episodes after stereotactic intervention to the PAG 
which responded to 5HTib/id agonists (Raskin et al., 1987; Veloso et al., 1998). A 
multiple sclerosis plaque in the PAG (Haas et al., 1993), a midbrain arteriovenous 
malformation (Goadsby, 2002a) and a brainstem cavemoma (Afridi and Goadsby, 2003) 
have been reported to produce migraine-like headaches.
Migraine and MRI
Cao et al (Cao et al., 2002) used functional MRI-BOLD in a series of patients with 
visually-triggered migraine, and showed increased signal in the red nucleus and 
substantia nigra before occipital cortex signal elevation or the onset of visually triggered 
symptoms in 75% of the patients. Having previously documented bilateral activation of 
these areas in spontaneous migraine with aura (Welch et al., 1998), they concluded that 
these brainstem structures are part of a neuronal network in the brainstem which initiates 
the migraine attack. Studies using high-resolution MRI to measure iron homeostasis in 
the PAG found that it was selectively, progressively and persistently impaired in patients 
with episodic migraine and chronic migraine, thus emphasising the role of the PAG as a 
possible generator of migraine attacks, potentially by dysfunctional control of the 
trigeminovascular nociceptive system (Kruit et al., 2002; Welch et al., 2001)
23.2 Cluster Headache
The stereotypical attacks of unilateral pain with associated cranial autonomic symptoms, 
lasting 15-180 minutes (Headache Classification Committee of The International 
Headache Society, 2004) should make CH relatively easy to identify, but many go 
undiagnosed and suboptimally treated (Bahra and Goadsby, 2004). One reason for this is 
that until recently, there has been little known of the pathophysiology of these headaches. 
Given the strong circadian rhythmicity of the headache attacks (Russell, 1981), and the 
often seasonal variation of the bouts of episodic CH (Kudrow, 1987), it has been 
suggested that a central neuronal origin such as the hypothalamus may be the generator of 
the headaches (Cohen and Kaube, 2005; Goadsby, 2002b).
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Cerebral Blood Flow Imaging and Cluster Headaches
Various studies have been performed including SPECT and Xe inhalation (Krabbe et 
al., 1984; Nelson et al., 1980; Norris et al., 1976), and have shown heterogeneous results, 
with reports of high, or low, or no change, in cortical blood flow. Methodological 
differences probably account for these conflicting results. A single photon emission 
tomography (SPET) study (Di Piero et al., 1997) showed altered responses in rCBF in 
CH sufferers, which may reflect a marker of the biological modification of the pain 
system. These occurred even out of the cluster headache bout, and therefore were 
proposed to indicate the involvement of central tonic pain mechanisms in the 
pathogenesis of CH.
PET studies and CH
In a small study, Hsieh at al (Hsieh et al., 1996a) reported activation in the non-dominant 
anterior cingulate cortex (ACC) in nitroglycerin-induced CH attacks; as would be 
expected, since in most human PET studies of pain, activation of this region is observed, 
perhaps as a part of the affective response (Derbyshire et al., 1997). In a larger series 
there was activation ascribable to the acute CH induced by nitroglycerin in the ipsilateral 
posterior hypothalamic grey matter, when compared to the headache-free state (May et 
al., 1998a). This highly significant activation was not seen in cluster headache patients 
out of the bout when compared to patients experiencing an acute attack (May et al.,
2000). Moreover, there was no change in the brainstem, midbrain or pons, as has been 
reported for migraine. In one patient with both CH and migraine, whose attack was 
captured by PET, the phenotype of the attack (migraine without aura) matched the 
functional activation result (pontine change) without any hypothalamic activation (Bahra 
et al., 2001). This makes the point that although migraine and CH may share a common 
pain pathway, the trigeminovascular innervation, their underlying pathogeneses are 
probably significantly different, as indicated by their different clinical phenotypes and 
responses to preventive medications (Goadsby, 1997b; Lance and Goadsby, 2005).
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Furthermore no hypothalamic activation was seen in experimental pain induced by 
capsaicin injection into the forehead (May et al., 1998b), which would activate first 
division (ophthalmic) afferents that are the trigeminal division predominantly responsible 
for pain activation in cluster headache. This plus the strong circadian and seasonal 
rhythmicity, implies that the hypothalamus is the primary generator of the cluster 
headache attacks, rather than simply representing a response to pain in the first trigeminal 
division.
A PET study showed posterior hypothalamic activation during a spontaneous CH attack 
in a patient who had undergone stereotactic deep brain hypothalamic stimulation, after 
the stimulator was switched off (Sprenger et al., 2004). The beneficial effect of 
hypothalamic stimulation in intractable CH has strengthened the clinical role of the 
hypothalamus in these syndromes (Franzini et al., 2003; Leone et al., 2004a; Schoenen et 
al., 2005).
Morphometric Studies
A fundamental tenet of primary headache syndromes is the view that they are due to 
abnormal brain function with normal brain structure. Voxel-based morphometry (VBM) 
is an automated non-biased whole brain technique which analyses changes in brain 
structure (Ashbumer and Friston, 2000). Used to study the structure of brains in patients 
with cluster headaches, a significant structural difference in grey matter corresponding to 
an increase in volume in the ipsilateral posterior hypothalamic grey was noted, when 
compared to healthy volunteers (May et al., 1999a). This provides further co-localisation 
of morphometric and functional changes to the hypothalamus which has been previously 
considered on clinical and neuroendocrine grounds to be specific to cluster headache. A 
decrease in grey matter was found in patients with chronic tension type headache in the 
dorsal rostral and ventral pons, the anterior and posterior cingulate cortices, the anterior 
and posterior insulae, the posterior temporal lobe, the orbitofrontal cortex and 
parahippocampus and the cerebellum (Schmidt-Wilcke et al., 2005). It is interesting to 
note that there have been no such changes observed in the same study in patients with
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medication overuse and a history of migraine. In a separate study using VBM in 
migraine, no changes in the structure of the brain were noted (Matharu et al., 2003b).
2.3.3 Other Trigeminal Autonomic Cephalgias
The involvement of trigeminal pathways in PH and SUNCT, and particularly the episodic 
nature, unilaterality and autonomic features in SUNCT similar to those in CH, have led to 
investigations into elucidating a common neural pathogenesis for the TACs, likely the 
hypothalamus.
A study involving transcranial Doppler ultrasonography demonstrated an 
interhemispheric asymmetry in blood flow velocity in the middle cerebral artery, with 
vasodilation coinciding with attack onset (Poughias and Aasly, 1995). However SPECT 
analysis demonstrated normal tracer uptake and symmetrical hemispheric perfusion. It 
was thought that the brevity of the attacks in SUNCT probably did not allow rCBF 
differences to be established. In contrast, using fMRI in 6 consecutive spontaneous pain 
attacks in a patient with SUNCT, activation was seen in the ipsi lateral inferior posterior 
hypothalamic grey when compared to the resting state (May et al., 1999b). The BOLD 
contrast signal closely tracked the patient’s reported pain which came in attacks every 2-3 
minutes. The activation in the hypothalamus was seen solely in the pain states as was 
activation bilaterally in the thalamus and insulae. These results further suggest that 
trigeminal activation can be associated with cranial autonomic activation as a clinical 
characteristic of primary headaches (Goadsby, 2001b). Bilateral hypothalamic activation 
has been detected on fMRI in SUNCT (Sprenger et al., 2005), and the hypothalamus has 
also been reported in a TAC not otherwise specified, but likely to be longer-lasting 
attacks of SUNCT (Sprenger et al., 2004b). This has proven to be of clinical use, as deep 
brain hypothalamic stimulation has relieved a case of drug-resistant SUNCT (Leone et 
al., 2005).
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As the hypothalamic activation was in the same area as was demonstrated to be active in 
cluster headache patients, this may suggest a common pathophysiological substrate 
between these two syndromes.
A PET study in PH reported activity in the contralateral posterior hypothalamus and the 
ventral midbrain, extending over the red nucleus and substantia nigra, in association with 
the headache attacks (Matharu et al., 2006b). There was also persistent activation of the 
pain neuromatrix such as cingulate cortices, insulae, primary and secondary 
somatosensory cortices, frontal cortices including the premotor and supplementary motor 
area temporal cortices, basal ganglia and the cerebellum, during the acute PH attacks and 
the interictal pain-free state when off indomethacin, which were deactivated by the 
administration of indomethacin.
2.3.4 Hemicrania Continua
Hemicrania continua, which is neither migraine nor currently classified as a TAC, shares 
symptoms of both. HC is a strictly unilateral, continuous headache of moderate intensity, 
with superimposed exacerbations of severe intensity that may be accompanied by 
trigeminal autonomic features and migrainous symptoms. A complete response to 
indomethacin is a prerequisite for diagnosis by the revised IHS classification criteria 
(Headache Classification Committee of The International Headache Society, 2004). A 
recent PET study in HC demonstrated activation of the contralateral posterior 
hypothalamus, which correlates with hypothalamic activation in CH and the TACs, and 
also in the dorsal rostral pons, ventrolateral midbrain (extending over the red nucleus and 
substantia nigra) and pontomedullary junction (Matharu et al., 2004c). The ipsilateral 
dorsal pontine locus correlates with those previously found to be active in migraine 
(Bahra et al., 2001; Matharu et al., 2004a). Therefore it can be deduced from clinical and 
imaging evidence that HC may represent an overlapping of these two syndromes, or even 
a distinct syndrome with phenotypic overlay reflected in the areas of brain activation. Its 
absolute response to indomethacin, a similarity shared with PH, may in part be due to the
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activation of the ventral midbrain, red nucleus and substantia nigra, which is active in the 
painful phases in both conditions and inactive after treatment with indomethacin.
2.4 Brainstem activation
Brainstem activation in functional imaging studies of head pain, hitherto, seemed specific 
for migraine, given that it had not been observed in acute CH (May et al., 1998a),
SUNCT syndrome (May et al., 1999b), atypical facial pain (Derbyshire et al., 1994) and 
experimentally-induced facial pain (May et al., 1998b). However brainstem activation has 
been recently reported in cluster headache (Sprenger et al., 2004a), although a 
significance analysis was not performed on this region.
In terms of non-headache pain, evidence from both human and animal studies has 
demonstrated a key role for brainstem centres in the control of ascending nociceptive 
input (Brooks and Tracey, 2005). The PAG is also known to have an inhibitory effect on 
the nociceptive response to trigeminovascular activation (Knight et al., 2005). The PAG 
and the rostral ventromedial medulla have been shown to be active during somatic and 
visceral pain, with the PAG activity correlating with the subjects’ anxiety (Dunckley et 
al., 2005b). Activity in the mesencephalic reticular formation in the region of the nucleus 
cuneiformis and PAG was demonstrated in allodynia (Petrovic et al., 1999) and a 
paradigm of somatic secondary hyperalgesia (Zambreanu et al., 2005).
Further studies will help to elucidate whether this region is indeed specific for migraine, 
or whether it has a more general role in the modulation of nociceptive traffic. Given the 
primary inhibitory role of the PAG in modulating trigeminovascular nociception (Knight 
et al., 2002; Knight and Goadsby, 2001), it may be that a dysfunction within the PAG, 
such as the P/Q-type calcium channels that are dysfunctional in familial hemiplegic 
migraineurs (FHM) (Ophoff et al., 1996), may cause a reduction in the PAG-mediated 
antinociceptive effect and a heightened pain state as seem in migraine. This would 
correlate with the finding of pontine activation with deactivation in the contralateral pons 
during migraine (Afridi et al., 2005b); it may be that the nociceptive inhibitor is
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hypofunctioning on one side. Other areas of the brainstem suggested to be involved in 
migraine, namely the locus ceruleus and dorsal raphe, form part of the antinociceptive 
network and are involved in cerebrovascular control (Lance et al., 1983). The 
serotonergic and noradrenergic systems are also involved in the modulation of cortical 
activity and attentiveness to environmental stimuli (Parvizi and Damasio, 2003). This 
may help to explain the so-called associated symptoms of migraine, such as photophobia 
and phonophobia (Afridi et al., 2005b).
2.5 The Hypothalamus, CH and TACs
The striking circadian and circannual periodicity in CH implicates a role for the 
suprachiasmatic nucleus of the hypothalamic grey matter, which is the area involved in 
the human biological clock system (Albers et al., 1984; Moore-Ede, 1983). The 
hypothalamus is known to regulate circadian (and seasonal) rhythms, through the 
suprachiasmatic nucleus (SCN) (Ralph et al., 1990), with information about the level of 
ambient light through the retino-hypothalamic tract (Reppert and Weaver, 2002). Photic 
information relayed from the SCN to the pineal gland is closely reflected there in the 
secretion of melatonin, which is low during the day and increases during the hours of 
darkness (Brzezinski, 1997; Utiger, 1992).
Neuroendocrine studies provided the first evidence of deranged hypothalamic function in 
CH. It was initially demonstrated that plasma testosterone concentrations were altered 
during the CH period in men (Kudrow, 1976). Subsequently, it has been observed that 
there are abnormalities in the secretion of melatonin and cortisol, alterations in the 
secretion of luteinising hormone and prolactin, and altered responses of luteinising 
hormone, follicle stimulating hormone, prolactin, growth hormone, and thyroid 
stimulating hormone to challenge tests in patients with CH (Leone and Bussone, 1993). 
Treatment with melatonin reduced headache frequency in episodic (Leone et al., 1996), 
and chronic CH sufferers (Peres and Rozen, 2001), and high-dose steroids can have a 
beneficial effect in CH (Antonaci et al., 2005; Couch and Ziegler, 1978). These 
treatments may be addressing the imbalance in melatonin and cortisol secretion,
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respectively. A male patient with SUNCT with low serum testosterone had beneficial 
effects on treatment with clomiphene, which raised his testosterone levels (Rozen et al.,
2005). It was postulated by the authors that the clomiphene acted directly on 
hypothalamic oestrogen receptors to modulate hypothalamic activity and thus suppress 
SUNCT attacks.
Deep brain electrical stimulation of the posterior hypothalamus has had beneficial effects 
in both intractable CH (Leone et al., 2004a) and SUNCT (Leone et al., 2005). Moreover, 
observations from psycho-surgery suggest that stimulation of the posterior hypothalamic 
region initially produces agitation and restlessness, and necessitates a general anaesthesia 
(Bejjani et al., 2002; Sano et al., 1970). This is a remarkable observation given that such 
behaviour is typical in up to 93% of patients’ acute cluster headache attacks (Bahra et al., 
2002). Taken together, the clinical observations, neuroendocrine studies, functional and 
structural imaging data, and the neuromodulation studies strongly suggest a pivotal role 
for the hypothalamus in CH.
However, in functional imaging studies and deep brain stimulation, the area activated and 
stimulated is the posterior hypothalamus, which is anatomically distinct from the 
suprachiasmatic nucleus. This, together with the mechanism by which the hypothalamic 
activation may induce pain, gives rise to the question that hypothalamic activation may 
not be the direct perpetrator of the painful attacks. The issue then remains: functional 
imaging demonstrates hypothalamic activation during attacks of these headaches, but this 
may be an association rather than a direct causation, and the hypothalamic link between 
the attacks and sleep may not be as direct as previously thought.
The hypothalamus may play a role in other headache syndromes such as migraine. It has 
been noticed that 55-63% of migraine sufferers can be woken at night or in the morning 
with headache (Galego et al., 2002), and migraine patients prior to an attack may show 
sleep disturbances (Goder et al., 2001), changes of wakefulness and alertness (Dalkvist et 
al., 1984), as well as changes of appetite (Blau, 1980), which would all implicate 
hypothalamic involvement. Furthermore there is biochemical (Peres et al., 2001) and
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functional imaging (Denuelle et al., 2004) evidence for hypothalamic involvement in 
migraine. Thus the delineation between migraine and TACs in terms of brainstem or 
hypothalamic function, and also the role of the hypothalamus in different headache 
syndromes with varying degrees of circadian rhythm, needs to be elucidated.
Activation in the region of the hypothalamus has been reported in other pain studies 
(Ingvar, 1999; Jones et al., 2003; Kupers et al., 2000; Sanchez del Rio and Alvarez 
Linera, 2004), not specifically head pain. Significant hypothalamic activation has been 
reported in experimental arm pain (Hsieh et al., 1996a) and anginal pain (Rosen et al., 
1994), although there was no significant difference between painful and painless 
myocardial ischaemia (Rosen et al., 1996). A single case report PET study on a patient 
with neuropathic facial pain treated with thalamic stimulation for pain control showed 
hypothalamic activation when scans of the painful state were contrasted with the pain- 
free state immediately after stimulation; post-stimulation analgesia has been attributed to 
activation of central structures beyond the stimulation period (Linderoth, 2002; Roberts 
and Rees, 1986), making the significance of the hypothalamic activation hard to interpret. 
Several studies of acupuncture stimulation at analgesic points in pain-free volunteers 
have reported hypothalamic activation (Hui et al., 2000; Wu et al., 1999; Wu et al.,
2002). It is noted that the hypothalamic area activated in all these studies is a different 
area than that reported in CH (May et al., 1998a).
It is interesting to observe that the clinical feature that is common to the four primary 
headache syndromes in which posterior hypothalamus activation has been reported (i.e. 
PH, CH, SUNCT and HC) is prominent cranial autonomic features in association with the 
headache. It has been suggested that the pathophysiology of these syndromes revolves 
around the trigeminal-autonomic reflex (Goadsby and Lipton, 1997). There is 
considerable experimental animal literature to document that stimulation of trigeminal 
efferents can result in cranial autonomic outflow, the trigeminal-autonomic reflex (May 
and Goadsby, 1999). In fact, some degree of cranial autonomic symptomatology is a 
normal physiologic response to cranial nociceptive input (Frese et al., 2003; May et al.,
2001) and patients with other headache syndromes, such as migraine, may report these
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symptoms (Barbanti et al., 2002; Benoliel and Sharav, 1998). .The distinction between 
these and other headache syndromes is the degree of cranial autonomic activation. It has 
been suggested that the cranial autonomic symptoms may be prominent in these 
syndromes due to a central disinhibition of the trigeminal-autonomic reflex by the 
hypothalamus (Benjamin et al., 2004). Indeed there are direct hypothalamic-trigeminal 
connections (Malick and Burstein, 1998), and the hypothalamus is known to have a 
modulatory role on the nociceptive and autonomic pathways, specifically 
trigeminovascular nociceptive pathways (Bartsch et al., 2004). Hence, the posterior 
hypothalamic activation observed in this study provides further support for the notion that 
this structure may have a crucial role in the pathophysiology of TACs and HC (May and 
Goadsby, 1999).
How do these data inform the role played by posterior hypothalamic activation observed 
in TACs and HC? The weakness of functional imaging techniques is that they provide 
regions of significant change on brain volumes without directional information about the 
ascending or descending nociceptive inputs from which these changes result (Jones et al.,
2003). They can, therefore, only be interpreted with reference to clinical, anatomical, 
biochemical, electrophysiological and pharmacological studies derived from animal and 
human studies. With the currently available data on these syndromes, it remains 
inconclusive whether the posterior hypothalamic activation is central or epiphenomenal 
to the pathophysiology of the TACs.
2.6 Experimental Head Pain
The PET study by May et al in nitroglycerin-induced CH attacks (May et al., 1998a) 
reported activation in areas which fell into three categories: the hypothalamus which is 
specific to CH attacks, areas generally associated with pain, and vascular structures. The 
areas associated with pain were the non-dominant ACC, the frontal cortex and insulae, 
and the ventroposterior thalamus contralateral to the side of the pain.
The same group investigated healthy males with no history of headache, during an 
experimental pain state by injecting capsaicin subcutaneously in the forehead to evoke a
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painful sensation in the first division of the trigeminal nerve (May et al., 1998b). During 
the acute pain state compared to the resting state, increases in rCBF were found 
bilaterally in the anterior insula, the contralateral thalamus, the ipsilateral anterior 
cingulate cortex and bilaterally in the cerebellum. Activation of the ACC has been 
repeatedly reported in PET studies on the sensation of somatic or visceral pain and 
attributed to the emotional response to pain (Casey et al., 1994; Hsieh et al., 1996a; Jones 
et al., 1992). Activations in the insula have been demonstrated in previous studies 
following application of heat (Casey et al., 1994; Coghill et al., 1994), subcutaneous 
injection of ethanol (Hsieh et al., 1996b), somatosensory stimulation (Burton et al.,
1993), and during cluster headache (Hsieh et al., 1996a) and atypical facial pain 
(Derbyshire et al., 1994). The insula is known to be involved in the regulation of 
autonomic responses, and has been suggested to relay information to the limbic system 
(Mesulam, 1985). Activation of the contralateral thalamus due to pain is known from 
experimental animals (Goadsby, 1997a) and functional imaging studies in humans (Casey 
et al., 1994; Davis, 2000; Derbyshire et al., 1994). However there was no activation 
reported in the capsaicin-induced pain in the brainstem, as compared to spontaneous 
migraine (Weiller et al., 1995), or in hypothalamus as in nitroglycerin-induced CH attack 
(May et al., 1998a). This confirms that the activations seen in these primary headache 
syndromes are specific to these syndromes and not purely as a result of first division 
trigeminal pain.
A functional MRI study to compare facial pain representation for different divisions of 
the trigeminal nerve showed activation in contralateral somatosensory cortices, with 
bilateral activation for Vj (ophthalmic) division pain, but there was no mention of change 
in brainstem or hypothalamic activity (Iannetti et al., 2003).
2.7 Magnetic Resonance Spectroscopy
Magnetic resonance spectroscopic (MRS) studies have arisen in migraine on the basis of 
evidence of abnormal cortical information processing in electrophysiological studies 
(Afra et al., 1998; Wang et al., 1996), and decreased mitochondrial energy reserve from
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MRS studies in migraine with (Barbiroli et al., 1992; Welch et al., 1989) and without aura 
(Montagna et al., 1994). 31Phosphorus MRS can ascertain abnormalities in energy 
metabolism as reduced levels of phosphocreatine, reduced cellular-free energy and 
increased rate of adenosine triphosphate (ATP) biosynthesis. Abnormalities in energy 
metabolism were found interictally, and not necessarily selective to brain but also in 
extraneural tissues such as muscle (Montagna, 1995; Montagna et al., 1994). The authors 
concluded that these abnormalities in energy metabolism, particularly a generalised 
disorder of mitochondrial oxidative phosphorylation, predisposed migraineurs to develop 
an attack triggered by conditions of increased brain energy demand.
Proton MRS has also shown metabolic abnormalities in migraineurs, with high lactate 
levels in the interictal period (Watanabe et al., 1996), thus suggesting that anaerobic 
glycolysis occurs in the brains of patients with migraine during the interictal period, 
although a long attack-free period could normalise the subclinical disturbance. It has been 
suggested (Schoenen, 1994; Schoenen, 1998) that as well as reduction in mitochondrial 
energy reserve, a reduced habituation of information processing may cause excessive 
cortical activation. These two mechanisms may induce biochemical shifts, leading 
possibly via cortical spreading depression (Bolay et al., 2002), to migraine attacks by 
means of activation of the trigeminovascular system (Moskowitz et al., 1993). Clinically 
the schema of aura triggering migraine headaches seems unlikely (Goadsby, 2001a).
A recent study using functional magnetic resonance spectroscopic imaging showed high 
baseline levels of lactate in the occipital region, and an abnormal response to visual 
stimulus in patients with migraine with visual and motor or sensory aura (Sandor et al., 
2005b). This would be compatible with an abnormal metabolic strain during stimulation, 
possibly due to dishabituation, and a predominant mitochondrial dysfunction in migraine 
with aura.
Mitochondrial impairment has been shown in proton spectroscopy of skeletal muscle in 
migraine and cluster headache (Lodi et al., 1997), and in cluster headache brains (Lodi et 
al., 1997; Montagna et al., 1997). A reduction in free magnesium was found in brains of
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migraine and CH patients, with the greatest reduction in keeping with the severity of the 
clinical state in migraine (Lodi et al., 2001). The authors concluded that this was 
secondary to the bioenergetics deficit in tissues with mitochondrial dysfunction.
Mitochondrial dysfunction has also been suggested by the response by migraine patients 
to riboflavin prophylaxis (Schoenen et al., 1994), the nitric-oxide scavenger 
hydroxycobalamin (van der Kuy et al., 2002), Coenzyme Q (Sandor et al., 2005a), and 
magnesium (Peikert et al., 1996), although a recent trial showed no statistical difference 
between riboflavin and magnesium and placebo (Maizels et al., 2004). These all point to 
the suggestion that abnormalities in energy metabolism predispose migraine and cluster 
headache sufferers to develop an attack under conditions of increased energy demand, 
and that treatment with protagonists of the cellular respiratory cycle, such as the 
aforementioned vitamins, may be effective by reducing the oxidative stress (Montagna,
2002). High-flow oxygen, which is effective in the abortive treatment of CH (Fogan, 
1985; Kudrow, 1981), and in hyperbaric pressures in migraine with aura (Wilson et al.,
1998), may exert a therapeutic effect reducing oxidative stress and promoting cellular 
respiration.
2.8 Functional or Metabolic Abnormality?
The presence of mitochondrial abnormalities suggests a hereditary component to 
migraine. A multinational study of sets of twins indicates a contribution of genes to the 
liability of migraine (Mulder et al., 2003). Indeed the genetics of migraine, mainly 
familial hemiplegic migraine, are well documented (De Fusco et al., 2003; Dichgans et 
al., 2005; Haan et al., 2005; Ophoff et al., 1997; Ophoff et al., 1996; Terwindt et al.,
1998). Cluster headache has also been reported with family histories, although to a lesser 
extent than migraine (Leone et al., 2001; Russell, 2004; Russell et al., 1996; Russell et 
al., 1995a; Russell et al., 1995b). There have also been reports of family histories in PH 
(Cohen et al., 2006) and SUNCT (Gantenbein and Goadsby, 2005).
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This has to be reconciled with the functional imaging work showing activation of 
brainstem structures in migraine, and hypothalamus in the TACs. It is possible in 
migraine that an external trigger may cause an oxidative stress in an already 
metabolically hypofunctioning brain. The attack itself will be generated or facilitated 
through the brainstem and dorsal rostral pons, leading to more widespread changes, 
especially in the occipital region with visual auras, as the attack develops.
Functional imaging shows only an association between the activation in a particular area 
and the clinical features at that time. In CH, it is possible that the hypothalamic activity 
seen on functional imaging may not be a direct generator of the CH attacks, and that an 
abnormality in hypothalamic function facilitates a cascade of metabolic and other 
biochemical events, including deranged melatonin, cortisol and 5HT metabolism (Cohen 
and Kaube, 2005), which in turn would trigger an attack in a brain already compromised 
by abnormal metabolic activity.
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Chapter 3 
Aims and Objectives
This project is a set of studies to explore aspects of TACs as primary headache 
syndromes, with an emphasis on SUNCT and SUNA, from a phenotypical, treatment and 
functional imaging point of view.
3.1 Phenotype of SUNCT and SUNA
The aim of this prospective study is to ascertain and further clarify the clinical and 
phenotypic characteristics of SUNCT and SUNA, in terms of the International Headache 
Society Classification of these syndromes (Headache Classification Committee of The 
International Headache Society, 2004), and to make comments about these syndromes 
based on a large clinical population of 52 patients with SUNCT and SUNA.
3.2 Treatment of SUNCT and SUNA
The aim of this study was to record and assess the response of a large clinical population 
of patients with SUNCT and SUNA to medications and treatments. These included:
1) abortive attack therapies: inhaled oxygen, intranasal lidocaine and subcutaneous 
sumatriptan
2) short-term preventive therapies:
a. intravenous lidocaine and intramuscular indomethacin
b. a single-blinded placebo-controlled indomethacin test (the modified 
Indotest) was performed in 14 patients
3) preventive therapies:
a. double-blind placebo controlled trial of lamotrigine
b. double-blind placebo controlled trial of topiramate
c. open-label trials of lamotrigine, topiramate, gabapentin, carbamazepine, 
and others including other neuromodulators, melatonin, verapamil,
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corticosteroids, non-steroidal anti-inflammatory drugs, adrenoreceptor 
blockers, serotonergic agonists and antagonists, tricyclic antidepressants 
and lithium
4) non-pharmacological interventions:
a. greater occipital nerve injections
b. local nerve blockades
c. invasive surgical procedures involving the trigeminal nerve.
3.3 Functional Imaging in SUNCT and SUNA
The aim of this study was to elucidate the involvement of the hypothalamus in SUNCT 
and SUNA, by means of functional magnetic resonance imaging and voxel-based 
morphometry.
The hypotheses are:
1) there is activation in the region of the posterior or anterior hypothalamus during 
attacks of SUNCT and SUNA
2) this activation increases in correlation with the level of severity of the pain
3) there is a structural difference in grey matter in the region of the hypothalamus 
between SUNCT/SUNA patients and healthy controls, as measured by voxel- 
based morphometry.
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PART II. CLINICAL STUDIES IN SUNCT AND SUNA 
Chapter 4 
Clinical Studies in SUNCT and SUNA
4.1 Introduction
SUNCT, Short-lasting Unilateral Neuralgiform headache attacks with Conjunctival 
injection and Tearing, is a rare primary headache syndrome first described in 1978 
(Sjaastad, 1978). The syndrome has been described more fully over subsequent years 
(Pareja and Sjaastad, 1997; Sjaastad et al., 1989), although only in small series. It has 
been suggested that it be grouped together with cluster headache and paroxysmal 
hemicrania as a Trigeminal Autonomic Cephalgias (TACs) (Goadsby and Lipton, 1997) 
based on the now classical clinical combination of head pain and activation of cranial 
autonomic efferents (May and Goadsby, 1999). The syndrome was included in the second 
edition of the International Headache Classification (Headache Classification Committee 
of The International Headache Society, 2004), as was a syndrome of SUNA: Short- 
lasting Unilateral Neuralgiform Headache attacks with cranial Autonomic features. Here 
the first substantial series of patients with SUNCT or SUNA are described in an attempt 
to define these conditions better.
4.2 Methods
This study prospectively addresses the clinical characteristics of the syndrome, the 
management strategies used, including pharmacological manipulations as diagnostic 
tests, acute abortive therapies, short-term preventive therapies, and outpatient preventive 
therapies. Most of the preventive medications were given as open-label trials, as patients 
were generally unwilling to participate in placebo-controlled trials, given the option of
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receiving an active drug for their extremely painful conditions which had hitherto been 
inadequately treated.
Another observation was the time taken from the start of the symptoms to the actual 
diagnosis of SUNCT and SUNA, the number and types of practitioners whom the 
patients had seen prior to the final diagnosis, and other diagnoses which had been made, 
as this would influence the types of treatments which the patients would have received 
during the course of their illness.
The study group was taken from patients attending the outpatient clinics at the National 
Hospital for Neurology and Neurosurgery, between 1995 and 2005. Some were seen 
further when admitted for inpatient investigations. Most patients (49/52) were contacted 
by telephone after giving their written consent, or gave their consent in the clinic 
appointment. Of the remaining 3 patients, one contacted the National Hospital by phone 
directly, and the other two were lost to followup and their medical notes provided the 
source of information. The study was approved by the National Hospital for Neurology 
and Neurosurgery and Institute of Neurology Joint Research Ethics Committee (ref 
03/N107).
4.2.1 Clinical Study of Phenotype of SUNCT and SUNA
In the course of the history taking, for the Phenotype study, each patient was asked the 
same questions about their SUNCT/SUNA: the side, site and character of their pain; 
duration, frequency and periodicity of their attacks; triggering and relieving factors; the 
duration of their symptoms, number and types or practitioners seen prior to diagnosis, 
personal and family history of headache, and any other medical problems.
The patients’ notes were also used for information about previous diagnoses and imaging 
reports. Where possible relatives, particular partners, were questioned regarding the 
presence or absence of clinical features during the acute attacks.
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4.2.2 Clinical Study of Treatment of SUNCT and SUNA
SUNCT has until recently been considered refractory to treatment. However it has now 
been shown in open-label trials that neuromodulatory treatments such as lamotrigine 
(D’Andrea et al., 1999a; D1 Andrea et al., 2001; Gutierrez-Garcia, 2002; Leone et al., 
2000b; Malik et al., 2002), carbamazepine (Matharu et al., 2003a; Matharu et al., 2004b), 
topiramate (Kuhn et al., 2005; Matharu et al., 2002; Matharu et al., 2004b; Rossi et al.,
2003), and gabapentin (Graff-Radford, 2000; Hunt et al., 2002; Porta-Etessam et al., 
2002) have been successful in the preventive treatment of some cases of SUNCT.
For the Treatment study, each patient was asked the same questions about their response 
to medications and the Modified Indotest (lOOmg intramuscularly with a blinded placebo 
control); their responses to non-pharmacological treatments; previous medications, 
current medications, doses, effects and side effects; and also non-pharmacological 
procedures and alternative therapies. They were asked to categorise the effect of each 
treatment as one of the following:
1) ‘none’- no beneficial effect on their symptoms, or making their symptoms worse
2) ‘mild’ -  a mild effect on their symptoms but not substantially improved
3) ‘moderate’- a substantial improvement in their symptoms but the attacks were not 
entirely suppressed
4) ‘good’- entire suppression of the attacks
The patients’ notes were also used for information about response to medications.
Some patients (10 with SUNCT and 5 with SUNA) were admitted to the National 
Hospital for Neurology and Neurosurgery for investigation and therapeutic trials of acute 
abortive and short-term preventive therapies.
Acute abortive therapies:
1) Oxygen delivered at high dose and flow (100% at 9-12 litres/min for 15 minutes), 
through a standard non-rebreathable mask with the air vents taped up to increase
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oxygen concentration. One patient also had low flow oxygen (4 litres/ minute) 
under the care of other doctors, and the response was reported here.
2) Intranasal lidocaine 4% delivered to the ipsilateral nostril.
3) Sumatriptan 6mg subcutaneously, or 20mg intranasally. Some patients also had 
oral triptans as abortive therapy as outpatients. These were sumatriptan, 
rizatriptan and naratriptan, at unknown doses, which were taken previously, and 
their effects were reported by the patients.
Short-term Preventive Therapies:
1) Modified Indotest (Matharu et al., 2004b); lOOmg indomethacin intramuscularly 
on one day, with saline placebo injection on another day, in a blinded fashion. The 
treatments were given in a random order from patient to patient. Each patient kept 
a diary as to the frequency and severity of the attacks over those days.
2) Intravenous lidocaine as a solution in 500ml of 5% dextrose with 2g lidocaine. 
This was infused at 15-45 ml/hour, which is a rate of 1.5-3.5 mg/kg/hour, starting 
at the lower infusion rate and increasing on a daily basis, depending on the 
patient’s response in terms of reduction of attacks and side effects. The infusion 
rate was stopped at whatever dose either reduced the attacks considerably, or until 
side effects intervened. Each patient was attached to a cardiac monitor for the 
duration of the infusion in case of cardiac arrhythmia. The patient kept a diary as 
to the frequency and severity of the attacks during the course of the infusion, and 
for the duration of the painfree period.
Triggering
Amongst the patients admitted to hospital, 6 SUNCT and 2 SUNA patients received 
glyceryl trinitrate (GTN) by sublingual spray, on two occasions each, and were observed 
for the immediate onset of an attack, either of SUNCT/SUNA, or of other headaches in 
those patients with concomitant migraine.
68
4.3 Analysis of Results
All results were all collated on a Microsoft Excel® spreadsheet.
Phenotype of SUNCT and SUNA
The following categories were explored:
Epidemiology
1) Number of patients with SUNCT and those with SUNA
2) Epidemiological factors- age, gender
3) Age at onset of the symptoms and duration of symptoms
4) Time taken to final diagnosis and previous diagnoses
5) Precipitating events in the three weeks prior to their attacks commencing (this 
differs from the International Headache Society criteria which require the 
headache to be present at most 7 days after the traumatic event in order to qualify 
as post-traumatic headache (Headache Classification Committee of The 
International Headache Society, 2004)
6) Personal or family history of migraine
Phenotype
7) Laterality and site of the attacks
8) Autonomic symptoms and their association with the site of pain
9) Type and severity of pain. The patients were asked to rate the severity of their 
attacks on a verbal rating scale (VRS) of 0 to 10, 0 being no pain at all, and 10 
being the most severe pain imaginable, as has been used in migraine studies (de 
Tommaso et al., 2005; Iversen et al., 1989; Tvedskov et al., 2004)
10) Other symptoms, such as agitation, or migrainous symptoms such as worsening 
by movement, photophobia and phonophobia
11) Character of the attacks, length and frequency of the attacks
12) Diurnal variation of attacks
13) Triggering of attacks and refractory period between attacks
14) Periodicity and chronicity of the syndrome
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15) Background pain and analgesic overuse in relation to concomitant migraine 
biology
16) SUNCT and SUNA with abnormal examination and MRI findings- defined as 
symptomatic SUNCT and SUNA
Treatment of SUNCT and SUNA
For the acute abortive therapies, the primary endpoint for effectiveness was cessation of 
the attack of SUNCT and SUNA. A moderate effect in that the attack was shortened or 
the severity was reduced was also considered as ‘effective’. Minimal or no effects were 
considered as ‘ineffective’.
For the short-term preventive therapies, the primary endpoint for effectiveness was the 
suppression of attacks of SUNCT or SUNA for 12-24 hours following the Indotest, and 
for the duration of the lidocaine infusion up to several months afterwards. A moderate 
effect in that the attacks were reduced in frequency but not totally abolished was also 
considered as ‘effective’. No reduction in the frequency or severity of the attacks was 
considered as ‘ineffective’.
For the long-term preventive therapies, these were all done as outpatients and therefore 
the diary-keeping was less reliable than those done as inpatients. The primary endpoint 
for effectiveness was the suppression of attacks of SUNCT or SUNA whilst on a suitable 
dose of the preventive medication. A moderate affect in that the attacks were mostly 
suppressed, or that the medication was having a moderate effect at a suboptimal dose 
which could not be escalated because of side effects, was also considered as ‘effective’. 
Minimal or no effect on the frequency of attacks, or if the attacks were worsened or 
increased in frequency, was regarded as ‘ineffective’.
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Triggering
For the GTN triggering, a positive effect was the immediate triggering of an attack of 
SUNCT or SUNA.
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4.4 Double-blind, placebo-controlled crossover trial of topiramate in SUNCT
4.4.1 Introduction
Topiramate is a neuromodulator which is effective in the prevention of migraine as 
shown in placebo-controlled trials(Brandes et al., 2004; Silberstein et al., 2004) and 
compared to active treatment (Diener et al., 2004). Its efficacy has been shown in open- 
label trials in cluster headache (Forderreuther et al., 2002; Lainez et al., 2003; Mathew et 
al., 2002; Wheeler and Carrazana, 1999), although such a robust response has not been 
seen in all open-label trials (Leone et al., 2003a). There are isolated case reports of the 
effectiveness of topiramate in hemicrania continua (Matharu et al., 2006a) and 
paroxysmal hemicrania (Boes et al., 2003), (Cohen and Goadsby 2006, Paroxysmal 
hemicrania responding to topiramate; accepted for publication in Journal of Neurology 
Neurosurgery and Psychiatry, Appendix 2).
Topiramate has been reported to be effective in 6 SUNCT patients at doses up to 300mg 
daily (Kuhn et al., 2005; Matharu et al., 2002; Matharu et al., 2004b; Rossi et al., 2003), 
and ineffective in three patients (Black and Dodick, 2002; Koseoglu et al., 2005).
Topiramate is also used in the treatment of other painful conditions, including painful 
diabetic neuropathy (Pappagallo, 2003; Raskin et al., 2004). It has been reported as useful 
in intercostal neuralgia (Bajwa et al., 1999), and in a case series of trigeminal neuralgia 
(Zvartau-Hind et al., 2000), but not in a placebo-controlled study (Gilron et al., 2001).
There have been no double-blind placebo controlled trials of preventives in SUNCT or 
SUNA, largely because of the rarity of the disease and thus the paucity of patient 
numbers to enter a research trial. This study aimed to perform a randomised double-blind 
controlled trial in order to ascertain the effectiveness of topiramate in SUNCT.
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4.4.2 Methods
Five male patients (aged 51-72, mean 59.2 years) with SUNCT were recruited from the 
Outpatient department at the National Hospital for Neurology and Neurosurgery, London. 
They were diagnosed with SUNCT according to the classification criteria proposed by 
Goadsby and Lipton (Goadsby and Lipton, 1997), as the study was conducted prior to the 
International Headache Society classification (Headache Classification Committee of The 
International Headache Society, 2004). 2 of these had primary chronic SUNCT, 2 had 
episodic SUNCT, and one had secondary episodic SUNCT. One patient with primary 
chronic SUNCT had a histoiy of migraine and cluster headache, and has been previously 
reported as a case report (Empl et al., 2003). The clinical characteristics are given in 
Table 4.1. They gave their informed consent and were free to withdraw from the study at 
any time. The study was approved by the National Hospital for Neurology and 
Neurosurgery and Institute of Neurology Joint Research Ethics Committee (reference 
00/N072).
Table 4.1
Clinical characteristics of patients in topiramate study
Patient* Episodic or
chronic
SUNCT
Other
headaches
Mean duration 
SUNCT attack
Mean number 
of attacks/day 
untreated
#47 episodic nil 120 sec 45
#21 primary chronic nil 10 sec >100
#27 secondary
chronic
nil 5 sec 85
#34 primary chronic migraine with 
aura, cluster 
headache
l-300sec >100
#38 episodic episodic
migraine
60 sec 10
* Identification numbers refer to the entire cohort of SUNCT/SUNA patients reported in 
this series
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The design of the study was a randomised, double-blind, placebo-controlled crossover 
trial. The treatments were identical tablets labelled Treatment 1 and Treatment 2, to be 
taken in the first and second arm of the study respectively. The order of active treatment 
and placebo was randomised by the National Hospital’s pharmacy, and each participant 
was assigned a randomisation number. The code was held by the pharmacy until study 
completion and database locking.
Patients were required to withdraw from preventive medications prior to commencement 
of the study. After an initial washout drug-free period of 10 days, treatment was started at 
12.5mg nightly and increased every 5 days to a maximum of 50mg bd for 10 days, after 
which the dose was reduced over the next 10 days. A 10 day washout drug-free period 
followed, after which the patients commenced the second arm of the study in the same 
paradigm. The patients with episodic SUNCT started the 10 day washout period at the 
start of their bout.
The patients were instructed to keep a diary for the duration of the study, which 
documented the date, time, severity and duration of each attack.
4.4.3 Analysis of results
The primary endpoint was the reduction of attack frequency, as measured by the mean 
daily number of attacks during the 10 days at maximum dose as compared to the 10 drug 
free days pre-treatment. The results would be analysed on an n-of-1 basis. Given the large 
variability in numbers of attacks per day, the change in attack frequency was expressed as 
a percentage change. A positive result was declared if the attack frequency was reduced 
by 50% or more. A negative result was declared if the attack frequency was reduced by 
less than 50%, or indeed if it increased on the treatment as compared to the pre-treatment 
observation phase.
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A secondary endpoint was employed: the ‘attack load’; this is the number of minutes of 
pain per day for each patient. This would take into account the lengthening or shortening 
of duration of attacks, as these can be variable in SUNCT (see Chapter 5). It would also 
take into account other types of headache which were experienced during the treatment 
phases, such as migraine or cluster headache, which are also affected by topiramate 
(Brandes et al., 2004; Lainez et al., 2003; Silberstein et al., 2004). One patient (#4) had 
episodic migraine, and one (#8) had migraine and cluster headache as well as SUNCT.
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4.5 Double-blind, placebo-controlled trial of lamotrigine in SUNCT/SUNA 
4.5.1 Introduction
Lamotrigine is a relatively new anticonvulsant drug effective in partial and generalised 
tonic clonic seizures. Recently, lamotrigine given in an open-label manner at doses up to 
300mg a day has been reported to be highly efficacious in 10 patients with SUNCT 
(D'Andrea et al., 1999a; D1 Andrea et al., 2001; Gutierrez-Garcia, 2002; Leone et al., 
2000b; Malik et al., 2002), although it has been reported as ineffective in 4 patients 
(Black and Dodick, 2002; Matharu et al., 2004b; Sprenger et al., 2005), and ineffective at 
400mg a day in a patient with SUNCT related to trigeminal nerve compression (Koseoglu 
et al., 2005).
4.5.2 Methods
A double-blind, placebo-controlled crossover trial of lamotrigine in SUNCT/SUNA, at 
doses up to 200mg daily, was started. The trial had been approved by the National 
Hospital for Neurology and Neurosurgery and Institute of Neurology Joint Research 
Ethics Committee (REC No 02/N132). Patients gave their written consent and were free 
to withdraw from the trial at any time.
Patients were randomised to receive either lamotrigine or placebo first as Treatment 1. 
After a 2-week period on no medications, they were to take the medication starting at 
25mg daily for 2 weeks, and increasing by 25mg every week to a maximum of lOOmg 
twice a day for two weeks, and then reduce to zero over a period of 3 weeks. After a 2- 
week washout period, a crossover protocol was performed and the same regime was 
undertaken as Treatment 2 with either placebo or lamotrigine. Patients were asked to 
keep a diary from the beginning of the pre-treatment phase to the end of the second 
treatment, detailing the frequency, severity, duration of attacks, and attack load on a daily 
basis.
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4.5.3 Analysis of Results
The primary endpoint was the reduction of attack frequency, as measured by the mean 
daily number of attacks during the 10 days at maximum dose as compared to the 10 drug 
free days pre-treatment. The results would be analysed on an n-of-1 basis. Given the large 
variability in numbers of attacks per day, the change in attack frequency was expressed as 
a percentage change. A positive result was declared if the attack frequency or load was 
reduced by 50% or more. A negative result was declared if the attack frequency or load 
was reduced by less than 50%, or indeed if it increased on the treatment as compared to 
the pre-treatment observation phase.
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Chapter 5 
Results: Clinical Study of Phenotype of SUNCT and SUN A
5.1 Epidemiology
Of the 52 patients, 31 were male and 21 were female (male:female ratio of 1.5:1). Forty- 
three of these patients had SUNCT as defined by the International Headache Society 
(Headache Classification Committee of The International Headache Society, 2004), and 
nine had syndromes whose cranial autonomic symptoms did not include both 
conjunctival injection and lacrimation, and whose syndromes were better described as 
SUN A (Headache Classification Committee of The International Headache Society,
2004). It is not clear whether SUNCT is a sub-group of all SUNA, as suggested by the 
Classification Committee, or the two are separate. Here they are described separately to 
act as a basis for further research. Therefore SUNCT patients make up an 83 % subset of 
all SUNCT and SUNA. There were 28 male and 15 female SUNCT patients (male:female 
ratio 2:1), and three male and six female SUNA patients (male:female ratio 0.5:1).
5.2 Age of patients and duration of symptoms
At the time of interview, the mean age of patients was 57 years (range 32-87, median 58 
years). The mean age at onset of symptoms was 48 for SUNCT (range 19-75, median 48 
years). The mean age at onset of symptoms for SUNA was 44 (range 15-57, median 50). 
The mean duration of symptoms for SUNCT was 10 years (range 2-28 years, median 8 
years). The mean duration of symptoms for SUNA was 8 years (range 1-46 years, median 
3 years; Table 5.1). It took a mean 6.7 years (range 0.25-24) for SUNCT and mean 7.1 
years (range 1-46) for SUNA to be diagnosed. Previous diagnoses included trigeminal 
neuralgia, cluster headache, paroxysmal hemicrania, TAC otherwise unclassified, 
hemicrania continua, migraine, and others including stress, psychiatric conditions, 
shingles, seizures and Bell’s palsy. Three SUNA patients had original diagnoses of 
SUNCT before they were recognized as SUNA (Table 5.2).
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Table 5.1
Duration of symptoms and previous diagnoses
SUNCT SUNA SUNCT and SUNA
median age at onset (range) 48(19-75) 50(15-57) 48.5(15-75)
mean duration of symptoms 10 8 9
median duration (range) 8 (2-28) 3(1-46) 6(1-46)
Table 5.2
Diagnoses made prior to SUNCT/SUNA, and years to diagnosis
SUNCT 
n (%)
SUNA 
n (%)
TN 18(42) 1(11)
CH 11 (26) 1(11)
PH 4(9) 4(44)
TAC 6(14) 1(H )
HC 1(2) 1(11)
migraine 5 (12) 2(22)
other 13(30) K ID
SUNCT n/a 3(33)
years to diagnosis 6.7 7.1
median 5 2
range of years to diagnosis 0.25-24 1-46
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Some patients went into remission, especially those who had SUNCT or SUNA 
secondary to a precipitating cause which was treated. One patient (#37) had SUNCT 
secondary to a prolactinoma (Matharu et al., 2003c). His symptoms started 13 years 
previously and resolved on cabergoline therapy, so he had been pain free for the last 8 
years whilst on treatment and had not tried to stop the cabergoline to see if the attacks 
recurred. One patient with SUNA (#24) had 14 months of symptoms which then went 
into spontaneous remission, and she had remained pain free for 3.5 years at the time of 
interview.
53 Precipitating events
Seven patients with SUNCT and two with SUNA had precipitating events in the three 
weeks prior to their attacks commencing. These involved head or facial trauma in four 
cases, back trauma in one case, and viral infection, episode of extreme stress, analgesic 
withdrawal, and cabin pressure changes on an airline flight in each of the others (Table 
5.3). One patient (#2) had an episode of severe dizziness, ataxia and headache of sudden 
onset, which preceded his SUNCT attacks by a few weeks.
5.4 Laterality of attacks
Taking SUNCT and SUNA patients together, 20 (38 %) patients had attacks which were 
exclusively left-sided, and 22 (42 %) had exclusively right-sided attacks. Five had 
unilateral, side-variable attacks that affected the left more often than the right side, and 
three had unilateral, side-variable attacks that affected the right more often than the left. 
One SUNCT patient had unilateral attacks which could affect the left or right side in 
equal proportions, and one SUNCT patient had bilateral attacks. In SUNCT there were 
slightly more right than left sided attacks (47 % versus 33 %, respectively), whereas in 
SUNA there were more left than right sided attacks (67 % right, 22 % left; Table 5.4).
80
Table 53
Precipitating events
Patient Time to
Diagnosis Number Precipitating Event Attacks
SUNCT 10 glass bottle injury to ipsilateral side of face 7 days
52 fall onto face 1 day
17 ipsilateral dental root canal work 3 weeks
6 extreme stress- death of husband weeks
42 fall from a horse onto back same day
56 viral infection on return from Europe 2 weeks
21 withdrew analgesia for shoulder pain weeks
SUNA 1 flight from Turkey to the UK 2 weeks
26 bilateral trabeculectomy weeks
Table 5.4
Laterality of attacks in all patients
SUNCT SUNA All
left sided 14 (33%) 6 (67%) 20 (38%)
right sided 20 (47%) 2 (22%) 22 (42%)
left > right 4 (9%) 1(11%) 5 (10%)
right > left 3 (7%) 0 3 (6%)
left & right equally 1 (2%) 0 1 (2%)
bilateral 1 (2%) 0 1 (2%)
total 43 9 52
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5.5 Site of attacks
Eighty-eight per cent of SUNCT and 78 % of SUNA patients had pain in the distribution 
recognized by the IHC criteria (Headache Classification Committee of The International 
Headache Society, 2004); that is the eye, retro-orbital region and temple. The majority of 
SUNCT patients (29, 67 %) experienced pain in the eye, with 24 (56 %) having retro- 
orbital pain, 16 (37 %) with forehead pain, 16 (37 %) with pain in the nose, and 14 (33 
%) each in the temple and maxillary (second) division of the trigeminal nerve. Twelve 
had pain in the back of the head, nine had pain in the top of the head, nine in the teeth, 
four had pain in the side of the head, three in the eyebrow, and two in the ear. One patient 
had pain in the neck. In contrast, only two SUNA patients (22 %) had pain in the eye. The 
pain was in the retro-orbital region in five patients (56 %) and temple in five patients (56 
%). Four patients (44 %) had pain in the side of the head. There was pain in the second 
(maxillary) and third (mandibular) division of the trigeminal nerve in one patient each. 
Two further patients with SUNA (#59 and #43) had pain in both V2 and V3 . Two patients 
had pain in the teeth, two in the back of the head, and one each in the neck, ear and 
forehead (Table 5.5).
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Table 5.5
Site of attacks
SUNCT SUNA
eye 29 (67%) 2 (22%)
retro-orbital region 24 (56%) 5 (56%)
eyebrow 3 (7%) 0 (0%)
forehead 16 (37%) 1 (11%)
temple 14(33%) 5 (56%)
side head 4 (9%) 4(44%)
top head 9(21%) 0 (0%)
back head 12 (28%) 2 (22%)
nose 16 (37%) 1 (11%)
v2 14 (33%) 3 (33%)
v3 0 (0%) 3 (33%)
teeth 9(21%) 2 (22%)
neck 1 (2%) 1 (11%)
ear 2 (5%) 1 (11%)
Table 5.6
Associated autonomic symptoms
SUNCT SUNA CH*
conjunctival injection 
(CI) 43 (100%) 2 (22%) 77
lacrimation
43 (100%)
3 ipsilateral, 1 
contralateral 
(44%)
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both CI and 
lacrimation 43 (100%) 0 (0%)
nasal blockage 17 (40%) 2 (22%) 75
rhinorrhoea 23 (53%) 2 (22%) 72
eyelid oedema 21 (49%) 1 (11%) 74
ptosis 22 (51%) 3 (33%) 74
facial flushing
2 unilateral, 2 
bilateral (9%) 1 (11%)
sweating
2 unilateral, 1 
bilateral (7%) 1 bilateral (11%)
other 4 (9%) 3 (33%)
* After Bahra et al (Bahra et al., 2002)
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5.6 Autonomic Symptoms
All of the SUNCT patients had both ipsilateral conjunctival injection and lacrimation 
associated with their attacks, by definition (Headache Classification Committee of The 
International Headache Society, 2004). Twenty-two patients (51 %) had ipsilateral ptosis, 
17 (40 %) had nasal blockage and 23 (53 %) had ipsilateral rhinorrhoea associated with 
their attacks. Twenty-one patients (49 %) noticed ipsilateral eyelid oedema, four (9 %) 
had facial flushing, two of which were unilateral and two bilateral. Three (7 %) had facial 
sweating, two of which were unilateral and two bilateral. A further four (9 %) had other 
cranial autonomic symptoms, such as blotchy skin in the face and neck, ipsilateral gritty 
eye (after Newman (Goadsby and Lipton, 1997; Newman et al., 1994)), ipsilateral cheek 
oedema, and a sense of ipsilateral aural fullness. The ipsilateral cheek oedema was in a 
patient whose pain affected both the first (ophthalmic) and second (maxillary) divisions 
of the trigeminal nerve (#17). One patient also experienced her autonomic symptoms 
even without the attacks (#57).
Of the nine SUNA patients, two (22 %) had ipsilateral conjunctival injection and four (44 
%) had lacrimation. Of those with lacrimation, three were ipsilateral and one was 
contralateral. None had both conjunctival injection and lacrimation. Two patients (22 %) 
had both nasal blockage and rhinorrhoea. Three patients (33 %) had ipsilateral ptosis, one 
(11%) had ipsilateral eyelid oedema, and one (11%) had bilateral facial sweating. Three 
patients (33 %) had other symptoms including visual blurring in the ipsilateral eye, 
ipsilateral mydriasis, and a feeling of flushing red hot ipsilateral ear in one patient each 
(Table 5.6). The diagnosis of ‘red ear syndrome’ (Lance, 1996) was considered but 
discounted by the history.
Association between site o f pain and autonomic symptoms
Thirty patients with SUNCT had attacks affecting the second division of the trigeminal 
nerve (V2) (cheek and nose). Of these 30 patients, 17 (73 %) had associated nasal 
autonomic symptoms. There were only eight patients who had V2 pain but no nasal 
autonomic symptoms.
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Of the four SUNA patients who had V2 and V3 pain, two had nasal autonomic symptoms. 
One patient (#59) specifically reported lacrimation when his pain was predominantly in 
V2 and nasal congestion when his pain was predominantly in V3 .
5.7 Type of pain
Thirty-two of the fifty-two patients (62 %) described their attacks as stabbing. Ten (19 %) 
had electric-shock type attacks, nine (17 %) described theirs as sharp and eight (15 %) as 
shooting. Five patients (10 %) described their attacks as burning, five as throbbing and 
four (8 %) as a pressure. Three patients said their attacks had a boring quality (6 %), and 
a further three patients (6 %) described needle-like sensations. Two patients (4 %) 
described the pain as hot, and two patients said they experienced jabs of pain. There was 
one description each of the following characteristics of the pain: burning, bursting, 
metallic, scrape, squeeze, sting, tight, twang and twitching (Table 5.7).
5.8 Severity of pain
The patients were asked to rate the severity of their attacks on a verbal rating scale (VRS) 
of 0 to 10, 0 being no pain at all, and 10 being the most severe pain imaginable. The 
majority of SUNCT patients (36 patients, 84 %) rated their most painful attacks at 10/10 
on the VRS. The range of severity was from 5-10/10, and the range of their most painful 
attacks was 6-10/10. The median was 10.
In contrast, out of the nine patients with SUNA, only three patients (33 %) recorded their 
maximum severity as 10/10. A further three patients recorded their maximum severity as 
9/10. The range of severity was 5-10/10 and the median was 9 (Table 5.8).
Out of the SUNCT patients, most said that this was the most painful condition they had 
ever experienced. None could name a pain which they had experienced which was more 
painful than their SUNCT attacks. Specifically, patients said that their attacks were worse
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than childbirth in six patients, tooth abscesses and associated pains in two patients, and 
gallstones, fractured ribs, renal stones and other headaches in one patient each. For 
SUNA patients eight had not experienced pain greater than their SUNA attacks. 
Specifically, the pain was described as worse than childbirth and appendicitis in one 
patient each. Only one patient cited the pain of bilateral trabeculectomies as greater than 
the pain of her SUNA attacks.
Table 5.7
Characteristics of pain
Type of attack SUNCT SUNA All
stab 29 (67%) 3 (33%) 32 (62%)
electric shock 9(21%) 1 (11%) 10 (19%)
sharp 7 (16%) 2 (22%) 9 (17%)
shooting 7(16%) 1 (11%) 8 (15%)
bum 5 (12%) 0 (0%) 5 (10%)
throb 3 (7%) 2 (22%) 5 (10%)
pressure 3 (7%) 1 (11%) 4 (8%)
needle 3 (7%) 0 (0%) 3 (6%)
boring 2 (5%) 1 (11%) 3 (6%)
jab 2 (5%) 0 (0%) 2 (4%)
hot 1 (2%) 1 (11%) 2 (4%)
burning 1 (2%) 0 (0%) 1 (2%)
burst 1 (2%) 0 (0%) 1 (2%)
scraping 1 (2%) 0 (0%) 1 (2%)
squeeze 1 (2%) 0 (0%) 1 (2%)
sting 1 (2%) 0 (0%) 1 (2%)
tight 1 (2%) 0 (0%) 1 (2%)
twang 0 (0%) 1 (11%) 1 (2%)
twitching 0 (0%) 1 (11%) 1 (2%)
metallic 0 (0%) 1 (11%) 1 (2%)
Table 5.8
Severity of pain
SUNCT SUNA
no of patients 43 9
patients with attacks 10/10 36 (84%) 3 (33%)
range of severity (VRS) 5 to 10/10 5 to 10/10
mean 9.7 8.9
median 10 9
patients with pain worse 0 1(trabeculectomy)
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5.9 Other symptoms
Agitation
Of the 43 SUNCT patients, there was data on 40 patients as to whether they felt agitated 
during the attack. Twenty-five patients (62 %) were agitated during an attack, with five 
patients with SUNA (55 %) having agitation. Agitation has been reported in 88 % of 
patients with cluster headache (Torelli and Manzoni, 2003), and in 50% of patients with 
paroxysmal hemicrania (Antonaci and Sjaastad, 1989; Cohen et al., 2006), but is less of a 
feature in migraine, where movement classically makes the pain worse (Headache 
Classification Committee of The International Headache Society, 2004). Of the 30 
agitated patients, 11 of them (37 %) had migraine. Of the nine patients in whom 
movement made the pain worse, six of them (67 %) had migraine, and of the remaining 
three patients, one had a family history of migraine (Figure 5.1).
Migrainous symptoms
Photophobia and phonophobia are also generally associated with migraine, although 
usually this is bilateral. Unilateral photophobia and phonophobia can occur in migraine 
(Drummond, 1986; Vingen et al., 1998a), cluster headache (Vingen et al., 1998b) and has 
also been reported in paroxysmal hemicrania (Irimia et al., 2005). In this group, 21 
SUNCT patients (49 %) and six SUNA patients (67 %) had migrainous biology: a 
personal or family history of migraine. Twenty-two SUNCT patients experienced 
photophobia or phonophobia, and of these 12 were patients with migrainous biology. 
Three SUNA patients experienced photophobia or phonophobia, and of these two had 
migrainous biology. Of the four SUNCT patients with a combination of nausea, 
photophobia and phonophobia, all had migrainous biology (Figure 5.2).
Sixteen SUNCT patients had photophobia, and of these eleven had photophobia 
ipsilateral to the pain (69 %). Two SUNA patients had photophobia, both ipsilateral to the 
pain. Thirteen SUNCT patients had phonophobia, with four (31 %) ipsilateral to the pain. 
Two SUNA patients had phonophobia, both ipsilateral to the pain (Table 5.9).
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Figure 5.1
Agitation or restlessness during attacks of SUNCT/SUNA
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Figure 5.2
Photophobia and phonophobia in SUNCT/SUNA
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Table 5.9
Laterality of photophobia and phonophobia
SUNCT SUNA SUNCT and SUNA
Total photophobia 16 (37%) 2 (22%) 18 (35%)
unilateral photophobia 11 (26%) 2 (22%) 13 (25%)
Total phonophobia 13 (30%) 2 (22%) 15 (29%)
unilateral phonophobia 4 (9%) 2 (22%) 6(12%)
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The vast majority of patients in this cohort had no symptoms of aura such as visual, 
speech or sensory disturbances (Headache Classification Committee of The International 
Headache Society, 2004), nor any motor disturbance associated with their attacks. One 
patient (#56) had some dizziness with his attacks. The SUNA patient (#SUNA44) with 
visual blurring only in the ipsilateral eye, and only for the duration of the attack, was not 
considered to have aura.
5.10 Character, duration and frequency of attacks
Attacks took one or more of three forms: single stabs, a group of stabs or a long attack 
with a ‘saw-tooth’ pattern of stabs between which the pain would not return to the 
baseline (Figure 5.3).
Of the SUNCT patients, 15 had single attacks only, two had groups of stabs only (of 
whom one had groups of groups- #21), and eight had saw-tooth attacks only. Nine 
patients had single attacks and groups of stabs, five patients had single attacks and saw 
tooth attacks, and one patient had groups of stabs and saw tooth attacks. Three patients 
had all three types of attacks. In the SUNA patients, three patients had single attacks 
only, two patients had groups of stabs only, and one had saw tooth attacks only. Two 
patients had single attacks and groups of stabs, and one had single attacks plus saw tooth 
attacks (Figure 5.4).
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Figure 5.3
The three types of clinical picture of attacks of SUNCT/SUNA
Pain (Verbal Rating Scale from 0 to 10)
1. Single stabs 2. Each attack is a group of stabs 3. Saw-tooth pattern
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Figure 5.4
Distribution of types of attacks illustrated in Figure 5.3 by condition
single
15SUNCT 
3 SUNA
5 SUNCT 
4 SUNA
3 SUNCT
8 SUNCT 
1 SUNA
2 SUNCT 
2 SUNA 1 SUNCT
groups of stabs saw tooth
93
5.11 Attack timing
Length o f attacks
The International Headache Society criteria for the length of attacks is 5-240 seconds 
(Headache Classification Committee of The International Headache Society, 2004). 
However patients may have groups of attacks for which each individual stab is of the 
order of 5-240 seconds, but the attacks themselves are perceived as much longer in the 
order of minutes or even hours. This may have caused some diagnostic confusion in the 
past, as patients with attacks lasting more than 240 seconds may have had the diagnosis 
of SUNCT or SUNA falsely ruled out, whereas in fact their individual attacks were much 
shorter. In this study, the length of the individual stab attacks is reported in addition to the 
duration of groups of stabs or saw tooth attacks.
For all patients, the range of length of stab attacks was 1 -600 seconds, with a mean length 
of 58 seconds and median 10 seconds. This included the stabs which came as part of a 
group of stabs, or as part of the saw-tooth attacks. The groups of stabs ranged in length 
between 10 and 1200 seconds, with a mean of 396 seconds and median of 300 seconds. 
The saw tooth attacks ranged from 5 to 12000 seconds (200 minutes), with a mean of 
1160 seconds and median 285 seconds. One patient (#21) had stabs lasting one second 
each, which would come in groups of 10 seconds, which in turn would occur in groups of 
groups, lasting 3600 seconds at a time. One patient (#51) had attacks which lasted as long 
as the trigger lasted; for instance pulling his hair for one second or one hour would result 
in an attack lasting one second or one hour, respectively. This patient’s data was not 
included in the analysis of length of attacks. The rest of the results are in Table 5.10.
Table 5.10
Length of attacks and number of attacks per day, and attack load in minutes per day
attack
length
single
stab stab groups saw tooth
number of 
attacks/day
attack load per 
day
mean 58 sec 396 sec 1160 sec 59 139 min
median 10 sec 300 sec 285 sec 20 47 min
range 1-600 sec 10-1200sec 5-12000 sec 2-600/day 2-1350 min
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Number o f attacks per day
The International Headache Society criteria for the number of attacks a day is 20-300 
(Headache Classification Committee of The International Headache Society, 2004). 
However 10 patients, of whom 8 had SUNCT and 2 had SUNA, had so many attacks a 
day that they could not accurately quantify them. The number of attacks ranged from 2 to 
‘many hundreds’. In total, 42 of the 52 patients were able to quantify their attacks. The 
number of attacks per day ranged from 2 to 600, with a mean of 59 attacks per day and 
median of 20 attacks per day.
Some patients had longer attacks than others, and some had groups of attacks. For 
instance one patient (#30) had stabs lasting 120 seconds which would occur 12 times per 
hour, for 3 hours at a time, and she would get 3 of these attacks a day. This could either 
be reported as 3 attacks, or as 108 attacks a day. It would therefore make sense to report 
both the number of attacks per day and the attack load per day, which would be the 
number of minutes of pain per day. This may better marker for monitoring the therapeutic 
response to treatments; the results are illustrated in Table 5.10.
Diurnal Variation o f Attacks
Thirty-seven of the forty-three SUNCT patients and eight of nine SUNA patients could 
specify whether their attacks occurred more during waking or sleeping hours. In three 
patients (7 %) with SUNCT their attacks occurred primarily during sleep. Seventeen 
patients (40 %) experienced attacks mainly during waking hours, and 17 patients (40 %) 
experienced attacks equally during sleep and wakefulness. Attacks were specifically 
worse in the early morning in four patients. Four patients with SUNA had attacks mainly 
during waking hours, with one especially in the early mornings, and four experienced 
attacks both during sleep and wakefulness (Table 5.11).
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Table 5.11
Diurnal variation of attacks
SUNCT SUNA total
awake (early morning) 17 (3) (40%) 4(1) (44%) 21
asleep 3 (7%) 0 3
both 17(1) (40%) 4 (44%) 21
unspecified 6 1 7
5.12 Triggering of Attacks
In the SUNCT patients, one patient (#51) only had triggered attacks with no spontaneous 
ones. Twelve patients (28 %) said that most of their attacks were triggered, seven had 
equal numbers of triggered and spontaneous attacks, 12 (28 %) had more spontaneous 
than triggered attacks, and six (14 %) had entirely spontaneous attacks with no triggers.
In contrast, in the SUNA patients, two (22 %) had mostly triggered attacks, and six (67 
%) had entirely spontaneous attacks with no triggers.
In thirty-four SUNCT patients (79%) and three SUNA patients (33%), the attacks could 
be triggered by various cutaneous stimuli. Touching the face was a trigger in 27 SUNCT 
patients. This was the ipsilateral first division of the trigeminal nerve in six patients, 
ipsilateral second division of the trigeminal nerve in seven patients, ipsilateral side of the 
face in both divisions or unspecified area in 13 patients, and bilateral first division in one 
patient (#47) with strictly unilateral attacks. Other triggers included chewing or eating,
t
wind on the face, washing the face, brushing teeth, movement of the head or jaw, talking, 
washing or brushing the hair, exercise, light on the face, showering, shaving, blowing the 
nose; and smoke, strong smells, and a warm environment. Alcohol was a trigger in one 
SUNA patient (#40) in that it would trigger attacks of ptosis. Other trigger factors 
included dental work, lifting heavy objects, blinking, stretching of the skin on the 
ipsilateral side of the face, and licking the lips on the ipsilateral side in one SUNCT 
patient each. Lying on the ipsilateral side was a trigger to attacks in one SUNA patient.
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Factors making the attacks worse, by increasing the frequency or severity of attacks, 
included stress in three SUNCT and one SUNA patients, travel across time zones in three 
SUNCT patients, tiredness in one SUNCT and one SUNA patients, and bad weather in 
one SUNCT patient.
When asked about a refractory period between attacks, only two of the SUNCT patients 
(5 %) and one SUNA patient (11%) had a refractory period; that is, 95 % of SUNCT 
patients and 89 % of SUNA patients could have one attack triggered or occurring 
spontaneously immediately after cessation of another one (Table 5.12).
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Table 5.12
Triggered attacks and refractory period
Triggers to attacks SUNCT SUNA total
touch 27 (63%) 0 (0%) 27 (52%)
chew/eat 26 (60%) 2 (22%) 28 (54%)
wind 17 (40%) 1 (11%) 18 (35%)
wash face 17 (40%) 0 (0%) 17 (33%)
brushing teeth 16 (37%) 0 (0%) 16(31%)
move 14 (33%) 2 (22%) 16(31%)
talk 9 (21%) 1 (11%) 10 (19%)
wash or brush hair 5 (12%) 0 (0%) 5 (10%)
exercise 5 (12%) 1 (11%) 6 (12%)
light 4 (9%) 0 (0%) 4 (8%)
shower 4 (9%) 0 (0%) 4 (8%)
shaving 4 (9%) 0 (0%) 4 (8%)
blow nose 3 (7%) 0 (0%) 3 (6%)
alcohol 0 (0%) 1 (11%) 1 (2%)
smoke 1 (2%) 0 (0%) 1 (2%)
smells 1 (2%) 0 (0%) 1 (2%)
warm 1 (2%) 0 (0%) 1 (2%)
others 5 (12%) 0 (0%) 5 (10%)
Factors making attacks worse
stress 3 (7%) 1 (11%) 4 (8%)
tired 1 (2%) 1 (11%) 2 (4%)
travel 3 (7%) 0 (0%) 3 (6%)
weather 1 (2%) 0 (0%) 1 (2%)
all triggered 1 (2%) 0 (0%) 1 (2%)
mostly triggered 12 (28%) 2 (22%) 14 (27%)
equal triggered and 
spontaneous 7 (16%) 0 (0%) 7(13%)
mostly spontaneous 12 (28%) 0 (0%) 12 (23%)
all spontaneous 6 (14%) 6 (67%) 12 (23%)
unknown 5 (12%) 1 (11%) 6 (12%)
refractory period 3 (5%) 1 (11%) 4 (8%)
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5.13 Background Pain, Migraine and Analgesic Overuse
Classically SUNCT and SUNA are not associated with background pain. This study 
identified 20 patients with SUNCT and two patients with SUNA who had interictal 
background pain. Initially some of these patients were misdiagnosed as having 
hemicrania continua, but negative placebo-controlled Indomethacin tests ruled this out as 
a diagnosis (see Table 7.4).
Fifteen SUNCT patients (35 %) had a personal history of migraine, and in total 21 (49 %) 
had migrainous biology, that is, a personal history of migraine or a family history of 
migraine in a first- degree relative. Six SUNA (67 %) patients had migraine, and all had a 
family history of migraine. The relationship between migrainous biology and 
SUNCT/SUNA was assessed, and found in total 40 % of patients had a personal history 
of migraine and 52 % had migrainous biology.
Analgesic overuse, defined as the use of analgesics on 15 or more days per month, was 
present at some point in seven SUNCT patients and four SUNA patients. The analgesics 
used were codeine, paracetamol, dihydrocodeine, codeine and paracetamol combinations 
in most patients, and codeine and morphine in one patient (#52). Of these 11 patients, six 
had migrainous biology. Analgesic overuse is known to lead to chronic daily headache, 
especially in migraine patients (Bahra et al., 2003), and it was found that two SUNCT 
patients with migrainous biology and analgesic overuse developed a chronic daily 
headache. However even without analgesic overuse, there was background pain present 
in 15 SUNCT patients and one SUNA patient, of whom nine had migrainous biology. 
These interactions are illustrated in Figure 5.5.
99
Figure 5.5 SUNCT/SUNA
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5.14 Periodicity and Chronicity of SUNCT and SUNA
All the SUNA patients had primary chronic SUNA; that is attacks occurring for a year or 
more without more than a month’s break. One patient (#24) went into spontaneous 
remission after 1 year and had been pain free for 2Vi years at the time of interview.
Thirteen SUNCT patients (30 %) had primary episodic SUNCT. Their bouts lasted for a 
mean 7.5 weeks (range 1-30 weeks and median 4 weeks). The average remission time 
was 52 weeks, with a range of 3-364 weeks (7 years) and a median of 26 weeks. 
Seventeen SUNCT patients had primary chronic SUNCT (40 %). Ten patients (23 %) had 
secondary chronic SUNCT, with average time from the start of the disease to chronic 
SUNCT being 8.4 years (range 1-16 years, median 8.5 years).
One SUNCT patient (#3) and one SUNA patient (#SUNA24) had primary chronic forms 
of the syndromes for more than a year, and then went into remission for 2 years and 3 
years, respectively. One SUNCT patient (#49) had primary chronic SUNCT for 2 years, 
then went into remission for 14 years, then had secondary episodic SUNCT with a bout 
lasting 8 months and remission to date. One patient (#14), had primary chronic SUNCT 
which went into remission for a year and then the patient was lost to follow-up (Table 
5.13).
Table 5.13
Periodicity and Chronicity of SUNCT and SUNA
SUNCT SUNA SUNCT & SUNA
primary episodic 13 (30%) 0 (0%) 13 (25%)
primary chronic 17 (40%) 8 (89%) 25 (48%)
primary chronic plus remission 2 (5%) 1 (11%) 3 (6%)
secondary chronic 10 (23%) 0 (0%) 10(19%)
secondary episodic 1 (2%) 0 (0%) 1 (2%)
comments
episodic SUNCT bouts mean 7.5 weeks, range 1-30 weeks, median 4 weeks
remissions mean 51.6 weeks, range 3-364 weeks, median 26 
weeks
secondary chronic SUNCT time to chronicity 8.4 years, range 1-16 years, median 8.5 years
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5.15 SUNCT and SUNA with abnormal examination and MRI findings- symptomatic 
SUNCT and SUNA
Thirteen SUNCT patients (30 %) and one SUNA patient (11%) had abnormal findings 
on neurological examination. These were mainly ipsilateral sensory changes, either 
reduced sensation to pinprick in Vi or V2 (five SUNCT (12 %) and one SUNA patient 
(11%)) or hyperaesthesia to pinprick in Vi (one SUNCT (2%)). One SUNCT patient had 
ipsilateral reduced sensation in V2 secondary to an infraorbital nerve block. Six SUNCT 
patients (14%) had other abnormal signs; one had a mildly abnormal response to pinprick 
on the ipsilateral side of the body (#27), and one with a Homer’s syndrome, which was 
investigated and no cause was round (#23). The remaining three patients had signs 
relating to other pathology, which were: reduced field of vision in one eye in a patient 
with microprolactinoma (#25), ipsilateral VI and contralateral XII nerve palsy after a 
head injury (#51), and contralateral pyramidal weakness following surgery to remove 
astrocytoma (#57).
Thirty-six SUNCT and eight SUNA patients had results of cranial imaging, which in the 
majority of cases was MRI. Nineteen SUNCT patients (44%) and seven SUNA patients 
(78%) had normal intracranial appearances. Of the remainder, five SUNCT patients had 
incidental findings, such as scattered cerebral white matter lesions consistent with age- 
related infarctions.
Twelve SUNCT and one SUNA patient had abnormal intracranial findings. These were:
1) Vascular loops compressing on the trigeminal nerve in one patient. One was 
ipsilateral to the pain (#13), one had bilateral loops but only unilateral pain (#46), 
and one had a loop on one side but had bilateral attacks (#55).
2) Pathological white matter changes in two SUNCT patients and one SUNA patient. 
One SUNCT patient had scattered cerebral white matter lesions (#7 reported in 
(Matham et al., 2004b) and one with a lesion on the ipsilateral cerebral peduncle 
(#52). The SUNA patient had primary progressive multiple sclerosis with
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extensive white matter changes and lesions in the midbrain, pons and middle 
cerebral peduncle (#SUNA4).
3) Pituitary lesions in three SUNCT patients, of whom two had macroadenomas (#37 
reported in (Matharu et al., 2003c) and #20), which resolved on treatment of the 
macroadenoma; and one had a microprolactinoma (#25), the excision of which 
rendered her pain free for 8 months.
4) Space occupying lesions in two patients, which included a parietal astrocytoma in 
one patient (#57), which on excision did not cause a resolution of her SUNCT. 
The other patient (#51) had an ipsilateral parieto-occipital lesion with meningeal 
inflammation of unknown cause, which had been excised two years before the 
onset of his SUNCT. This patient had also suffered a head injury and was left 
with a residual ipsilateral VI nerve and contralateral XII nerve palsy (Table 5.14).
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Table 5.14
Secondary SUNCT/ SUNA and abnormal intracranial imaging
SUNCT SUNA all
Abnormal examination:
ipsilateral reduced sensation to pinprick 5 (12%) 1 (11%) 6 (12%)
ipsilateral hyperaesthesia 1 (2%) 0 (0%) 1 (2%)
ipsilateral changes post procedures 1 (2%) 0 (0%) 1 (2%)
other neurological abnormalities 6 (14%) 0 (0%) 6 (12%)
Intracranial imaging:
total number imaged 37 8 45
normal intracranial appearances 20 (54%) 7 (88%) 27 (60%)
incidental findings 6(16%) 0 (0%) 6(13%)
abnormal intracranial appearances:
vascular loops 3 (8%) 0 (0%) 3 (7%)
pathological white matter changes 2 (5%) 1 (12%) 3 (7%)
pituitary lesions 3 (8%) 0 (0%) 3 (7%)
space occupying lesions 2 (5%) 0 (0%) 2 (4%)
unusual configuration in brainstem and 
lacune in thalamus 1 (3%) 0 (0%) 1 (2%)
total abnormal intracranial appearances 11 (29%) 1 (12%) 12 (27%)
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Chapter 6
Discussion: Clinical Study of Phenotype of SUNCT and SUNA
This study reports the first substantial case series clinically characterising 
SUNCT/SUNA. The syndrome fundamentally is of unilateral, episodic severe pain that 
occurs in stabs or jabs and is associated with ipsilateral cranial autonomic outflow. The 
attacks are more severe than has hitherto been reported; they can be prolonged, and are 
triggerable without an apparent refractory period in the vast majority. The series clearly 
establishes the existence of what has been called SUNA, and provides a basis for 
considering the two syndromes as closely related, with the majority having SUNCT. The 
data suggest the need for changes in the International Headache Society classification and 
provide a firm basis for neurologists to recognize this relatively newly identified, highly 
disabling form of primary headache.
6.1 Epidemiology
The prevalence of SUNCT is unknown, although the low number of hitherto reported 
cases suggests that it is very rare. The fact that at the National Hospital for Neurology and 
Neurosurgery there are only 52 SUNCT and SUNA cases referred in the UK with a 
population of 59.6 million (www. statistics. gov.uk! may highlight the rarity of the 
syndrome. Moreover, since we have seen in excess of 600 patients with trigeminal 
autonomic cephalgias over the same period, this is a small group. However, the fact that 
the majority of the patients had previous diagnoses before they were diagnosed with 
SUNCT or SUNA (Table 5.2) suggests that there may be more cases of SUNCT and 
SUNA which have been misdiagnosed.
6.2 Male:female ratio
SUNCT has been though to have a male preponderance, with a recent review giving a 
male:female ratio of 1.3:1 (28 males and 22 females) (Matharu et al., 2003a). This study
105
finds a slightly higher ratio of 1.5:1 for total SUNCT and SUNA combined. However, 
when separated into SUNCT and SUNA, there is a higher male:female ratio in SUNCT 
(2:1), and almost the opposite ratio in SUNA (0.5:1). Thus it could be that the full 
syndrome of SUNCT with both conjunctival injection and tearing is commoner in men 
than in women, with SUNA being commoner in women than men. Alternatively the 
sample number for SUNA (9 patients) may be too small to make a significant comment.
6.3 Site of Pain
The International Headache Society describes the site of pain in SUNCT as unilateral 
orbital, supraorbital or temporal pain (Headache Classification Committee of The 
International Headache Society, 2004). In our series, the majority of SUNCT patients 
conformed to these criteria (78%), with orbital (67 %), supraorbital/forehead (37 %), or 
temporal (33 %) pain, the latter of which was present in 56 % of SUNA patients. 
However, 56 % of both SUNCT and SUNA patients reported retro-orbital pain, and the 
pain was reported in wider areas of the head and face, including the top, side and back of 
head, nose, second and third divisions of the trigeminal nerve, teeth, neck and ear. It is 
interesting to note that only a small proportion of SUNA patients had pain in the eye, 
supraorbital region or forehead, but pain was more likely to be reported in the temple. 
Three patients with SUNA (33 %) had pain which radiated to the third (mandibular) 
division of the trigeminal nerve, whereas no SUNCT patients had pain in V3. This may 
illustrate a difference between the two syndromes, such that SUNCT is more likely to 
affect the orbital and supraorbital regions, and SUNA is more likely to affect the temple 
and V2 and V3.
6.4 Laterality of Attacks
Attacks of SUNCT and SUNA have been typically described as strictly unilateral and 
side-locked (88 %), with a slight preponderance of SUNCT attacks on the right (Matharu 
et al., 2003a). In this series 80% of patients had side-locked attacks. Side-alternating 
attacks are documented in 20 % of SUNCT patients, which have been observed in a few
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cases previously (D'Andrea and Granella, 2001; D'Andrea et al., 2001; Matharu et al., 
2004b). One patient reported attacks which affected both sides simultaneously (#55). This 
is considered atypical of SUNCT but has been reported before (Pareja and Sjaastad,
1997; Sabatowski et al., 2001). In that patient’s case a vascular loop was noticed on MRI 
on the right side only, even though his pain was bilateral. Conversely another patient 
(#46) had bilateral vascular loops impinging on the brainstem, but only suffered attacks 
on the right side. It seems that a pathogenetic role of vascular loops compressing the 
brainstem or trigeminal nerve may not be as important in SUNCT as in trigeminal 
neuralgia (Goadsby et al., 2001).
6.5 Severity of Pain
The pain of SUNCT and SUNA is usually excruciating, on a verbal rating scale of 10/10 
in severity. This serves to highlight the devastating morbidity of these syndromes, 
especially with a mean time to diagnosis of 6.7 years in SUNCT and 7.1 years in SUNA 
(Table 5.2), and subsequent failure of response to conventional medications (Pareja et al., 
1995).
6.6 Duration, Frequency and Temporal Profile of Individual Attacks
The International Headache Classification specifies attack length of 5-240 seconds, with 
3 to 200 attacks per day. These results demonstrate that attacks may take on different 
characters; single stabs, groups of stabs, or a longer attack comprised of many stabs 
between which the pain does not resolve to normal, thus giving a ‘saw-tooth’ 
phenomenon (Figure 5.3). Although this variability in the character of attacks is well 
recognised in the literature (Antonaci and Sjaastad, 1989), it may have led to confusion in 
the description of length of attacks.
The length of single stabs, whether alone, as part of a group, or as part of a saw-tooth 
attack, ranged from 1-600 seconds with a mean of 56 seconds. This correlates reasonably 
well with the IHS classification of length of attacks. The shorter stabs (1-5 seconds in 
length) may make up part of a group of stabs or a saw-tooth attack which will last longer
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in total. Groups of stabs, or saw-tooth attacks may be made up of many individual stab 
attacks, thus a ‘single attack’ would be perceived as longer than 240 seconds leading to 
wrong diagnoses of paroxysmal hemicrania or cluster headache, since they have longer 
attacks at 2-30 minutes and 15-180 minutes respectively (Headache Classification 
Committee of The International Headache Society, 2004).
Another consideration in assessing the temporal profile of attacks is the wide inter-patient 
variation in the number of attacks per day, and the length of these attacks. For example, a 
patient with 200 attacks a day, each lasting 2 seconds, will have a rather different 
experience from the patient with 3 saw-tooth attacks a day, lasting up to thirty minutes at 
a time. The first patient will have 400 seconds of pain a day, which is just less than 7 
minutes. The second patient will have 180 minutes of pain a day. From a therapeutic 
point of view it would be desirable to reduce both the number of attacks per day, but also 
the attack load; that is the number of minutes of pain per day. A system of quantifying 
SUNCT and SUNA attacks is hereby proposed, in the following terms for the purpose of 
therapeutic studies:
1) type of attack (stab, group or saw-tooth)
2) number of attacks per day
3) attack load in minutes per day
6.7 Frequency and Periodicity of Attacks
Most cases of SUNCT in the literature have occurred in an episodic manner, with the 
symptomatic bouts alternating with remissions in an erratic manner. In a series of 21 
patients, the symptomatic bouts last from a few days to several months and occurred once 
to twice annually, although a maximum of 22 episodes per year have been reported, and 
the symptomatic periods appeared to increase in frequency and duration over time (Pareja 
and Sjaastad, 1997). Remissions typically lasted for a few months, but have been reported 
to last from 1 week to 8.5 years (Jimenez-Huete et al., 2002). Both the episodic and 
chronic forms of SUNCT have been included in the International Headache Society 
Classification of Headache (Headache Classification Committee of The International
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Headache Society, 2004). In this series only 13% of SUNCT patients and no SUNA 
patients had the primary episodic form of the disease. Indeed, most of the SUNA patients 
(89%) had primary chronic disease. Most, SUNCT patients (63%) had either primary 
chronic or secondary chronic SUNCT. The average time from the start of the syndrome to 
chronicity was 8.4 years. There also exist one SUNCT and one SUNA patient with 
primary chronic disease, that is attacks occurring for more than a year without more than 
a month’s remission, who then went into spontaneous remission for 2 and 3 years, 
respectively. Additionally a patient with 2 years of SUNCT had a spontaneous remission 
for 14 years, and then had a bout lasting 8 months with remission afterwards (to date).
These data differ from cluster headache databases, where most patients have the primary 
episodic form of cluster headache (79 %), and a small percentage (8 %) go on to develop 
secondary chronic CH (Bahra et al., 2002). Chronic cluster headache can revert or evolve 
to secondary episodic CH in as many as 50% of affected individuals (Manzoni et al., 
1991).
The study also highlights differences in the diurnal variation of SUNCT attacks. Only 7 
% of SUNCT patients reported predominantly nocturnal attacks as opposed to up to 73 % 
of CH patients (Bahra et al., 2002; Russell, 1981). However, a further 40 % of SUNCT 
patients experienced attacks that could occur equally during sleep and wakefulness. This 
may be due to the fact that SUNCT attacks are triggered by cutaneous stimuli that would 
occur more often during wakefulness; however the diurnal variation in the attacks was 
equally diverse between those patients who had predominantly triggered and those with 
mainly spontaneous attacks.
6.8 Interictal pain
This study describes 20 patients with SUNCT and 2 patients with SUNA who had 
interictal background pain (Figure 5.5). SUNCT is not usually thought of as having a 
component of background pain, although a persistent dull interictal ache has been 
described in association with SUNCT in 2 cases (Matharu et al., 2004b; Pareja et al.,
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1996b). The differential diagnosis for what may appear to be prolonged attacks includes 
paroxysmal hemicrania and cluster headache. For constant interictal pain the differential 
diagnosis would include hemicrania continua. However there are important clinical 
characteristics which lead to the suspicion of a diagnosis of SUNCT, such as the 
cutaneous (or other) triggerability of attacks and the lack of a response to indomethacin.
It is helpful to perform a controlled indomethacin test to rule out paroxysmal hemicrania 
and hemicrania continua (Antonaci et al., 1998).
6.9 Concomitant Headache, Migraine and Background Pain
As seen in Figure 5.5, 34 % of patients had a personal history of migraine and 50% had 
migrainous biology. This is in contrast to the 15 % migraine prevalence in the general 
population (Steiner et al., 2003). Migraine is considered to be more common in patients 
with cluster headache (Bahra et al., 2002), and may coexist with paroxysmal hemicrania 
(Cohen et al., 2006). The increased prevalence of migraine in this cohort of SUNCT and 
SUNA patients may reflect a predisposition for primary headache syndromes, or simply 
that the patients more readily are coming to medical attention because of the 
SUNCT/SUNA. Patients with primary headache syndromes, notably migraine (Bahra et 
al., 2003) or cluster headache (Paemeleire et al, 2004) may develop chronic daily 
headache with analgesic overuse. SUNCT and SUNA patients with migraine biology, 
especially those who overuse analgesics, may also be at increased risk of developing an 
interictal chronic background pain.
6.10 Family History
There is only one reported case in the literature of a family history of SUNCT 
(Gantenbein and Goadsby, 2005). This case is in the current cohort (#12). It is well 
known that migraine has a significant genetic component (Ferrari, 1998), and this is 
strengthened by the description of clear genetic mutations in familial hemiplegic migraine 
(Ophoff et al., 1996). As for the TACs, there have been reports of familial cluster 
headache (El Amrani et al., 2002a; Leone et al., 2001), and recently in paroxysmal
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hemicrania (Cohen et al., 2006). These syndromes are so rare that an accurate evaluation 
of their genetic inheritance is difficult, although a primarily inherited basis seems a 
reasonable way to think about the underlying determinant for these syndromes.
6.11 Triggers
It is known that the following can trigger SUNCT attacks: touching the face or scalp, 
washing, shaving, chewing, eating, brushing teeth, talking and coughing (Pareja and 
Sjaastad, 1997). Additional to this list the following potential triggers are included: 
washing or brushing the hair, light (including sunlight and fluorescent lights), blowing 
the nose, exercise, and showering. Movement of the neck has previously been shown 
either to precipitate or abort an attack (Calvo et al., 2004; Pareja and Sjaastad, 1997; 
Sjaastad et al., 1989). Triggers which are characteristically associated with CH, such as 
alcohol, smoke, strong smells and a warm environment (Matharu and Goadsby, 2002b), 
can trigger SUNCT or SUNA in a small proportion of patients. It is known that patients 
can have a mixture of spontaneous and triggered attacks, but purely triggered attacks (2 
% in this series) are hitherto unreported. This may be due to the fact that purely triggered 
attacks have been previously diagnosed as trigeminal neuralgia. It is therefore useful to 
recognise that some patients with SUNCT syndrome may experience only triggered, and 
not spontaneous, attacks.
6.12 Refractory period
Unlike trigeminal neuralgia (TN), SUNCT patients have generally been thought not to 
have a refractory period (Matharu et al., 2003a; Pareja et al., 1997). This case series bears 
out the general lack of a refractory period between attacks, so that 92 % of all patients 
can experience one attack spontaneously occurring immediately after the previous one, or 
that they can trigger an attack immediately on top of the previous one. This serves as a 
good clinical feature to distinguish TN and SUNCT, and should be asked of all patients 
who are suspected to have SUNCT or TN.
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6.13 Neurological examination
Generally the neurological examination is normal in SUNCT. There are some reports of 
allodynia or hyperaesthesia in the face (Graff-Radford, 2000; Pareja et al., 1997;
Raimondi and Gardella, 1998; Sabatowski et al., 2001), and a case of post-traumatic 
SUNCT with a sensory deficit in the first distribution of the trigeminal nerve (Putzki et 
al., 2005), and one with a persistent ipsilateral Homer’s syndrome (Prakash and Lo,
2004). This series includes six patients with SUNCT (12 %) with abnormal sensation to 
pinprick in Vj and V2 , and one with SUNA (11 %). Interestingly only one patient had 
hyperaesthesia (#46). He also had vascular loops compressing on his trigeminal nerve 
root bilaterally. The hyperaesthesia was only on the side ipsilateral to the pain. Five of six 
SUNCT patients had reduced sensation to pinprick, and in none of them was the SUNCT 
attributable to a structural cause. Therefore reduced facial sensation may occur in 
SUNCT and SUNA as a normal part of the syndromes. Trigeminal sensory pathways can 
be impaired in cluster headache as reflected by measurements of trigeminal 
somatosensory evoked potentials (van Vliet et al., 2003c), and this was thought to be due 
to higher cortical functions or central neuroplasticity (van Vliet et al., 2003c). This may 
also be due to hypothalamic activity in SUNCT or SUNA. The hypothalamus is known to 
have a role in general nociceptive control (Millan et al., 1983), there are direct 
hypothalamic-trigeminal connections (Malick and Burstein, 1998; Malick et al., 2000), 
and the hypothalamus is known to have a modulatory role on the nociceptive and 
autonomic pathways, specifically trigeminovascular nociceptive pathways (Bartsch et al., 
2004).
One patient with SUNCT had abnormal facial sensation after an infraorbital nerve block, 
which did nothing to stop his attacks. This is consistent with the notion that SUNCT is a 
centrally-driven pain syndrome, as even with iatrogenic reduction of sensation the attacks 
still occurred. This is also seen in cluster headache, where attacks have continued despite 
surgical ablation of the trigeminal nerve (Matharu and Goadsby, 2002a).
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6.14 Symptomatic SUNCT
Most cases of SUNCT are idiopathic, but there are a few cases in the literature which are 
secondary to intracranial lesions. These are either due to pituitary lesions or posterior 
fossa lesions. This study found three cases of pituitary lesions causing SUNCT: two 
macroadenomas, one of whose symptoms resolved completely and one almost completely 
on treatment of the pituitary lesion, and one microprolactinoma whose symptoms 
resolved initially for 8 months, then recurred with return of the tumour. One of the 
patients with macroadenoma has been reported previously (Matharu et al., 2003c). A 
patient with a pituitary macroadenoma had experienced symptoms of SUNCT which 
were labeled as trigeminal neuralgia (Ferrari et al., 1988). SUNCT has been described in 
patients both with microprolactinomas (Levy et al., 2003) and macroprolactinomas 
(Massiou et al., 2002; Matharu et al., 2003c), with attacks occurring on the side ipsilateral 
to the side of the tumour, suggesting a role for a direct or mechanical mode of action in 
macroadenomas, but this would not account satisfactorily for microadenomas. It has 
therefore been suggested that the attacks were predominantly neurohormonally mediated 
rather than by the size or invasiveness of the tumour (Matharu et al., 2003c). It is also 
interesting to note that headache symptoms can precede pituitary symptoms by 3-10 years 
(Ferrari et al., 1988; Massiou et al., 2002). It is now seen that headache symptoms can 
continue beyond the treatment of the tumors as in one of our patients (#20).
Cases of symptomatic SUNCT secondary to a posterior fossa abnormality include the 
following: ipsilateral cerebellopontine arteriovenous malformations in two patients 
(Bussone et al., 1991; Morales et al., 1994), a brainstem cavernous haemangioma (De 
Benedittis, 1996), a posterior fossa lesion associated with HIV/AIDS (Goadsby and 
Lipton, 1997), severe basilar impression causing pontomedullary compression in a patient 
with osteogenesis imperfecta (ter Berg and Goadsby, 2001), craniostosis resulting in a 
foreshortened posterior fossa (Moris et al., 2001) ischaemic brainstem infarction (Penart 
et al., 2001), and Devic’s syndrome (neuromyelitis optica) with lesions in both optic 
nerves and the medulla oblongata (Kursun et al., 2006). This series reports one new case 
of SUNCT secondary to an acute event of dizziness and ataxia, with an unusual
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configuration in the brainstem and lacune in the thalamus (#2). Moreover there is one 
case of SUNCT with pathological white matter changes and a lesion in the ipsilateral 
cerebral peduncle (#52), and also a case of SUNA apparently related to multiple sclerosis 
with lesions in the midbrain and pons that might account for the pain (#SUNA4).
Rare cases of SUNCT have been reported in association with vascular compression of the 
trigeminal nerve (Gardella et al., 2001; Koseoglu et al., 2005), in contrast to trigeminal 
neuralgia, for which the incidence of trigeminal nerve compression is 47-90 % (Kuroiwa 
et al., 1996; Love and Coakham, 2001; Majoie et al., 1997). In this series only three 
SUNCT patients (7 %) have vascular compression; one with the compression ipsilateral 
to the pain (#13), one with bilateral vascular compressions but only unilateral pain (#56), 
and one with unilateral compression but bilateral pain (#55). The question therefore arises 
as to the role of trigeminal nerve root compression by vascular loops, as it is possible to 
have vascular compression without attacks, and also attacks on the side contralateral to 
the compression. It may be that the vascular loops are incidental findings.
The database includes one SUNCT patient with generalised cerebral white matter lesions 
(#7), and 2 patients with parietal or parieto-occipital lesions that anatomically may not 
account for the pain: #57 and #51, who also had an ipsilateral VI nerve and contralateral 
XII nerve palsy due to a head injury. It is unclear as to whether these lesions were a direct 
cause of the SUNCT attacks, or whether they are incidental findings unassociated with 
the headache symptoms. Indeed in both patients with space-occupying lesions, the 
symptoms persisted even after their excision.
The concept of post-traumatic headache requires that the headache syndrome starts within 
seven days of sustaining the trauma (Headache Classification Committee of The 
International Headache Society, 2004). In this series there are two patients (#42 and #52) 
with onset of SUNCT within one week of trauma. For other SUNCT patients (Table 5.3) 
the trauma is less acute, although occurring within weeks in each case. However it may 
remain that these headache syndromes were precipitated as a result of the trauma 
sustained. Chronic headache following trauma to the head or neck is well described, with
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the duration of headache being independent of the type or severity of trauma (Warner, 
2000). Axonal injury and shearing effects are well documented in both animals and 
humans after direct mild to moderate head injury, and physiological changes have been 
noted after concussion injuries (Saper, 2000). It is therefore plausible to speculate that, 
just as the dorsal raphe nucleus may sustain a physiological abnormality post- 
traumatically, and lead to chronic migraine (Raskin et al., 1987), there may be a 
physiological shift in the hypothalamus following trauma which may lead to the 
development of SUNCT or SUNA.
6.15 SUNA
SUNA- Short-lasting Unilateral Neuralgiform headache attacks with cranial Autonomic 
features, may include SUNCT and simplifies the classification of patients without the C 
or the T component. However, for the moment given how distinctive SUNCT is 
clinically, keeping the separation may be useful. SUNA patients have attacks similar to 
SUNCT in location, duration, frequency and severity, but there is a lack of conjunctival 
injection, and instead there are other cranial autonomic symptoms (Headache 
Classification Committee of The International Headache Society, 2004). Pure SUNA is 
rather rare, having only one other case reported in the literature (Volcy et al., 2005). The 
clinical phenotype and response to medications are in most other respects very similar to 
SUNCT. The reason for labelling these patients with the diagnosis of SUNA is partly 
because SUNCT by definition requires conjunctival injection and tearing, and partly 
because there may be many more patients in general neurological and clinical practice 
who have SUNA but have been misdiagnosed due to the lack of autonomic symptoms in 
the eye. This study reports the only series of patients in the literature with SUNA. Most 
patients had primary chronic SUNA, with one patient experiencing spontaneous 
remission, as opposed to the 65 % of SUNCT patients who had episodic SUNCT at some 
point during their disease.
The site of attacks was more varied for SUNA than SUNCT; particularly the temple, side 
of the head, and V3 were affected more in SUNA than in SUNCT. There were no SUNA
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patients whose attacks could be triggered by touch, as opposed to 63 % of SUNCT 
patients in whom touching the face could trigger attacks. Cranial autonomic symptoms 
were more varied in SUNA, without the duo of conjunctival injection and lacrimation, 
and with more diverse autonomic symptoms, such as mydriasis and ear flushing, which 
were not present in SUNCT. Indeed one would predict from the experimental and human 
physiology that a different involvement of the trigeminal sub-divisions would produce 
differences in the activation of the cranial autonomic pathways (Goadsby and Lipton, 
1997; May et al., 2001). All of these differences, which would be contrary to the usual 
picture of SUNCT, could account for the under diagnosis of SUNA in the general and 
neurological clinics. However the basic phenotype of the disease remains the same in 
SUNCT and SUNA; that is the length, frequency and severity of attacks; the type and 
temporal character of the pain; the presence of cranial autonomic symptoms, the ability to 
trigger attacks, the lack of refractory period between attacks, and the nocturnal 
occurrence, but not preponderance, of attacks. A change to the current classification is 
therefore proposed for these headache syndromes, based on this series (Table 6.1).
116
Table 6.1
Proposed diagnostic criteria for SUNCT and SUNA
Short-lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and 
Tearing (SUNCT) or cranial Autonomic features (SUNA)
3.3R Diagnostic criteria:
A. At least 20 attacks fulfilling criteria B-E
B. Attacks of short-lasting (1-600 s) unilateral head pain
a. orbital, supraorbital, temporal or other trigeminal distribution of moderate or 
severe pain
b. occurring as
i. Single stabs
ii. Groups of stabs
iii. In a saw-tooth pattern
c. Triggerable without a refractory period
C. Pain is accompanied ipsilaterally by either:
a. Conjunctival injection and Tearing (SUNCT), or,
b. One or more of the following cranial Autonomic symptoms (SUNA)
i. conjunctival injection, or tearing, but not both
ii. nasal congestion and/or rhinorrhoea
iii. eyelid oedema
iv. ipsilateral sense of aural fullness or peri-aural swelling
v. ipsilateral forehead and facial sweating
vi. ipsilateral miosis and/or ptosis
D. Attacks occur with a frequency of >1 per day for more than half the time when the 
disorder is active
E. Not attributed to another disorder
A 3.3.1 Episodic SUNCT/SUNA
Description: SUNA attacks occurring for 7 days to 1 year with pain free intervals longer 
than 1 month
A 3.3.2 Chronic SUNCT/SUNA
Description: At least 2 attack periods last 7 days to 1 year separated by remission periods 
of less than one month (untreated).
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6.17 Summary
A prospective clinical study in 52 patients with SUNCT and SUNA was performed. This 
study revealed 43 patients with SUNCT and nine with SUNA. The clinical phenotype of 
both conditions has been characterised. Suggestions of changes to the International 
Headache Society classification have been made, based on these cases. In view of the 
widely varying range of attack character, frequency and duration, it appears that many 
patients were misdiagnosed with conditions such as trigeminal neuralgia and other 
trigeminal autonomic cephalgias (TACs), such as cluster headache and paroxysmal 
hemicrania. A system is proposed in order to assess the temporal pattern, duration and 
frequency of attacks in terms of stabs, groups of stabs and saw-tooth attacks; and the 
concept of attack load in terms of minutes of pain per day. The concept of a constant 
background pain in these syndromes is noted, along with the implication this has on 
patients with a history of migraine, migraine biology and analgesic overuse. The ability to 
trigger attacks is observed, specifically the concept of attacks which are 100% triggered; 
and the overwhelming lack of a refractory period between attacks that is now 
characteristic of SUNCT/SUNA. In terms of symptomatic SUNCT/SUNA, the 
importance of posterior fossa abnormalities is explored. The concept of post- traumatic 
SUNCT and SUNA has been discussed; as has the issue of vascular loops compressing 
on the trigeminal nerve root, for which the evidence as a causative factor to the pain is 
much less robust than in trigeminal neuralgia.
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Chapter 7
Results: Clinical Study of Treatment of SUNCT and SUNA
7.1 Diagnosis and time to diagnosis
All patients gave information about practitioners consulted prior to consulting or being 
referred to the National Hospital for Neurology and Neurosurgery. All patients had seen 
at least one GP. Thirty-eight SUNCT patients (88%) and 8 SUNA patients (89%) had 
seen another neurologist prior to consultation at the National Hospital. In total, 3 patients 
had seen dentists, 4 had seen ENT surgeons, 4 had seen ophthalmologists and 3 had seen 
pain specialists.
The diagnosis of SUNCT was made by the neurologists at the National Hospital for 
Neurology and Neurosurgery in 30 patients (70%). Diagnoses were made by neurologists 
at other hospitals in 12 (28%) of SUNCT patients. The diagnosis of SUNA was made 
entirely by neurologists at the National Hospital for Neurology and Neurosurgery. It took 
an average of 6.7 years from the onset of SUNCT (median 5, range 0.25-24 years) for a 
diagnosis to be made, and a mean 7.1 years (median 2, range 1-46 years) for the diagnosis 
of SUNA. These are illustrated in Table 7.1.
7.2 Previous Diagnoses
Patients were diagnosed with a number of conditions before their SUNCT or SUNA was 
diagnosed. These conditions include: trigeminal neuralgia (18 SUNCT, 1 SUNA), cluster 
headache (11 SUNCT, 1 SUNA), paroxysmal hemicrania (4 SUNCT, 4 SUNA), 
trigeminal autonomic cephalgia not otherwise specified (6 SUNCT, 1 SUNA), 
hemicrania continua (1 SUNCT, 1 SUNA), migraine (5 SUNCT, 2 SUNA), dental 
problems (2 SUNCT), post herpetic neuralgia (2 SUNCT), demyelination (2 SUNCT); 
and others including post herpetic neuralgia, cerebral vasculitis, migrainous facial 
neuralgia, psychosomatic symptoms, chronic daily headache with analgesic overuse, 
Bell’s palsy, multiple sclerosis, seizures, primary stabbing headache, stress and temporal
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arteritis in 1 SUNCT patient each; and temporal arteritis in 1 SUNA patient. 3 SUNA 
patients (33%) had been previously diagnosed with SUNCT. These are illustrated in 
Table 7.2.
Table 7.1
Practitioners seen prior to diagnosis of SUNCT/SUNA, final diagnostician, and years to 
diagnosis
Practitioners seen prior to 
diagnosis SUNCT SUNA total
GP 43
(100%) 9 (100%) 52 (100%)
Neurologist 38 (88%) 8 (89%) 46 (88%)
Dentist 3 (7%) 0 (0%) 3 (6%)
ENT surgeon 3 (7%) 1 (11%) 4 (8%)
Ophthalmologist 3 (1%) 1 (11%) 4 (8%)
Pain Specialist 2 (5%) 1 (11%) 3 (6%)
Diagnosis made by: SUNCT SUNA total
Other neurologist 12 (28%) 0 (0%) 12 (23%)
Neurologist at NHNN 30 (70%) 9 (100%) 39 (75%)
unknown 1 (2%) 0 (0%) 1 (2%)
Years to diagnosis
mean 6.7 7.1
median 5 2
range of years to diagnosis 0.25-24 1-46 years
Table 7.2
Diagnoses made prior to SUNCT/SUNA
SUNCT SUNA
Trigeminal neuralgia 18 (42%) 1 (11%)
Cluster headache 11 (26%) 1 (11%)
Paroxysmal hemicrania 4 (9%) 4 (44%)
TAC not otherwise specified 6 (14%) 1 (11%)
Hemicrania continua 1 (2%) 1 (11%)
Migraine 5 (12%) 2 (22%)
Other 13 (30%) 1 (11%)
SUNCT n/a 3 (33%) *
* missing C or T (conjunctival injection or acrimation)
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Treatments
7.3 Abortive Therapies
Triptans
Eleven SUNCT patients and 4 SUNA patients had triptans. Five SUNCT patients had 
oral triptans (sumatriptan, rizatriptan, naratriptan) with no effect. Subcutaneous 
sumatriptan 6mg in SUNCT aborted the attacks in one patient, reduced the length of the 
attacks in 1 patient and had no effect in a further 3 patients. It had no effect in all 3 
SUNA patients who tried it. Intranasal sumatriptan 20mg had a minimal effect in one 
SUNCT patient and no effect in 1 SUNA patient.
Oxygen
Oxygen at high flow (100%, 9-12 1/min) was delivered to 10 patients with SUNCT and 5 
with SUNA. It had no effect in 7 of the SUNCT patients, and no effect in any of the 
SUNA patients. In one SUNCT patient it changed the quality of the attacks from sharp to 
burning, one had a minimal effect on the attacks, and one patient reported that oxygen 
was useful in his concomitant cluster headache (#34). Oxygen at low flow (4 1/min) had 
no effect in 1 SUNCT patient.
Intranasal Lidocaine
Intranasal lidocaine had a moderate effect in one SUNCT patient and one SUNA patient, 
and minimal to no effect in 5 SUNCT and 2 SUNA patients. These are illustrated in 
Table 7.3.
Table 7.3
Abortive therapies
SUNCT SUNA
Number
of
patients
effective ineffective
Number
of
patients
effective ineffective
sumatriptan subcutaneous 5 2 (40%) 3 (60%) 3 0 (0%) 3 (100%)
sumatriptan intranasal 1 0 (0%) 1 (100%) 1 0 (0%) 1 (100%)
oral triptans 5 0 (0%) 5 (100%) 0 0 0
oxygen high flow 10 0 (0%) 10 (100%) 5 0 (0%) 5 (100%)
oxygen low flow 1 0 (0%) 1 (100%) 0 0 0
intranasal lidocaine or 
xylocaine 6 1 (17%) 5 (83%) 3 1 (33%) 2 (67%)
Table 7.4
Short-term preventive agents; intramuscular indomethacin and intravenous lidocaine
SUNCT SUNA
Number
of
patients
effective ineffective
Number
of
patients
effective ineffective
Indomethacin test 12 0 (0%) 12 (100%) 4 0 (0%) 4 (100%)
oral indomethacin 19 2 (11%) 17 (89%) 4 0 (0%) 4 (100%)
intravenous lidocaine 11 11 (100%) 0 (0%) 4 4 (100%) 0 (0%)
Table 7.5
Indotest in SUNCT and SUNA
patient
number diagnosis number of attacks/24 hours
post placebo post indomethacin effect on background pain
2 SUNCT 4 4
12 SUNCT same same
13 SUNCT
5-15 attacks of a few seconds, 5 
attacks lasting minutes
some reduction in the longer 
attacks
27 SUNCT same same
29 SUNCT 8 attacks without indomethacin 9
34 SUNCT same same
36 SUNCT 5/day 5/day
53 SUNCT same same
56 SUNCT 7 5
57 SUNCT 6 7
39 SUNCT indotest at another hospital reported as negative
55 SUNCT indotest at another hospital reported as negative
SUNA1 SUNA 22 9
reduced for 4-5 hours, not after 
placebo
SUNA44 SUNA 11 16
SUNA41 SUNA 16 22
SUNA59 SUNA 7 6 no significant changes for either
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7.4 Short-term Preventive Medications
Indomethacin
A modified Indotest was performed in 12 SUNCT and 4 SUNA patients, with single­
blinded placebo-controlled indomethacin injections, and their responses were recorded in 
terms of number of attacks in the 24 hours after each treatment. In one SUNCT patient 
(#29) the response to placebo was lost in the notes. Two SUNCT patients had this 
procedure done at other hospitals, and their results were reported in the notes. The 
modified Indotest was reported as negative in 100% of these patients; that is it did not 
significantly reduce the number, frequency or duration of their attacks as compared to a 
saline injection given in a blinded fashion. Although in 1 patient (#SUNA1), there was a 
reduction in the number of attacks and some reduction in the background pain, this was 
not considered to be a clearly positive result for indomethacin. This is illustrated in 
Tables 7.4 and 7.5.
Oral indomethacin was given in doses of 50mg-300mg a day in 19 SUNCT and 4 SUNA 
patients. It was ineffective in 17 SUNCT (89%) and all 4 SUNA patients (100%). It had a 
good effect for a few months at lOOmg daily in one SUNCT patient, before the effect 
wore off. It reduced the intensity of the attacks at 300mg daily in one SUNCT patient. It 
caused side effects in 2 SUNCT and 2 SUNA patients, including abdominal pain, 
haematuria and rectal bleeding.
Intravenous lidocaine
Intravenous lidocaine at doses of up to 3.5 mg/kg/minute was infused into 11 SUNCT 
and 4 SUNA patients. One SUNCT patient had the infusion on two occasions. It had a 
moderate to good effect in all 11 patients. It rendered 7 SUNCT patients pain free for 
times varying between the duration of the infusion to 6 months. In 2 SUNCT patients it 
reduced the severity of their attacks, and in a further patient it reduced the severity of the 
background pain and the frequency of the attacks. In one patient (#13) the attacks were 
completely abolished, and the patient was started on topiramate up to a dose of 150mg 
daily towards the end of the infusion, so it is unclear as to how long the infusion would
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have rendered him pain free. Patients suffered side effects of cognitive symptoms (7 
patients), including depression (2 patients), hallucinations, paranoid ideations and 
agitation. One patient (#34) suffered palpitations and had atrial fibrillation at 
2.45mg/kg/hour, which resolved on reducing the flow rate. One patient had a tachycardia 
and one had bradycardia with heart rate 45-49 bpm, both of which resolved on reducing 
the rate. In the four SUNA patients, all were rendered pain free or almost pain free for 2 
days to 12 weeks. Two of these patients suffered with emotional lability for the duration 
of the infusion.
Most patients were not taking concomitant preventive medications during the infusions. 
There are 2 exceptions: #13 who was started on topiramate up to a dose of 150mg daily 
towards the end of the infusion, and #21 who was taking gabapentin 3600mg daily 
throughout his hospital admission. These are illustrated in Table 7.4, and in more detail in 
Table 7.6. Figure 7.1 is a graphical representation of patient #SUNA41, who had the most 
striking result in that a 6-day lidocaine infusion at a maximum of 3mg/minute 
(2.5mg/kg/hour) rendered her pain free for 12 weeks.
One SUNCT patient (#36), in whom the subcutaneous sumatriptan had a moderate effect 
in reducing the length of the attacks, received an infusion of intravenous 
dihydroergotamine 3mg/24 hours for 3 days, and it had a moderate effect in reducing the 
length and frequency of her attacks. This was the same patient for whom subcutaneous 
sumatriptan reduced the attack length.
Table 7.6
Intravenous Lidocaine in SUNCT and SUNA
Patient
no diagnosis weight/ kg maximum dose lidocaine
duration of 
infusion
daily number of 
attacks other effect
duration 
of effect side effects
mg/min mg/kg/hour days
pre
lidocaine
on
lidocaine
2 SUNCT 102.5 4 2.34 7 5 0 eliminated background pain 1.5 weeks
7 SUNCT 87.5 3 2.06 5 19 0 3 weeks
nausea,
depression
12 SUNCT 72 3 2.5 2 many few 1 day
hallucinations,
anxiety
13 SUNCT unknown 2 4 8 0 highly effective in 1 hour unsure bradycardia
21 SUNCT 132 3 1.37 7 24 5 eliminated background pain 1 month mildly irritable
22
Episodic
SUNCT 90.5 2 1.33 3 5 0 6 months
tachycardia, 
facial flushing
53 SUNCT 62 3.7 3.5 5 same same reduced severity of attacks
duration
infusion
agitated,
tearful
27 SUNCT unknown 2 3 85 0
duration
infusion
34 SUNCT 98 4 2.45 5 <150 0 reduced background pain
duration
infusion
atrial
fibrillation
36 SUNCT 57
3.5 (1st 
admission) 3.4 4 3.5 0 reduced background pain 2 days paranoid
36 SUNCT 57
3 (2nd 
admission) 3.16 4 6 0 reduced background pain 2.5 days paranoid
57 SUNCT 107 4 2.24 4 16 3 reduced length & frequency
duration
infusion depressed
SUNA1 SUNA 70 3 2.57 6 14 1 2 days
agitated,
nightmares
SUNA44 SUNA 88 3 2.05 5 10 0
autonomic symptoms 
without pain 2 days tearful
SUNA41 SUNA 71 3 2.54 6 18 0 eliminated background pain 12 weeks dizzy
SUNA59 SUNA 83 2 1.45 6 9 3 eliminated background pain 1 week
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Figure 7.1
Graph showing number o f attacks per day for Patient SUNA41 before and after 
intravenous lidocaine
Graph for #SUNA41 on intravenous lidocaine
■lidocaine dose mg/min 
■number of attacks/day
days
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7.5 Preventive medications
7.5.1 Lamotrigine
Twenty-five SUNCT and four SUNA patients received lamotrigine in doses of 50-400mg 
daily in an open-label fashion. In nine SUNCT patients and one SUNA patient the 
lamotrigine had a good effect in suppressing their attacks. Lamotrigine was moderately 
effective in 8 SUNCT patients, either alone or in combination with gabapentin, 
amitriptyline, topiramate, or carbamazepine. In 6 of these patients the lamotrigine had to 
be stopped before the optimum dose was achieved, because they were experiencing side 
effects. In 8 SUNCT and 3 SUNA patients there was no beneficial effect; indeed 
lamotrigine actually made two patients’ SUNCT attacks worse.
Side effects were reported in 11 patients; these included anaphylactic reaction in 2 
patients, skin rash in 4 patients, and also arthralgia, cognitive slowing, flu-like symptoms, 
mood swings, and sedation. In one patient the lamotrigine suppressed the SUNCT but 
made her migraine worse.
7.5.2 Topiramate
Twenty-one patients with SUNCT received topiramate in an open-label fashion at doses 
of 25-400mg daily. There was a moderate to good effect in 11 patients (52%), nine of 
whom reported a good effect in abolishing their attacks. One patient combined topiramate 
with lamotrigine. In 10 SUNCT (48%) patients there was little or no beneficial effect of 
topiramate. In one SUNCT patient the attacks were worsened on topiramate. Side effects 
were reported in 9 SUNCT patients (43%); these included renal stones in 2 patients, 
which necessitated withdrawal of topiramate, peripheral paraesthesiae (2 patients), 
anorexia and weight loss (2 patients), and cognitive side effects including sedation, mood 
swings and memory loss (7 patients).
One patient with SUNA received topiramate 800mg daily. There was no beneficial effect 
at this dose, although it improved her migraine headaches.
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7.5.3 Carbamazepine
Thirty-six patients with SUNCT and 5 with SUNA received carbamazepine at doses of 
100-1600mg daily. There was a good effect in 4 SUNCT patients, either alone or in 
combination with lamotrigine, although in 2 of these this could have coincided with the 
end of their bout of attacks. In 10 SUNCT and 1 SUNA patient there was a moderate 
effect in that their attacks were reduced but not suppressed completely. In 22 SUNCT and 
4 SUNA patients there was little or no beneficial effect of carbamazepine. Side effects 
were reported in 2 SUNA and 14 SUNCT patients; these included drowsiness, skin rash 
and cognitive slowing.
7.5.4 Gabapentin
Twenty-two patients with SUNCT and 5 patients with SUNA received gabapentin at 
doses of 600-3600mg daily. In 1 SUNCT patient there was complete abolition of attacks. 
In 9 SUNCT patients and 3 SUNA patients gabapentin was moderately effective, either 
alone or in combination with other drugs such as amitriptyline, lamotrigine or 
carbamazepine. There was minimal to no effect in 12 SUNCT and 2 SUNA patients. In 2 
SUNCT patients their attacks were actually worsened on the gabapentin.
Side effects were reported in 7 SUNCT (32%) and 2 SUNA patients (40%). These 
included skin rash, sedation, mood swings, weight gain, diarrhoea and arthralgia.
7.5.5 Valproate
Sodium Valproate was given to 9 SUNCT patients and one SUNA patient, at doses of 
400- 1600mg daily. In all patients there was no effect.
7.5.6 Amitriptyline
Twenty-four SUNCT patients and 7 SUNA patients received amitriptyline at doses of 25- 
150mg daily. In 23 SUNCT and all 7 SUNA patients there was no effect. In one SUNCT 
patient there was a moderate effect at 150mg daily, but there were side effects of dry 
mouth and drowsiness.
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7.5.7 Melatonin
One SUNCT patient and two SUNA patients received melatonin at 9mg daily. In the 
SUNCT patient there was a reduction in the frequency of his attacks. In one SUNA 
patient there was a mild effect with melatonin but it made her migraine worse. It was 
ineffective in the other SUNA patient and caused drowsiness as an adverse effect.
7.5.8 Pregabalin
Two SUNCT patients and one SUNA patient received pregabalin at doses of 150-600mg. 
This had a good effect in one SUNCT patient which wore off after a few months, a 
moderate effect in 1 SUNCT patient in combination with topiramate and a greater 
occipital nerve injection, and minimal to no effect in the SUNA patient. Two patients 
experienced cognitive side effects which necessitated withdrawal of the pregabalin.
7.5.9 Steroids
Twelve SUNCT patients and 2 SUNA patients received prednisolone at doses of 30- 
80mg daily. In 2 patients this had a moderate effect (#20 who received 30mg daily in 
combination with cabergoline and octreotide after hypophysectomy for a pituitary 
macroadenoma, and #9 who took 80mg of prednisolone daily). In the remaining 10 
SUNCT and 2 SUNA patients there was no effect.
7.5.10 Verapamil
Nine patients with SUNCT received verapamil at doses between 120 and 800mg daily. It 
had a mild effect in one patient at 800mg but made him drowsy, and had no effect in the 
other patients. In SUNA, verapamil at 240 mg/day had a good effect in one patient 
(MC40) with a good effect in reducing his other TAC (cluster headache) as well.
7.5.11 Lithium
Two patients with SUNCT and one with SUNA had lithium, at therapeutic doses with 
serum lithium levels 0.8-1 -lumol/1. In all 3 patients there was no effect. These are 
illustrated in Table 7.7.
Table 7.7
Preventive medications and greater occipital nerve block (GON) in SUNCT/ SUNA
SUNCT SUNA
No. of patients effective ineffective No. of patients effective ineffective
lamotrigine (LTG) 25 17 (68%) 8 (32%) 4 1 (25%) 3 (75%)
topiramate (TPM) 21 11 (52%) 10 (48%) 1 0 (0%) 1 (100%)
carbamazepine (CBZ) 36 14 (39%) 22 (61%) 5 1 (20%) 4 (80%)
gabapentin (GBP) 22 10(45%) 12(55%) 5 3 (60%) 2 (40%)
valproate (VPA) 9 0 (0%) 9(100%) 1 0 (0%) 1 (100%)
amitriptyline (Ami) 24 1 (4%) 23 (96%) 7 0 (0%) 7 (100%)
melatonin 1 1 (100%) 0 (0%) 2 0 (0%) 1 (100%)
pregabalin (PRG) 2 2 (100%) 0 (0%) 1 0 (0%) 1 (100%)
prednisolone 12 2(17%) 10(83%) 2 0 (0%) 2 (100%)
verapamil 9 0 (0%) 9(100%) 1 1 (100%) 0 (0%)
lithium 2 0 (0%) 2 (100%) 1 0 (0%) 1 (100%)
combinations
GBP + CBZ 1 0 (0%) 1 (100%) 1 1 (100%) 0 (0%)
GBP + CBZ + Ami 1 1 (100%) 0 (0%)
TPM + CBZ 1 1 (100%) 0 (0%)
TPM + CBZ + Ami 1 0 (0%) 1 (100%)
GBP + LTG 2 1 (50%) 1 (50%)
GBP + LTG + Ami 1 1 (100%) 0 (0%)
TPM + LTG 2 2 (100%) 0 (0%)
LTG + CBZ 1 1 (100%) 0 (0%)
GBP + Ami + NSAID 2 1 (50%) 1 (50%)
CBZ + Ami 1 1 (100%) 0 (0%)
TPM + PRG + GON 1 1 (100%) 0 (0%)
GON injection 8 5 (63%) 3 (37%) 1 0 (0%) 1 (100%)
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7.5.12 Other Preventive Medications
One SUNCT patient had methysergide 4mg daily. Four SUNCT patients and 2 SUNA 
patients had propranolol up to 160 mg daily. None of these had any effect. Also tried 
were: paracetamol/codeine preparations (18 patients), ibuprofen (10 patients), diclofenac 
(6 patients), aspirin (5 patients), codeine (4 patients), dothiepin (4 patients), clonazepam 
(4 patients), celecoxib (3 patients), morphine (3 patients), pizotifen (3 patients); 2 patients 
each with oxcarbazepine, diazepam, phenytoin, lofepramine, fluoxetine, baclofen; and 1 
patient each with naproxen, rofecoxib, leviteracetam, tizanidine, prothiaden, sertraline, 
mirtazapine, cannabis, ketamine, chlorpromazine, nabilone, and intranasal EMLA. All of 
these had no effect apart from a mild effect with ibuprofen, diclofenac and morphine in 1 
patient each. Leviteracetam1000 mg daily in one patient made the SUNCT worse.
7.5.13 Combinations of Preventives
Combinations of preventive medications were used in 11 SUNCT and 1 SUNA patient. 
Some patients had more than one combination. The following combinations of 
preventives were used in SUNCT: gabapentin and carbamazepine (ineffective in one 
patient, effective in one patient with addition of amitriptyline), topiramate and 
carbamazepine (effective in one patient, and in one further patient with addition of 
amitriptyline), gabapentin and lamotrigine (effective in one patient, ineffective in one 
patient, effective in one patient with addition of amitriptyline), topiramate and 
lamotrigine (effective in 2 patients), lamotrigine and carbamazepine (effective in one 
patient), gabapentin and amitriptyline and a NSAID (effective in one and ineffective in 
one patient), carbamazepine and amitriptyline (effective in one patient), and topiramate 
and pregabalin plus a greater occipital nerve injection (effective in one patient). A 
combination of gabapentin and carbamazepine was effective in one SUNA patient. These 
are illustrated in Table 7.7.
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7.6 SUNCT secondary to pituitary disease
Three patients had SUNCT secondary to pituitary disease. One (#20) had a 
macroadenoma for which he underwent a transsphenoidal hypophysectomy and 
radiotherapy. His SUNCT persisted and he was treated with cabergoline 500mg twice a 
week, prednisolone 30 mg daily, and octreotide injections once a month, which almost 
abolished his SUNCT.
The second (#25) had a microadenoma which was resected in 1987 and a residual 
microadenoma removed in 2002, with some resolution of her SUNCT after the second 
resection. She was treated with bromocriptine, cabergoline and octreotide, all of which 
increased her SUNCT symptoms. She had a good effect with Lamotrigine 125mg daily, 
but this gave her side effects of a skin rash and flu-like symptoms.
The third patient (#37) had SUNCT secondary to a large prolactinoma. His SUNCT 
resolved on both bromocriptine 2.5mg twice daily, and cabergoline 1.5mg/week, with 
corresponding resolution of his pituitary symptoms and prolactin levels. His case has 
been previously reported (Matharu et al., 2003c).
7.7 Non-pharmacological manipulations
7.7.1 Greater Occipital Nerve Injection
Eight SUNCT patients and one SUNA patient underwent injection of 2% lidocaine and 
80mg depomedrone in the region of the ipsilateral greater occipital nerve (GON), the 
method of which has been described previously (Shields et al., 2004).
Five SUNCT patients (63%) experienced a good effect in that it rendered them pain free 
for one week to 6 months. In one of these patients the attacks returned after 2 weeks but 
on the contralateral side to the injection. In 3 SUNCT patients (37%) there was no effect, 
and the SUNA patient had a minimal transient effect. These are illustrated in Table 7.7.
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7.7.2 Other non-pharmacological manipulations
Six SUNCT patients underwent other procedures. Some patients had more than one 
intervention. These were: microvascular decompression, sphenopalatine marcaine 
injection, retrogasserian alcohol block, all of which had no effect at all. One patient had a 
supraorbital nerve injection and one had an infraorbital nerve injection which caused 
numbness but the attacks were still triggerable. One patient had a C2 nerve block which 
rendered her pain free for one year. One had a trigeminal nerve procedure otherwise 
unspecified, which rendered her pain free for 3 years.
Two SUNCT patients and one SUNA patient had TENS therapy (Transcutaneous 
Electrical Nerve Stimulation); in all three patients this was ineffective.
7.8 Alternative therapies
Eleven SUNCT and one SUNA patients sought alternative therapies. Eight SUNCT and 
one SUNA patient had acupuncture. This had a good effect in one patient, rendering him 
painfree for weeks at a time, with reproducible effects on repeated treatments. It had a 
moderate effect in 2 patients and a mild effect in one patient. It had no effect in 4 SUNCT 
patients and the SUNA patient. Indian head massage had no effect in 3 SUNCT patients. 
Osteopathy had a mild effect in one patient, and homeopathy was ineffective in one 
patient. These are illustrated in Table 7.8.
1JH-
Table 7.8
Acupuncture and other alternative therapies in SUNCT and SUNA
SUNCT SUNA
Number
of
patients
effective ineffective
Number
of
patients
effective ineffective
acupuncture 8 5 (63%) 3 (37%) 1 0 (0%) 1 (100%)
Indian head massage 3 0 (0%) 3 (100%)
osteopathy 1 0 (0%) 1 (100%)
homeopathy 1 0 (0%) 1 (100%)
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7.9 Triggering
There was no nitroglycerin-triggering of attacks in 5 of 6 SUNCT patients (83%), and 
both SUNA patients. The one patient in whom GTN triggered an attack (#20) had 
SUNCT secondary to a prolactinoma. GTN did not trigger migraine in the 2 SUNCT and 
2 SUNA patients who had a history of migraine, although it did cause a generalised 
featureless headache in one SUNCT patient (#35). This is illustrated in Table 7.9.
In five of 6 SUNCT patients (83%) and both SUNA patients (100%), sublingual GTN 
would not trigger an attack. Two SUNCT and both SUNA patients had personal histories 
of migraine. In one patient with no previous history of migraine, nor any family history of 
migraine (#35), the GTN triggered a generalised throbbing headache with nausea which 
lasted for one hour, but not an attack of SUNCT. One SUNCT patient (#20) had one 
attack triggered by GTN. This patient had SUNCT secondary to a pituitary 
macroadenoma. These results are tabulated in Table 7.9.
Table 7.9
Concomitant migraine, nitroglycerin triggering and oxygen
Patient
number Diagnosis Effect of GTN Effect of oxygen Migraine
7 SUNCT - no effect no
12 SUNCT negative no effect no
13 SUNCT mild no
20
secondary
SUNCT positive no
22 SUNCT - no effect yes
29 SUNCT negative no effect yes
34 SUNCT - no effect yes and CH
35 SUNCT
no SUNCT but generalised 
headache no
36 SUNCT negative no effect no
46 SUNCT negative no effect at low flow yes
53 SUNCT - no effect yes
56 SUNCT - no effect no
57 SUNCT - changed quality of pain no
SUNA1 SUNA - minimal no
SUNA40 SUNA - no effect yes and CH
SUNA41 SUNA negative no effect yes
SUNA44 SUNA - no effect yes
SUNA59 SUNA negative no effect yes
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Chapter 8
Results: Double-blind, placebo-controlled trial of topiramate in SUNCT
and SUNA
All 5 patients completed the trial. One patient (#5) only gave data for attack frequency, 
and not for the duration of his attacks.
One patient (#47) had a good effect whilst on placebo, with complete cessation of his 
attacks. On topiramate there was an increase of both attack frequency and attack load.
The total headache load was the same as attack load, as he had no other headache 
syndromes.
One patient (#21) had increased frequency of his attacks on topiramate, although the 
attack load and headache load in terms of minutes per day of pain, were both reduced on 
topiramate. The headache load was also reduced on placebo. This patient had no other 
primary headache syndromes documented; however his ‘other headaches’ reported in this 
study were painful episodes lasting 25-720 minutes (mean 174 minutes). These could 
have been prolonged attacks of SUNCT, as this patient was known to suffer groups of 
stabs of SUNCT; each individual stab would last one second but the groups could go on 
for an hour or more. In this case the patient recorded each of these prolonged episodes as 
one attack. The analysis was done both including and excluding these episodes.
The third patient (#27) had complete cessation of his attacks on topiramate, and a milder 
but less significant reduction of frequency of his attacks (15% reduction) on placebo. He 
did not give any information as to the length of each attack.
The fourth patient (#34) had a mildly reduced SUNCT attack load on topiramate, but an 
increase in headache load on topiramate when his other headache syndromes were taken 
into account. There was no beneficial effect on placebo.
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The fifth patient (#38) had an insignificant reduction of his attack frequency on 
topiramate, but an increase in attack load, which was the same as his total headache load. 
He had a history of episodic migraine, but had no actual migraine attacks during the trial. 
He had no beneficial effect on placebo.
The results are shown in Table 8.1.
Side effects
One patient (#8) reported peripheral paraesthesiae on topiramate. One patient (#4) 
reported peripheral paraesthesiae on both treatments, and also had dull headache attacks 
whilst on both treatments, which were not related to his SUNCT or migraine, and not 
recorded as such. He had one episode of diplopia lasting an hour on placebo, and reported 
indigestion whilst on topiramate.
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Table 8.1
Change in attack frequency for placebo and topiramate
Patient
Patient number #47 #21 #27 #34 #38
Age 72 54 60 59 51
Episodic or chronic Episodic Primary chronic Secondary
chronic
Primary chronic Episodic
Other headaches Nil Nil Nil migraine with aura 
cluster headache
Episodic
migraine
Mean duration of 
SUNCT attacks
120-
1800sec
1 sec stabs, up to 
3600sec groups
5 sec 1 sec stabs, 300sec 
groups
60 sec
Daily frequency of 
attacks pre plac/max plac
7; 0 13; 19 140; 118 13; 16 10; 9
% change in frequency 
on placebo
-100% +52% -15% +22% -10%
Daily frequency of 
attacks pre TPM/max 
TPM
2; 35 23; 28 138; 0 10,13 6; 5
% change in frequency 
on TPM
+2063% +19% -100% +27% -18%
Daily attack load pre 
plac/max plac
2.93; 0 5.42; 15.1 n/a 92.6;271.1 10.7; 15.5
% change in attack load 
on placebo
-100% +178% n/a +192% +45.2%
Daily attack load pre 
TPM/max TPM
56.9;
580
33.1; 9.56 n/a 197;164 3.15; 8.175
% change in attack load 
on TPM
+920% -71.1% n/a -16.8% +160%
Total headache load pre 
plac/max plac
2.93; 0 5945; 160 n/a 105; 271 10.7; 15.5
% change total headache 
load on placebo
-100% -97.3% n/a +159% +45.2%
Total headache load pre 
TPM/max TPM
56.9;
580
161; 9.56 n/a 207; 232 3.15; 8.175
% change total headache 
load on TPM
+920% -94% n/a +12.2% +160%
Effect of placebo on 
frequency
1 0 0 0 0
Effect of placebo on 
attack load
1 0 n/a 0 0
Effect of placebo on 
headache load
1 1 n/a 0 0
Effect of TPM on 
frequency
0 0 1 0 0
Effect of TPM on attack 
load
0 1 n/a 0 0
Effect of TPM on 
headache load
0 1 n/a 0 0
Key: plac = placebo, TPM = topiramate, max TPM = maximum dose topiramate
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Chapter 9 
Results: Double-blind, placebo-controlled trial of lamotrigine in SUNCT 
and SUNA
Six patients with SUNCT and one with SUNA were screened for the study. Other patients 
were excluded because they were already taking lamotrigine, or had experienced side 
effects on it previously. Some patients declined to participate in the study as they were 
already established on an effective preventive medication, or did not want to take a 
placebo for a few months with the prospect of the attacks being uncontrolled during that 
time.
3 SUNCT and 1 SUNA patient were randomised to the study. Of the other 3 patients, 2 
had episodic SUNCT and went into remission, and one was well controlled on 
carbamazepine, so declined entry to the study.
Of the 4 patients randomised, only one SUNCT patient (#33) completed the trial and 
returned a full dataset of results. One patient withdrew from the study after 2 weeks 
because the pain of the SUNCT was too great after he had stopped his prior preventive 
medications, and he was not prepared to take a placebo. One SUNCT and one SUNA 
patient completed the study but did not complete any diaries. They reported that neither 
lamotrigine nor placebo had any beneficial effect on their attacks. Both patients had 
minor side effects of some nausea, myalgia, tiredness and mild cognitive difficulties, 
which did not necessitate withdrawal of the drug in either patient. In one patient the side 
effect was on lamotrigine and in the other one the side effect was on placebo.
An ‘n of 1 ’ study approach was used for the one complete dataset. It was found that 
neither lamotrigine nor placebo had any effect in suppressing the SUNCT attacks, both in 
terms of attack frequency (number of attacks/day) or attack load (number of 
minutes/day).
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On lamotrigine, the frequency of attacks increased by 772% and the attack load increased 
by 680% as compared to the pre-treatment control phase. On placebo, the frequency of 
attacks increased by 39% and the attack load increased by 21% from the pre-treatment 
control phase. These are illustrated in Table 9.1.
Table 9.1
Trial of lamotrigine (LTG) in SUNCT; results from 1 patient
Pre
lamotrigine
Max
lamotrigine % change on LTG
Effect of 
lamotrigine
Frequency; attacks/day 0.786 6.86 +112% nil
Attack load; minutes/day 6.68 52.1 +680% nil
Pre placebo Max placebo
% change on 
placebo
Effect of 
placebo
Frequency; attacks/day 1.08 1.5 +39.3% nil
Attack load; minutes/day 0.602 0.728 +20.8% nil
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Chapter 10
Discussion: Treatment in SUNCT and SUNA
10.1 Time to diagnosis, practitioners seen, and previous diagnoses
For SUNCT and SUNA there was a delay to correct diagnosis of 6.7 and 7.1 years 
respectively. In the extreme case in one SUNA patient, the diagnosis was only made after 
46 years of his symptoms. Other diagnoses were considered, including paroxysmal 
hemicrania, cluster headache and ‘TAC not otherwise specified’, which shows that 
SUNCT/SUNA can bear a striking resemblance to the other TACs. Diagnoses such as 
trigeminal neuralgia, paroxysmal hemicrania, cluster headache and migraine amongst 
others, have prompted doctors to offer treatments specific to those syndromes. This study 
now reports the efficacy of these treatments, and in so doing can highlight the differences 
in response between SUNCT/SUNA and the other primary headache syndromes.
As awareness of SUNCT and SUNA is increased, especially with this current series of 43 
SUNCT and 9 SUNA patients, it is hoped that these syndromes will be more readily 
recognised in clinical neurological practice, and that the treatments offered will reflect 
those which are reported to be effective in SUNCT and SUNA.
Treatments 
10.2 Abortive therapies
Triptans, serotonergic agonists and antagonists
Sumatriptan is used in the abortive therapy of migraine in oral, intranasal, suppository or 
subcutaneous preparations (Tfelt-Hansen, 1998; Tfelt-Hansen, 2004) and in cluster 
headache in intranasal or subcutaneous preparations (Sumatriptan Cluster Headache 
Study Group, 1991; van Vliet et al., 2003a). It has been used either in oral form (100-
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300mg daily), or subcutaneously (6mg), with little or no response in SUNCT (Matharu et 
al., 2003a), as was generally borne out in the current cohort, with 2 exceptions.
Oral or intravenous dihydroergotamine was also ineffective, although it had a moderate 
effect in one patient (#36), in whom subcutaneous sumatriptan had a moderate effect in 
reducing the length of her saw-tooth attacks.
Oxygen
High-dose high-flow oxygen has been used to good effect in cluster headache (Fogan, 
1985; Kudrow, 1981), but has had little or no effect in SUNCT (Matharu et al., 2003a; 
Matharu et al., 2004b). It is arguable that any benefit seen in SUNCT patients may be due 
to the spontaneous resolution of each attack over seconds to a few minutes, rather than 
any beneficial therapeutic effect. The exceptions to this are 3 patients: one with 
concomitant cluster headache, one in whom there was a minimal effect, and one in whom 
the oxygen changed the quality of the pain from sharp to burning, although this patient 
also suffered from constant background pain which may have confused the situation 
somewhat.
10.3 Oxygen and GTN triggering
Nitric oxide has been shown to play a pivotal role in primary headache syndromes. Both 
migraine and cluster headache attacks are inducible by nitric oxide donors such as 
nitroglycerin (Ekbom, 1968; Olesen et al., 1995; Sances et al., 2004). Nitric oxide is 
thought to act as an inhibitor of cytochrome oxidase (Decking et al., 2001), and increases 
the cell’s requirement for oxygen for cellular respiration (Cooper et al., 2003).
It has been proposed that migraine is a disorder of energy metabolism in the brain, 
reviewed by (Tepper et al., 2001), and mitochondrial impairment has been shown in 
proton spectroscopy in migraine and cluster headache (Lodi et al., 1997). Mitochondrial 
dysfunction has also been suggested by the response by migraine patients to riboflavin 
prophylaxis (Schoenen et al., 1994), the nitric-oxide scavenger hydroxycobalamin (van
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der Kuy et al., 2002) and Coenzyme Q (Sandor et al., 2005a). These all point to the 
suggestion that abnormalities in energy metabolism predispose migraine and cluster 
headache sufferers to develop an attack under conditions of increased energy demand, 
and that treatment with protagonists of the cellular respiratory cycle, such as the 
aforementioned vitamins, may be effective by reducing the oxidative stress (Montagna,
2002). Oxygen may also exert a therapeutic effect reducing oxidative stress and 
promoting cellular respiration.
The current results showed that sublingual nitroglycerin did not trigger an attack in 83% 
of SUNCT and both SUNA patients. In all of these patients, including the one SUNCT 
patient in whom GTN triggered an attack, oxygen had no effect in aborting their attacks. 
Although these numbers are small, they indicate that SUNCT and SUNA are not 
precipitated by nitric-oxide donors, unlike migraine and CH. Therefore the lack of 
response to oxygen is unsuiprising. Furthermore any response to oxygen at a cellular 
level may be missed as the attacks being of short duration will end before they can be 
terminated by inhaled oxygen.
10.4 Short-term preventive medications
Indomethacin
Oral indomethacin in doses up to 300mg a day has been reported as mainly ineffective 
(Gardella et al., 2001; Hunt et al., 2002; Koseoglu et al., 2005; Matharu et al., 2004b; 
Narbone et al., 2005; Prakash and Lo, 2004; Rossi et al., 2003; Volcy et al., 2005). The 
Indotest (Antonaci et al., 1998) and modified Indotest (double-blind, placebo-controlled, 
intramuscular indomethacin lOOmg) have also been found to be negative (Matharu et al., 
2004b).
In this study, the modified Indotest was universally minimally effective or negative in all 
SUNCT and SUNA patients who underwent it, even in those patients with longer-lasting 
attacks or constant background pain, in whom the differential diagnosis would be 
paroxysmal hemicrania and hemicrania continua respectively. It is therefore proposed
1
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that a diagnostic indicator for SUNCT would be a negative response to the modified 
Indotest. A positive response to an indomethacin challenge in each patient with suspected 
SUNCT would negate the diagnosis of SUNCT, and point towards either HC or PH.
Oral indomethacin is also ineffective in 89% of SUNCT and SUNA. In the two patients 
who reported a moderate effect, the fact that neither patient reported an absolute response 
to indomethacin as is characteristic of paroxysmal hemicrania (Antonaci et al., 1998), 
would suggest that indomethacin is generally not a useful treatment in SUNCT/SUNA.
Lidocaine
In this study, all patients receiving intravenous lidocaine reported some relief to total 
abolition of their symptoms, the longest pain-free period being 3 weeks in a patient with 
chronic SUNCT, 12 weeks painfree in chronic SUNA, and 6 months painfree in a patient 
with episodic SUNCT. In the case of episodic SUNCT it could be argued that the 
painfree period was just that the patient was in remission between her bouts of pain; 
however her usual remission period was only 4 weeks.
Intravenous lidocaine has been reported previously in 4 patients with SUNCT, providing 
them with pain-free times of up to 12 hours (Matharu et al., 2004b), and in a further case 
with pain relief of an unknown duration (Shiiba et al., 2005). Lidocaine has also been 
used in 2 patients with cluster headache (Sakamoto et al., 2005).
Intravenous lidocaine has been demonstrated to provide effective analgesia in a variety of 
acute and chronic pain states (Galer et al., 1993; Mao and Chen, 2000). It has been 
reported to be effective in several headache syndromes including trigeminal neuralgia 
(Kugelberg, 1959), chronic migraine (Kaube et al., 1994) and cluster headache 
(Maciewicz, 1988). It has been proposed as treatment for chronic daily headache 
including analgesic rebound headache (Hand and Stark, 2000), and was found to be 
helpful in acute or chronic migraine or status migrainosus in a retrospective study 
(Jauslin et al., 1991), although a brief infusion at 1 mg/kg/minute did not prove effective 
in migraine in one trial (Reutens et al., 1991). Pareja and colleagues have reported that
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intravenous lidocaine 100 mg bolus followed by 4 mg/minute over 48 hours was 
ineffective when administered to two patients with SUNCT (Pareja et al., 1995), although 
these were only given for a duration of 48 hours. Since then, lidocaine has been found to 
be useful in two retrospective series of 71 patients (Williams and Stark, 2003), and 12 
patients (Siow, 2005), most of whom had chronic migraine, and in case reports of cluster 
headache and SUNCT (Sakamoto et al., 2005). In thus study intravenous lidocaine was 
highly effective in patients with SUNCT and SUNA. The range of response varies from 
reduction of severity or frequency of the attacks for the duration of the infusion, to a pain 
free state lasting up to 6 months. Remarkably there are no cases encountered of SUNCT 
that have not responded to some extent to intravenous lidocaine.
Intravenous lidocaine, which is an amide local anaesthetic and anti-arrhythmic agent, was 
first used in 1961 for post-operative pain treatment (Bartlett and Hutserani, 1961). It is 
often used for the treatment of peripheral neuropathic pain (Mao and Chen, 2000). It 
blocks peripheral and central sodium channels (Nagy and Woolf, 1996; Woolf and 
Wiesenfeld-Hallin, 1985) and selectively inhibits abnormal ectopic neuronal discharges 
(Devor et al., 1993) but without blocking normal nerve conduction in animal models 
(Devor et al., 1992). The abnormal ectopic discharges may be explained by increased 
numbers of sodium channels which have been found in the demyelinated brain lesions of 
human multiple sclerosis and in demyelinated central axons of rodents (England et al.,
1996), and the NaVj channel subtype in peripheral nerve injury, which is alleviated both 
by the lidocaine derivative mexiletene and lamotrigine (Lindia et al., 2005).
Neuropathic pain states such as hyperalgesia and allodynia respond to systemic lidocaine 
(Chaplan et al., 1995; Jasmin et al., 1998). In clinical studies, intravenous lidocaine 
(3mg/kg over 3 minutes followed by a continuous infusion of 4mg/kg for 60 minutes) 
was effective in treating thalamic pain, trigeminal neuralgia, and phantom limb pain, but 
had no benefit on peripheral (nociceptive) pain such as pressure-cuff induced ischaemic 
pain (Boas et al., 1982). A meta-analysis of 16 randomised, double-blind, placebo- 
controlled trials showed beneficial effect of intravenous lidocaine (l-5mg/kg) compared 
to placebo in chronic neuropathic pain such as diabetic neuropathy, postherpetic
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neuralgia, post-traumatic peripheral neuropathy, cancer-related neuropathy, and 
central/mixed neuropathy such as that due to stroke, amputation and spinal cord injury 
(Challapalli et al., 2005).
The effectiveness of lidocaine in SUNCT may be due to the neuralgiform characteristics 
of the attacks. SUNCT differs from other primary headache syndromes and TACs by the 
ability to trigger attacks from cutaneous stimuli such as touching the face. It could 
therefore be suggested that lidocaine acts on the trigeminal nerve in the periphery or at 
the level of the trigeminal ganglion in order to block nociceptive transmission. However 
this would not explain why it had a good effect on those patients whose attacks were 
mainly or all spontaneous (Patients #2, 7, 12, 22, 27, 34, 36, 57 and 3 out of 4 SUNA 
patients). The beneficial effects of lidocaine in other primary headache syndromes such 
as migraine may be due to the development of central sensitisation (Burstein, 2001; 
Burstein et al., 1998), as manifested by cutaneous allodynia and intracranial 
hypersensitivity (Yamamura et al., 1999). Central sensitization may be mediated by 
sodium channel-related ectopic discharge from chronically injured neurons in the 
spinothalamocortical pathways (Max and Hagen, 2000). A study of intravenous lidocaine 
(5mg/kg over 30 minutes) in allodynia and hyperalgesia in central pain syndromes 
suggested that lidocaine has a central as well as a peripheral effect (Attal et al., 2000). 
This in combination with the observation that three drugs that reduce central pain- 
amitriptyline, lamotrigine and lidocaine- all block sodium channels, raises the possibility 
that this is one of their mechanisms of action in primary headache syndromes. However 
we have reported an overwhelming lack of response to amitriptyline in SUNCT and 
SUNA, which is borne out in the literature (Matharu et al., 2003a; Matharu et al., 2004b; 
Pareja et al., 1995), except when used in combination with other drugs such as 
gabapentin, topiramate, carbamazepine and lamotrigine.
The apparent discrepancy between this study’s findings and those of Pareja et al (Pareja 
et al., 1995) may be due to a number of factors. First, the plasma level of lidocaine (2-5 
pg/ml) appears to be the determinant of effectiveness of systemic lidocaine, regardless of 
the route of administration (Devulder et al., 1993), and this was not measured in either
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study. Secondly, the rate of intravenous infusion appears to be a determinant factor of the 
outcomes (Chaplan et al., 1995), although these were comparable between the two 
studies. Third, the duration of the infusion differs between a bolus injection (Maciewicz, 
1988), to 48 hours (Pareja et al., 1995), to up to 7 days (in our study), to a maximum of 
17 days (Williams and Stark, 2003). Other factors include the number of patients studied 
in each trial, and differing endpoints for reporting effectiveness, such as reduction in 
attack frequency or complete abolition of attacks.
Occasionally, patients with SUNCT syndrome experiencing severe exacerbations with 
frequent, easily triggered, high-intensity pain attacks are encountered (Montes et al.,
2001; Pareja et al., 1996a). In this situation, acute interventions are needed because the 
patients are severely affected and may not be able to eat or drink because these actions 
trigger attacks. This report draws attention to the possibility of utilising intravenous 
lidocaine in this situation to ameliorate the attacks temporarily while conventional 
therapy is being optimised. One great advantage of a successful response to lidocaine 
infusion is that the patient may be rendered pain free for up to many weeks after the 
infusion, which has been noted in animal models with prolonged reduction of tactile 
allodynia far beyond the pharmacological half-life of lidocaine (Chaplan et al., 1995; 
Sinnott et al., 1999). This allows a period of time where the patient can be drug free, or 
for titration of preventive medications. Appendix 3 outlines the protocol we employ when 
administering intravenous lidocaine. Treatment with intravenous lidocaine is associated 
with significant side effects, especially when high doses are utilised (Ferrante et al., 1996; 
Rowbotham et al., 1991; Wallace et al., 1996). As it mediates its effect through blockade 
of sodium channels, including those in the heart, brain and peripheral nerve, it may cause 
adverse effects at each site, including pro-arrhythmic effects, cognitive impairment and 
neuropsychiatric side effects, dizziness, nausea, and diarrhoea. For this reason, it is 
imperative to monitor the patient carefully for adverse effects.
Therefore it is suggested that infusion of intravenous lidocaine, up to 3.5mg/kg/hour, has 
both diagnostic and therapeutic use in SUNCT/SUNA. From a diagnostic point of view, 
the lack of response to intramuscular indomethacin, combined with a reduction of attacks
149
on intravenous lidocaine, would point strongly towards a diagnosis of SUNCT/SUNA. In 
terms of therapy, many patients especially with the chronic forms have not had a 
significant period of time free of pain, or have required preventive medications which 
may cause side effects. The prospect of an infusion for a few days which can render 
patients pain free (and therefore free of preventive drugs) for up to 6 months at a time is 
very attractive for this severely painful and otherwise undermanaged condition.
10.5 Preventive Medications
10.5.1 Lamotrigine
Lamotrigine is a relatively new anticonvulsant drug effective in partial and generalised 
tonic clonic seizures. It blocks voltage-sensitive sodium channels, thereby stabilising the 
neuronal membrane and inhibiting the release of excitatory neurotransmitters such as 
glutamate and aspartate. It has been shown to share broadly similar antinociceptive 
effects with lidocaine in different animal models of neuropathic pain (Erichsen et al.,
2003).
In randomised trials, it has been used to a good effect in 11 out of 13 patients with TN (at 
400mg/day) (Zakrzewska et al., 1997) and has also been shown to be beneficial in 
various neuropathic pain syndromes such as painful HIV-associated neuropathy 
(300mg/day) (Simpson et al., 2000) and central post-stroke pain (200mg/day)
(Vestergaard et al., 2001), although it was not better than placebo at 200mg/day in a trial 
of various neuropathic conditions (McCleane, 1999). It was first used in 37 patients with 
migraine at 200mg/day but was no better than placebo in preventing the migraine attacks 
(Steiner et al., 1997a). In subsequent studies at lOOmg/day, it was shown to be better than 
placebo in reducing aura symptoms in 15 patients (Lampl et al., 1999), and in patients 
with high frequency of migraine with aura (D'Andrea et al., 1999b). It was subsequently 
shown to reduce migraine attacks in those patients with aura, in an uncontrolled trial 
(Lampl et al., 2005). In terms of other primary headache syndromes, lamotrigine has been 
shown to be useful at mean doses of 250 mg/day in TN and trigeminal dysaesthesia but
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not CH or migraine in open-label trials (Delvaux and Schoenen, 2001). Interestingly it 
has been recently reported as ineffective in animal models of trigeminal neuralgia, 
whereas gabapentin was effective (Christensen et al., 2001).
Lamotrigine inhibits voltage-gated sodium channel conductance, thus inhibiting the 
excitatory neurotransmitters glutamate and aspartate, and stabilising the neuronal 
membrane (Cheung et al., 1992; Thomas, 1997). This action is shared by carbamazepine 
and phenytoin, although phenytoin has not been shown to have a beneficial effect in 
SUNCT; on the other hand carbamazepine has been reported to have some effect 
(Matharu et al., 2003a; Matharu et al., 2004b), but only 39% of patients in this study 
reported it to be effective, as opposed to 68% of SUNCT patients in whom there was a 
moderate to good effect of lamotrigine. It has been recently shown that lamotrigine also 
modulates calcium currents and the transient potassium outward current, presumably in a 
voltage-gated fashion (Grunze et al., 1998). This may be an additional method of action 
of lamotrigine which may be of benefit in SUNCT. It is interesting to note that it inhibits 
N-type channels (Wang et al., 1998), as opposed to L-type calcium channels which are 
antagonised by verapamil (Spedding and Paoletti, 1992). This may explain why 
lamotrigine has success in SUNCT and SUNA, whereas verapamil is either ineffective, or 
makes the attacks worse (Jimenez-Huete et al., 2002; May et al., 1999b).
Recently, lamotrigine given in an open-label manner at doses up to 300mg a day has been 
reported to be highly efficacious in 10 patients with SUNCT (D*Andrea et al., 1999a;
D'Andrea et al., 2001; Gutierrez-Garcia, 2002; Leone et al., 2000b; Malik et al., 2002), 
although it has been reported as ineffective in 4 patients (Black and Dodick, 2002;
Matharu et al., 2004b; Sprenger et al., 2005), and ineffective at 400mg a day in a patient 
with SUNCT related to trigeminal nerve compression (Koseoglu et al., 2005).
Sixty-eight per cent of SUNCT patients in this study reported a good or moderate effect 
with lamotrigine, at doses of 50-400mg daily. Of these, 9 had a good effect in that their 
attacks were completely suppressed, and 8 had a moderate effect either with lamotrigine
151
alone or in combination with other neuromodulatory drugs such as gabapentin, 
amitriptyline, topiramate, and carbamazepine.
Problems with lamotrigine include a skin reaction which may progress to Stevens- 
Johnson syndrome, and this necessitated the cessation of lamotrigine in at least one 
patient in the literature (Rossi et al., 2003). A sizeable proportion of our cohort (6 
patients) who tried lamotrigine had to stop it, often at suboptimal doses, due to side 
effects, such as anaphylactic reaction (4 patients), skin rash (4 patients reported this but 
only 2 patients actually stopped the lamotrigine because of it), arthralgia (1 patient), and 
suppressing the attacks but making the patient’s migraine worse (1 patient). In one patient 
the lamotrigine actually made the SUNCT attacks worse: it appears that this is the only 
case of lamotrigine worsening SUNCT attacks.
In the double-blind placebo-controlled study of lamotrigine in SUNCT, of the four 
patients who were randomised to the trial, one withdrew in the first two weeks because 
his pain was so severe on withdrawal of his previous preventive (carbamazepine 1600mg 
daily), and he did not want to take a placebo for a few months. Two patients completed 
both arms of the study, but did not complete the diaries. However they both reported that 
neither treatment had any beneficial effect on their attacks. The patient who did complete 
the trial had no beneficial effect with either lamotrigine or placebo; indeed both 
treatments increased both the attack frequency and attack load from baseline.
The disappointing results in the placebo-controlled trial may be due to a number of 
reasons. The first is that the patients who agreed to take part in the trial were self- 
selecting in terms of chronic SUNCT/SUNA which had not responded to other 
medications; thus their individual disease may have been more refractory to treatment 
than other SUNCT/SUNA patients. The second is that the dose of lamotrigine may not 
have been high enough at 200mg daily. Some of our patients taking lamotrigine in an 
open-label fashion required doses up to 400mg for a beneficial effect. The third reason is 
that the diary recording was inaccurate. It is disappointing that 2 patients defaulted on 
completion of the diaries; however with at least 20 and up to many hundreds of attacks a
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day, some patients find it arduous to complete the diaries at this frequency. In the patient 
whose attacks were worsened on both treatments, it may be that he unwittingly recorded a 
greater proportion of his attacks whilst on the treatments. It may also be that lamotrigine 
may have a differential effect on triggered and spontaneous attacks, in that it may 
suppress the spontaneous attacks but attacks could still be triggered by cutaneous stimuli. 
Of note, all 3 patients had attacks which were at least 50% triggered.
The open-label study showed a discrepancy between SUNCT (with 68% reporting 
moderate or good effects) and SUNA, where only one out of the 4 (25%) reported a good 
effect with lamotrigine. This may reflect either a difference between SUNCT and SUNA 
as disease states, such that SUNCT responds better to lamotrigine than SUNA; otherwise 
it could be a feature of the small number of SUNA patients who tried it.
Definitive answers would be obtained from placebo-controlled double-blind trials, 
although the current experience implies that these trials are impossible due to the rarity of 
the two syndromes, the incidence of side effects, and the reluctance of patients to take a 
placebo for a period of months at a time. The latter factor alone gives an indication as to 
the extraordinary degree of morbidity from such short-lasting attacks, both in terms of the 
severity of the pain and the debilitating effect of many attacks daily; that most patients 
refused to take a placebo when the active treatment was available.
Therefore, in the absence of double-blind placebo-controlled trials, the use of lamotrigine 
is recommended as a primary preventive agent in SUNCT/SUNA, as long as side effects 
do not intervene. The dosing regimen for lamotrigine treatment in SUNCT/SUNA is the 
same as in the double-blinded trial.
10.5.2 Topiramate
These results show a beneficial response of topiramate in SUNCT in two patients; one 
with complete cessation of his attacks, and one with reduction of his attack load in
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minutes per day. In the other three patients no beneficial response was seen with 
topiramate, according to the predetermined endpoints of the study.
Two patients had a placebo response. One (#47) had cessation of his attacks on placebo. 
However this patient had episodic SUNCT so it is possible that his attacks went into 
spontaneous remission, and this effect was wrongly ascribed to the tablets. The high 
success rate of placebo has been noted in a negative trial of valproate in episodic cluster 
headache with the same problem (El Amrani et al., 2002b).
The second patient (#21) noted a reduction in his headache load on placebo. These 
headaches were episodes of pain lasting up to 720 minutes each, and were probably 
prolonged attacks of SUNCT which occurred in groups of stabs. Each one was recorded 
by the patient as a single headache, although there may be an argument for each one to be 
recorded as multiple single stabs or groups of stabs. In this case it would be very difficult 
for the patient to record accurately the number of attacks he experienced; and it would 
also make a great difference to the attack frequency per day. On disregarding these long 
headache episodes and concentrating on the measurable SUNCT attacks, he had 
increased attack frequency on both topiramate and placebo, although less so on 
topiramate (+19%) than placebo (+52%). However in comparing the attack load, there 
was a large increase on placebo (+178%), as compared to a significant decrease on TPM 
(-71%), which would indicate that topiramate was effective in reducing the number of 
minutes of pain per day in terms of SUNCT attacks. It is therefore useful to employ a 
system of co-primary endpoints when assessing the efficacy of preventive medications.
In the open-label trial in SUNCT of topiramate at doses up to 400mg daily, there was a 
moderate or good response in 52% of patients, one of whom combined the topiramate 
with lamotrigine for an optimal effect. One SUNA patient took topiramate 800mg daily, 
which had a good effect on her migraine but no effect at all on her SUNA.
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Topiramate has been reported to be effective in 6 SUNCT patients at doses up to 300mg 
daily (Kuhn et al, 2005; Matharu et al., 2002; Matharu et al., 2004b; Rossi et al., 2003), 
and ineffective in three patients (Black and Dodick, 2002; Koseoglu et al., 2005).
Problems with topiramate included side effects, which in some patients necessitated the 
cessation of the drug even though it had a good effect on the attacks, and in other patients 
the topiramate was withdrawn before an optimal therapeutic dose could be achieved. 
Topiramate is known to cause the side effects which our patients experienced, although 
they are usually found at higher doses and in faster regimes of escalation than those used 
in our practice (Ojemann et al., 2001). In SUNCT, two patients reported mild 
hypersomnolence at doses of 75 and 300mg a day respectively, but as they were rendered 
pain free and the headaches recurred on reducing the dose, they maintained the 
topiramate treatment (Matharu et al., 2004b; Rossi et al., 2003).
Other known side effects of topiramate include commonly somnolence, paraesthesiae, 
diminished appetite, nausea, diarrhoea, weight loss, and dysgeusia (Silberstein, 2005). 
Central nervous system adverse events included somnolence, insomnia, memory 
difficulty, language problems, concentration difficulty, mood problems and anxiety 
(Silberstein, 2005). Additionally, renal calculi and paraesthesiae occur rarely (Rosenfeld,
1997), attributed to weak carbonic anhydrase inhibition by topiramate. It is suggested that 
starting at low doses, once or twice daily, and making small increments thereafter can 
minimize side effects; such was the case in a group of cluster headache patients (Wheeler 
and Carrazana, 1999).
Topiramate exhibits potent antiepileptic action in animal and clinical models (Abou- 
Khalil, 2000; DeLorenzo et al., 2000; Stephen et al., 2000; Yen et al., 2000). It has 
multiple mechanisms of action (Rosenfeld, 1997). They include modulating voltage-gated 
sodium ion channels, blocking excitatory glutamate receptors, modulating voltage-gated 
calcium ion channels, inhibiting carbonic anyhdrase, and enhancement of inhibitory 
GABA-mediated chloride influx through GABAa receptors (Chong and Libretto, 2003). 
Indeed animal models (Akerman and Goadsby, 2005; Storer and Goadsby, 2004) have
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shown that topiramate inhibits trigeminovascular activation, which is a surrogate marker 
for headache, and may explain the site of its anti-migraine action. Topiramate has been 
demonstrated to increase human cerebral GAB A concentrations in healthy subjects and 
patients with epilepsy using nuclear magnetic resonance spectroscopy (Kuzniecky et al., 
1998; Petroff et al., 2001). This is similar to the mechanism of action of valproate 
(Fariello, 1995), upon which its action in migraine (Hering and Kuritzky, 1992; Jensen et 
al., 1994) and cluster headache (Hering and Kuritzky, 1989) may be based.
Methodological and Analytical Issues
The primary endpoint in analysis was the reduction of frequency of attacks, as measure in 
attacks per day. It was originally decided to perform a group analysis using multi-level, 
multi-variate analysis (Snijders, 1999), using the software that has been developed by the 
Multi-level Project, MlwiN (available at http://www.ioe.ac.uk/multileven. as has been 
used in previous studies (Levy et al., 2005; van Vliet et al., 2003a).
However the large inter-patient range of numbers of attacks per day (from 7 to 140 in this 
series) would make statistical analysis rather difficult in a group setting.
The concept of ‘attack load’ has been introduced in Chapter 5.11, in order to account for 
the large variation in duration and frequency of attacks, both between patients and also in 
patients who experience longer attacks as a group of smaller stab-attacks This 
phenomenon occurred in 2 patients in this series (#21 and #34). Therefore the concept of 
‘attack load’ was measured, that is, number of minutes of pain per day. The ‘attack load’ 
was analysed both for the SUNCT attacks for which the trial was initially set out, and 
also for ‘total headache attack load’, which included other head pains such as dull 
background headaches which may have been a feature of the SUNCT (Cohen et al., 
2005b).
Another issue is the dose given. The patients in this trial received a maximum dose of 
lOOmg a day, yet in other trials and clinical work the dose has been increased to 300- 
400mg daily (Cohen et al., 2005c; Matharu et al., 2002; Matharu et al., 2004b; Rossi et 
al, 2003). It may be that a higher dose of topiramate would have a greater beneficial
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effect in some patients, although there has been a recent report of no observed increase in 
efficacy between 100 and 200 mg per day of topiramate in migraine prevention 
(Silberstein et al., 2004), and there was a higher incidence of adverse effects at the higher 
dose. Indeed it has been noted that patients at 200mg of topiramate had no response as 
opposed to patients in the same series on smaller doses (Leone et al., 2003a).
In summary, topiramate had a good effect in 2 of 5 patients as compared to placebo. In 
two patients there was no effect at all, and one patient had a marked placebo response 
which could be attributed to spontaneous remission of his attacks. The methodological 
shortcomings of the study have been discussed, and it is felt on balance that these results 
would not persuade us to reject topiramate as a treatment for SUNCT. SUNCT has until 
recently been thought of as an untreatable condition, and with a 40% success rate in this 
placebo-controlled trial and 52% success rate in an open-label study, the use of 
topiramate is still advised in SUNCT. Patients with a previous history of renal stones, 
glaucoma, depression, and those who are underweight, should not be offered topiramate 
as a first-choice agent, in case of developing known side effects.
1153 Gabapentin
Gabapentin was first used in trigeminal neuralgia in two patients at doses up to 2400mg 
daily with good effect (Sist et al., 1997), and has since been shown to be effective in 
open-label studies in idiopathic TN (Valzania, 1998) and in TN associated with multiple 
aclerosis (Khan, 1998; Solaro et al., 1998).It has also been effective on open-label in TN 
in combination with lamotrigine or carbamazepine, at mean doses of CBZ 400 mg and 
GBP 850 mg daily; or LTG 150 mg and GBP 780 mg daily in 11 patients with TN and 
MS (Solaro et al., 2000). It has been shown to be effective in animal models of trigeminal 
neuropathic pain as compared to lamotrigine (Christensen et al., 2001).
Gabapentin has been used with good effect in migraine (Di Trapani et al., 2000; Mathew 
«tal, 2001), cluster headache (Ahmed, 2000; Tay et al., 2001), and trigeminal neuralgia 
(Cheshire, 2002). SUNCT has been shown to respond to gabapentin, with complete
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suppression of attacks in three of nine patients treated with 800 to 2700 mg daily (Graff- 
Radford, 2000; Hunt et al., 2002; Porta-Etessam et al., 2002), and minimally effective in 
one patient with SUNA at an unknown dose (Volcy et al., 2005). However it has been 
reported as completely ineffective in 9 patients (Koseoglu et al., 2005; Malik et al., 2002; 
Matharu et al., 2003a; Matharu et al., 2004b), although in 1 patient this was SUNCT 
secondary to compression of the trigeminal nerve (Koseoglu et al., 2005).
The mechanism of action of gabapentin is not fully understood. It is structurally related to 
the neurotransmitter y- amino butyric acid (GABA), and it does not interact with GABA 
receptors or GABA metabolism, it increases brain GABA in animals (Loscher et al.,
1991) and humans with epilepsy (Petroff et al., 2000; Petroff et al., 1996). It has also 
been shown to bind to the a2-5 subunit of voltage-gated calcium channels (Gee et al., 
1996), and this plays an important role in the maintenance of mechanical hypersensitivity 
in animal models of neuropathic pain (Field et al., 2000). These have later been found to 
be L-type and P/Q-type calcium channels (Oka et al., 2003). Gabapentin attenuates the 
noxious stimulus-induced increases in spinal glutamate release in neuropathic rats in vivo 
(Coderre et al., 2005), and in trigeminal slices of rats in whom tactile allodynia was 
induced (Maneuf et al., 2004; Maneuf et al., 2001).
This series shows complete resolution of attacks in only one patient (5%), and with a 
moderate effect in 9 SUNCT patients (41%) and 3 SUNA patients (60%), either alone or 
in combination with other drugs such as lamotrigine, carbamazepine or topiramate. It is 
interesting to note that in one SUNCT patient with MS (#52) it had a good effect at 
1600mg for 3 months before wearing off, and subsequently had a mild effect at 3000mg 
when combined with lamotrigine 400mg, where other medications were unsuccessful for 
this patient (amitriptyline lOOmg, carbamazepine at unknown dose).
Interestingly in this series gabapentin was effective in 60% of SUNA but only 45% of 
SUNCT patients. It may be that the SUNA patients respond more in a pattern of 
hypersensitivity and stimulus-induced pain; although the argument against this is that our 
phenotype study shows that most of the SUNA patients (67%) had entirely spontaneous
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attacks which could not be triggered. In only 1 SUNA patient (#SUNA59) who 
responded to gabapentin were the attacks triggerable. It is also possible that due to the 
small numbers of patients, the difference between SUNCT and SUNA is not significant. 
Most striking is the beneficial effect of adding gabapentin to other neuromodulatory 
drugs such as lamotrigine, carbamazepine and amitriptyline. Gabapentin was initially 
used as an add-on therapy for epileptic seizures (Anhut et al., 1994; Morrell et al., 2000), 
although its efficacy as monotherapy for complex partial seizures has also been 
recognised (Bergey et al., 1997). It acts synergistically with other neuromodulators such 
as carbamazepine, lamotrigine, valproate, phenytoin and phenobarbital in models of 
epilepsy (Borowicz et al., 2002). In terms of pain, it has an additive analgesic effect with 
amitriptyline in animal models (Heughan and Sawynok, 2002), and is useful combined 
with either lamotrigine or carbamazepine for trigeminal neuralgia in multiple sclerosis 
(Solaro et al., 2000). Therefore it may be the synergistic effect of gabapentin with other 
anti-epileptic drugs which is successful in the treatment of neuralgiform-type pain.
This study shows complete resolution of attacks in only one patient (5%), and with a 
moderate effect in 9 SUNCT patients (41%) and 3 SUNA patients (60%), either alone or 
in combination with other drugs such as lamotrigine, carbamazepine or amitriptyline. It is 
therefore recommended that gabapentin be used as a second-line agent in SUNCT, 
possibly in combination with another neuromodulatory drug. It may prove a first-line 
agent in SUNA given its 60% response rate as monotherapy.
10.5.4 Carbamazepine
Carbamazepine has been a mainstay of treatment in trigeminal neuralgia (Backonja and 
Serra, 2004), and has also been reported as having a good or partial effect in SUNCT at 
doses up to 900mg a day (Matharu et al., 2003a; Matharu et al., 2004b), especially when 
used in combination with naloxone, verapamil and lithium (Sabatowski et al., 2001); 
prednisolone (Calvo et al., 2004; Gardella et al., 2001; Montes et al., 2001), topiramate 
(Matharu et al., 2004b), and indomethacin (Prakash and Lo, 2004). However there are 
some reports of carbamazepine having no effect at doses of 100-1200mg a day (Cohen et
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al., 2004; Koseoglu et al., 2005; Rossi et al., 2003), and only a mild effect at 1600mg a 
day (Gantenbein and Goadsby, 2005).
In this case series, 14 of the 36 SUNCT patients (39%) reported a moderate or good 
effect with carbamazepine, although only 4 of these (11%) actually reported complete 
cessation of their attacks. Only 1 SUNA patient (20%) reported a moderate effect; in the 
rest there was no beneficial effect.
10.5.5 Valproate
Valproate, which is used commonly in migraine (Hering and Steiner, 1994; Jensen et al., 
1994), has been ineffective in doses up to 2000 mg a day in eight patients with SUNCT, 
was partially effective in one, and transiently had a good effect when combined with 
nortriptyline and prednisolone in another patient (Matharu et al., 2004b; Pareja et al., 
1995; Sesso, 2001). It was ineffective in a patient with SUNA at 15mg/kg/day 
(375mg/day) (Volcy et al., 2005). This study found no effect of valproate in any of the 9 
SUNCT or 1 SUNA patients who tried it.
10.5.6 Other anticonvulsants
Other anticonvulsants tried in our SUNCT cohort were oxcarbazepine, phenytoin, 
clonazepam, leviteracetam; all with no beneficial effect. The leviteracetam made the 
attacks worse in the SUNCT patient who took it. Pregabalin had a moderate effect in 2 
SUNCT patients (although unsustained in one), and no effect in one SUNA patient.
These drugs have been used in the past as follows, with little or no effect in SUNCT: 
oxcarbazepine (2400mg/day (Sprenger et al., 2005)) (1800mg/day in the patient with 
SUNCT associated with compression of the trigeminal nerve) (Koseoglu et al., 2005), 
baclofen, both alone and in combination with carbamazepine (Calvo et al., 2004), and 
clonazepam (Matharu et al., 2004b).
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Phenytoin has been tried in 10 patients and was reported to be mostly ineffective (Malik 
et al., 2002; Pareja et al., 1995). It has been used in combination with carbamazepine, 
which had no beneficial effect but caused ataxia (Matharu et al., 2004b).
The use of pregabalin has not been previously reported in SUNCT or SUNA. It has been 
used with good effect in neuropathic pain and post-herpetic neuralgia (Freynhagen et al., 
2005; Sabatowski et al., 2004), and also reduced sleep disturbances (Sabatowski et al.,
2004). Pregabalin is known to alter sleep architecture by enhancing non-rapid eye 
movement sleep in rats and humans (Hindmarch, 2001; Kubota et al., 2001). Cluster 
headache and other hypothalamically-driven headaches are known to have distorted sleep 
architecture (Cohen and Kaube, 2005), and it is possible that pregabalin exerts its effect 
in SUNCT via this shared mechanism. This study reports 2 cases of SUNCT with 
moderate response to pregabalin, although in one patient the duration of its effect was 
limited. Pregabalin had no effect in the SUNA case.
10.5.7 Amitriptyline and tricyclic antidepressants
Amitriptyline and other tricyclic antidepressants are commonly used in the treatment of 
migraine (Couch et al., 1976; Punay and Couch, 2003; Ziegler et al., 1987), neuropathic 
pain (McQuay et al., 1996; Sindrup and Jensen, 1999) and atypical facial pain (Lascelles, 
1966), but there are no randomised controlled trials of amitriptyline in trigeminal 
neuralgia. It is interesting to note that a total of 31 of the cohort had been given 
amitriptyline in doses up to 150 mg a day, and only one patient reported a moderate 
benefit but with side effects of a dry mouth and drowsiness. Other patients have taken 
dothiepin and lofepramine with no effect on their attacks. One patient also took the 
antidepressant mirtazapine, with no beneficial effect on his attacks. It therefore seems 
that amitriptyline and tricyclic antidepressants are unlikely to produce major beneficial 
effects in SUNCT or SUNA. This further contributes to the separation of SUNCT/SUNA 
in terms of pathophysiology from other facial pains.
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10.5.8 Melatonin
The hypothalamus is known to regulate circadian rhythms, through the suprachiasmatic 
nucleus (SCN) (Ralph et al., 1990), with information about the level of ambient light 
through the retino-hypothalamic tract (Reppert and Weaver, 2002). Photic information 
relayed from the SCN to the pineal gland is closely reflected there in the secretion of 
melatonin (Brzezinski, 1997; Utiger, 1992). Melatonin secretion is known to be abnormal 
in cluster headache (Chazot et al., 1984; Leone and Bussone, 1993; Leone et al., 1995; 
Waldenlind et al., 1987), and has had some success as a therapeutic agent in cluster 
headache (Leone et al., 19%; Peres and Rozen, 2001). In the light of these findings, and 
on the basis that SUNCT/SUNA possibly share a common hypothalamic pathophysiology 
with CH, one SUNCT patient took melatonin with a moderate response, although 
interestingly it had little to no effect in the SUNA patients. This may be because SUNA 
patients generally are more refractory to medications than SUNCT patients, or that there 
is different hypothalamic activation between SUNCT and SUNA. Further SUNCT/SUNA 
patients may be offered melatonin as a relatively side-effect-free alternative to other 
preventive therapies, although with only one patient having a moderate effect, it may be 
premature to suggest that melatonin has a definitive effect in SUNCT.
10.5.9 Corticosteroids
Corticosteroids, particularly prednisolone, are used in the treatment of cluster headache 
(Antonaci et al., 2005; Couch and Ziegler, 1978; Kudrow, 1980), and there have been 
some benefits reported in SUNCT (Matharu et al., 2003a), and also at doses of 40- 
60mg/day in combination with carbamazepine (Calvo et al., 2004; Gardella et al., 2001; 
Montes et al., 2001). In this study, one patient reported a mild benefit at 80mg a day of 
prednisolone (#9), and another reported that 50mg a day of prednisolone reduced the 
frequency of his attacks (#20). However the latter patient had SUNCT secondary to a 
pituitary prolactinoma, and so the corticosteroids may have been acting on his pituitary- 
adrenal axis rather than on the headache attacks themselves. The rest of the SUNCT and
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all SUNA patients reported no benefit on prednisolone at doses up to 60mg, and there is 
another report showing no benefit of 60mg prednisolone for 1 month (Rossi et al., 2003).
10.5.10 Verapamil and Lithium
Verapamil at high doses (up to 960mg/day), and lithium (to a therapeutic range of 0.8-1.1 
pmol/1) are usually used in cluster headache (Bussone et al., 1990; Ekbom, 1981; Leone 
et al., 2000a), and have had little or no reported effect in SUNCT (Gardella et al., 2001; 
Matharu et al., 2003a; Rossi et al., 2003). Verapamil made the attacks worse in some 
cases (Jimenez-Huete et a l, 2002; May et al., 1999b), except in one recent case where 
verapamil at doses of480-960mg a day abolished attacks in a patient with SUNCT and an 
ischaemic lesion in the posterior fossa (Narbone et al., 2005). Lithium and verapamil are 
both known to accumulate in the hypothalamus (Bussone et al., 2003; Dodick et al.,
2003), which probably plays a role in the generation of both CH and SUNCT attacks, so 
it might be expected for them to have some beneficial effect in SUNCT. In nine SUNCT 
patients who took verapamil, one patient had a mild effect but this was not enough to 
control his attacks. One SUNA patient also had cluster headache, and the verapamil 
helped both for his cluster headache and also to reduce the frequency of his SUNCT 
attacks. There is as yet no firm evidence of the beneficial effect of lithium.
10.5.11 Other medications
Analgesics and non-steroidal anti-inflammatory drugs (NSAIDS)
Simple analgesics (paracetamol, aspirin), opiates (morphine, tramadol, buprenorphine, 
dihydrocodeine), and combination analgesics (paracetamol/codeine, 
jhydrocodone/acetaminophen), have all been reported as ineffective (Malik et al., 2002; 
^Matharu et al., 2003a; Matharu et al., 2004b; Putzki et al., 2005). NSAIDs, including 
ibuprofen, piroxicam, naproxen, ketoprofen, aspirin, mefenamic acid, are ineffective in 
fee treatment of SUNCT and SUNA (Matharu et al., 2003a; Matharu et al., 2004b; Rossi 
;,ctal., 2003; Volcy et al., 2005).
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This study adds a further list of NSAIDs, cyclooxygenase-2 inhibitors, simple and 
compound analgesics, and opiate analgesics, which are ineffective in SUNCT and SUNA. 
These include aspirin, aspirin/caffeine preparations, ibuprofen, diclofenac, 
paracetamol/opiate preparations, celecoxib and rofecoxib.
Serotonergic agonists and antagonists
Methysergide and pizotifen had no effect in the SUNCT patients in this study, and this 
corresponds to their ineffectiveness as reported in the literature (Goadsby and Lipton, 
1997; Matharu et al., 2004b; Pareja et al., 1995). Likewise selective serotonin reuptake 
inhibitors (SSRIs) have been used in SUNCT in the past, including sertraline 
( lOOmg/day) (Koseoglu et al., 2005) and fluoxetine (20mg/day) (Matharu et al., 2004b), 
with no effect.
Adrenoreceptor blockers
Beta-blockers such as propranolol, and alpha-blockers such as clonidine, have been 
reported to be ineffective in SUNCT (Matharu et al., 2003a), and as such their use has not 
been recorded since. This database adds a further 6 patients with propranolol up to 160 
mg a day, which had no effect on their SUNCT or SUNA.
10.6 Surgery
Several surgical approaches have been attempted for the treatment of SUNCT syndrome. 
These take the form either of local blockades, invasive procedures involving the 
trigeminal nerve, and neuromodulatory procedures using superficial nerve and deep brain 
stimulation.
10.6.1 Local Blockades
Local blockades of pericranial nerves with anaesthetics, alcohol, phenol, or opioids, have 
generally been reported as ineffectual. A pterygopalatine ganglion blockade with phenol 
produced a variable effect in one patient (Hannerz and Linderoth, 2002), and one had a
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partial response with opioid blockade of the superior cervical ganglion (Sabatowski et al., 
2001). Infraorbital blockades were ineffective in eight of nine patients (Hannerz and 
Linderoth, 2002), and lidocaine blockades of lacrimal nerve, orbicularis oculi muscles, 
and the retrobulbar region also had no effect, as did a stellate ganglion block with 
bupivacaine (Pareja et al., 1995). In the current cohort, there was no improvement from 
pterygopalatine marcaine injection or retrogasserian alcohol block.
Supraorbital blockades using lidocaine, bupivacaine or alcohol, have been reported as 
ineffective in suppressing spontaneous attacks in nine patients, but made triggering of 
attacks more difficult by touching the anaesthetised area (Hannerz and Linderoth, 2002; 
Pareja et al., 1995).
In this cohort, one SUNCT patient had a supraorbital nerve injection and one had an 
infraorbital nerve injection which caused numbness but the attacks were still triggerable. 
These would concur with the view that SUNCT and SUNA are not peripheral nerve 
disorders such as supraorbital neuralgia, which respond well to local nerve blockade 
(Sjaastad, 1999). Even though there was local numbness in the distribution of the blocked 
nerve, the painful attacks still occurred, which correlates to cluster headache and the 
persistence of painful attacks even after trigeminal nerve root section (Matharu and 
Goadsby, 2002a). These all support the theory that SUNCT/SUNA in particular, and the 
TACs in general, are generated originally from an abnormal drive in hypothalamic 
activity, with subsequent trigeminovascular and cranial autonomic activation.
10.6.2 Invasive surgical procedures involving the trigeminal nerve
One SUNCT patient in this series had no improvement with microvascular 
decompression. In the literature, two patients have been treated with the Jannetta 
procedure (microvascular decompression of the trigeminal nerve) with good effect at 
limited followup (up to 17 months) (Gardella et al., 2001; Lenaerts, 1997), although in 
one patient it made the symptoms worse (Matharu et al., 2004b), and in 2 further patients 
it was unhelpful, as were glycerol rhizotomy and y knife radiosurgery, and in fact the
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patients suffered post surgical side effects of anaesthesia dolorosa, unilateral deafness, 
chronic vertigo and disequilibrium (Black and Dodick, 2002). One patient underwent a 
right trigeminal radiofrequency thermocoagulation, after which she was pain free for 3 
years, but with marked hypoanaesthesia over the second and third trigeminal distributions 
on that side (Matharu et al., 2004b). Therefore trigeminal surgery is generally considered 
only as a last resort, and then with caution, given its uncertain outcomes and the potential 
for side effects.
10.6.3 Hypothalamic deep brain stimulation
Functional imaging work has shown activation of the posterior hypothalamic region 
during attacks of cluster headache (May et al., 1998a; Sprenger et al., 2004a), and 
SUNCT (Cohen et al., 2004a; May et al., 1999b; Sprenger et al., 2005). Sixteen patients 
with intractable chronic cluster headache and one patient with intractable SUNCT have 
undergone deep brain electrical stimulation to the posterior hypothalamus, with good 
results (Leone et al., 2004a; Leone, 2004). In another series of six patients, two were 
painffee with a third patient with much reduced frequency of attacks. However the side 
effect of diplopia limited the increase of the voltage, and one patient died of an 
intracerebral haemorrhage (Schoenen et al., 2005). Therefore the referral of patients for 
these procedures is done with great caution, and currently is reserved for those patients 
who are refractory to all other types of treatment.
10.7 Greater occipital nerve injections
Two patients with SUNCT and six patients with paroxysmal hemicrania have undergone 
lidocaine blockades of the greater occipital nerve with no benefit (Antonaci et al., 1997; 
Pareja et al., 1995). A combination of lidocaine and a steroid in cluster headache effected 
a good or moderate response in nine out of 14 patients (Peres et al., 2002). This study 
demonstrates a moderate to good effect of greater occipital nerve injection of steroid and 
lidocaine in 63% of SUNCT patients. A double-blind placebo controlled study of a
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mixture of long- and rapid-acting betamethasone in 16 ECH and 7 CCH patients showed a 
good effect in 61%, as opposed to no response with placebo (Ambrosini et al., 2005).
It may be the combination of steroid and lidocaine, or steroid alone, rather than the 
lidocaine itself that elicits a good response. Indeed it has been shown that suboccipital 
injection of local anesthetic alone have neither a beneficial nor a worsening effect on CH 
attacks (Anthony, 1987), and that steroid injections have been beneficial in a wide range 
of idiopathic headache syndromes in a group of 500 patients (Anthony, 1992). Steroids 
are used systemically in the treatment of cluster headache (Antonaci et al., 2005; 
Cianchetti et al., 1998; Couch and Ziegler, 1978; Kudrow, 1980; Mir et al., 2003). This 
may be linked to abnormalities in the secretion of diumally varying hormones in CH, in 
particular cortisol and melatonin. Cortisol production was significantly higher and the 
morning cortisol peak was delayed when compared to the remission periods and healthy 
controls (Waldenlind et al., 1987). This may in part explain the efficacy of high-dose 
steroids in the treatment of CH, especially in light of the diurnal nature of occurrence of 
the attacks and the involvement of the hypothalamus.
However it is probably the local action of steroid on the greater occipital nerve which has 
the effect. It has been noticed that GON injections have a greater effect in primary 
headache syndromes in patients who have localized GON tenderness (Shields et al.,
2004). Animal models have demonstrated an overlap of processing of nociceptive 
information from the C2 level and the trigeminal nucleus caudalis (Goadsby et al., 1997), 
and stimulation of nociceptive afferent C-fibres of the dura mater, which is innervated by 
the first division of the trigeminal nerve, leads to increased excitability of second-order 
neurons receiving cervical input (Bartsch and Goadsby, 2003a). This mechanism might 
be involved in the referral of pain from trigeminal to cervical structures and might 
contribute to the clinical phenomena of cervical hypersensitivity in migraine and cluster 
headache. Suboccipital electrical stimulation has been successful in CH and hemicrania 
continua (Dodick et al., 2003; Schwedt et al., 2006). A series of eight patients with 
chronic migraine reported a beneficial effect with suboccipital stimulators, with changes 
on PET imaging in the dorsal rostral pons, anterior cingulate cortex and cuneus (Matharu
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et al., 2004a). This suggests that suboccipital stimulators are capable of central 
neuromodulation, and it is possible that GON steroid injections may have a similar effect.
10.8 Other non-pharmacological procedures and alternative therapies
Acupuncture appears to have a moderate to good effect in some SUNCT patients, 
although the site of acupuncture, frequency and duration of treatment was not 
standardised. One patient tried a transcutaneous electrical nerve stimulation (TENS) 
machine, acupuncture, and a maxillary bite appliance, all with no effect, and has been 
reported previously (Matharu et al., 2004b). Acupuncture has been reported in cluster 
headache (Gwan, 1977), supraorbital neuralgia (Xia et al., 1987), and has been reviewed 
for other types of headache (Zhao et al., 2005).
10.9 SUNCT versus SUNA
It has been found in this series that the SUNA patients generally had a less favourable 
response to treatments than the SUNCT patients; particularly lamotrigine (68% effective 
in SUNCT yet only 25% in SUNA), topiramate (52% versus 0% response), and greater 
occipital nerve injection (63% versus 0% response).
SUNCT, with its characteristic conjunctival injection and tearing, is purported to be the 
syndrome which makes up the majority of this group, with cranial autonomic symptoms 
(Headache Classification Committee of The International Headache Society, 2004). It 
would be logical to assume that they share important aspects of pathophysiology; that is, 
an abnormality in the hypothalamus with subsequent trigeminovascular and cranial 
autonomic activation. There is abundant evidence that the hypothalamus has a role in 
mediating antinociceptive (Dafny et al., 1996; Wang et al., 1990) and autonomic 
responses (Lumb and Lovick, 1993), specifically trigeminovascular nociceptive pathways 
(Bartsch et al., 2004). A striking feature of CH, PH, SUNCT, and to a lesser extent 
hemicrania continua, is their cranial autonomic symptoms. It has been previously 
suggested that these are due to central disinhibition of the trigeminal-autonomic reflex by
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the hypothalamus (Goadsby et al., 2001), possibly by direct hypothalamic-trigeminal 
connections (Malick et al., 2000). These hypothalamic-trigeminal connections may be 
instrumental in the cutaneous triggering seen in SUNCT and SUNA.
However there is differential activation of the cranial autonomic symptoms, with SUNCT 
having at least both conjunctival injection and lacrimation, and SUNA having at least one 
cranial autonomic symptom, but not both conjunctival injection and lacrimation. This 
may reflect a difference in the two syndromes at the level of the hypothalamic-autonomic 
connection, which may also have a bearing on the differential function of the 
hypothalamic-antinociceptive or hypothalamic-trigeminal connections. In this way it may 
be that SUNA is generally less responsive to the treatments which are associated with a 
good response in SUNCT, such as lamotrigine and topiramate.
It has been noticed that SUNCT patients had a good response by to GON injections 
(63%), although less so in SUNA. This may be purely due to the very small number of 
patients who had the GON injection (8 SUNCT, 1 SUNA), and it would therefore be 
premature to state that GON injections have no use in SUNA.
10.10 Summary
This study reports a case series of 52 patients (43 with SUNCT and 9 with SUNA) and 
their responses to various medications and treatments. SUNCT has been hitherto thought 
of as refractory to treatment, with isolated case reports in the literature as to the effect of 
pharmacological and non-pharmacological interventions. The study presents the largest 
case series of SUNCT/SUNA hitherto reported, and record their responses to treatments 
within the wider context of treatments noted previously.
In terms of diagnosis, the lack of response of SUNCT/SUNA to the blinded Indotest 
seems to be a very valuable tool in differentiating it from paroxysmal hemicrania, which 
by definition has an absolute response to indomethacin. Similarly the moderate to good 
response of all patients to intravenous lidocaine will be a strong diagnostic tool for
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SUNCT/SUNA, and may also afford the patient some pain-free time after the infusion is 
discontinued (up to 6 months in our case series), which in these excruciatingly painful 
and usually suboptimally treated syndromes, is a bonus for both patient and clinician.
The good response to lamotrigine and topiramate in SUNCT, and gabapentin in SUNA, is 
also reported. The introduction of melatonin and pregabalin to the armoury of preventive 
medications is encouraging, especially in the light of melatonin’s effect in cluster 
headache and the effect of pregabalin on sleep cycles, and the pathophysiological link to 
the hypothalamus. This will be further elucidated as more SUNCT/SUNA patients take 
these treatments.
As for non-systemic treatments, a good response to Greater Occipital Nerve injections 
with steroid and lidocaine is seen in SUNCT. The response is less clear in SUNA; 
however given the fact that the numbers treated so far are small, and the relative absence 
of side-effects with GON injections, it would be premature to state that GON injections 
have no effect in SUNA.
The absence of placebo-controlled randomised trials in SUNCT and SUNA has been 
discussed. Definitive answers will come from these trials, but they have proven 
exceptionally difficult to conduct in this group of patients, owing to the rarity of the 
syndromes and the reluctance of patients to take placebo treatments.
The next stage forward will be neuromodulatory procedures, in the form of occipital 
nerve stimulators and deep-brain hypothalamic stimulators.
In summary, SUNCT and SUNA are not as refractory to treatment as was previously 
thought. The recommendations as diagnostic manipulation would be lack of response to 
indomethacin and a good response to intravenous lidocaine. For preventive medications, 
lamotrigine, topiramate and gabapentin are recommended. Greater occipital nerve 
injections also prove useful in the treatment of these excruciatingly painful and very 
debilitating primary headache syndromes.
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PART III. FUNCTIONAL IMAGING STUDIES IN SUNCT AND
SUNA
Chapter 11
Functional MRI in attacks of SUNCT and SUNA
11.1 Introduction
SUNCT and SUNA, being TACs, are thought to share the same pathophysiology as other 
TACs such as CH and PH. Functional imaging with PET has demonstrated activation in 
the ipsilateral posterior hypothalamus in CH (May et al., 1998a; Sprenger et al., 2004a), 
and the contralateral posterior hypothalamic region in PH (Matharu et al., 2006b) and in 
hemicrania continua, which although not classified as a TAC, shares some clinical 
characteristics with TACs (Matharu et al., 2004c).
In PET, volume acquisition takes 90 seconds, and there is an interscan interval of at least 
8 minutes in order to allow for decay of radioactivity (Matharu et al., 2004c). Therefore 
volumes can only be acquired once every 8 minutes at most. In contrast, fMRI has a 
much shorter acquisition time of 3.6 seconds per volume, and volumes can be acquired in 
immediate sequence. Therefore fMRI is an ideal imaging modality in short-lasting 
headache attacks such as in SUNCT and SUNA.
Ipsilateral posterior hypothalamic activation has been demonstrated on fMRI in SUNCT 
(May et al., 1999b), and bilateral activation has also been reported (Cohen et al., 2004a; 
Sprenger et al., 2005). Hypothalamic activation has been detected in a TAC not otherwise 
specified, but which was likely to be longer-lasting attacks of SUNCT (Sprenger et a., 
2004b).
This study used fMRI in 12 patients with SUNCT and SUNA, to detect activation in the 
region of the posterior hypothalamus, either ipsilateral, contralateral to the side of attacks, 
or bilaterally. The a priori hypothesis is that there is activation in the region of the
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hypothalamus, on either or both sides, during attacks of SUNCT or SUNA, as compared 
to the attack-free state, and that there is a differential increase in activation with 
increasing severity of the pain.
11.2 Methods
Twelve patients were recruited from our cohort of SUNCT and SUNA. Ten were male 
and two female. Two of these patients had SUNA (one male, one female), and eight 
patients had SUNCT. One patient (#2) had SUNCT secondary to a posterior fossa lesion, 
as is described in Chapter 5 and Chapter 6.14. Of the SUNCT patients, 6 had left-sided 
attacks during imaging. One patient (#7) could sometimes get right-sided attacks, but had 
none on this occasion. Three patients had exclusively right-sided attacks, and one patient 
had either left-or right-sided attacks equally. Of the SUNA patients, one had right-sided 
and one had left-sided attacks. One patient (#SUNA44) had another TAC on the right 
side which had been diagnosed as chronic cluster headache, and one (#34) had a history 
of cluster headache and migraine (Empl, 2003). The clinical characteristics are displayed 
in Table 11.1.
The study was approved by the National Hospital for Neurology and Neurosurgery and 
Institute of Neurology Joint Research Ethics Committee (REC Ref 97/033). The patients 
gave their written consent for the study, and were free to withdraw from the study at any 
time.
None of the patients who were on preventive medications were willing to come off their 
medications completely prior to the study, but all abstained from their medications for 24 
hours prior to the scan. All were having spontaneous attacks at the time of the scan. Their 
medications are shown in Table 11.1.
Table 11.1
Clinical Characteristics of patients for fMRI and VBM, including concomitant diagnoses
Patient
number
Diagnosis Age Male/
female
Left/ right 
attacks
fMRI VBM Medications and concomitant diagnoses
2 Secondary
SUNCT
53 M R y y gabapentin 4800mg, lamotrigine 600mg, amitriptyline 50mg 
daily
SUNA44 SUNA 58 F L y y pregabalin 300mg daily
SUNA40 SUNA 35 M R y y verapamil 160mg daily
Also had a TAC attack (not SUNA) on the left
6 SUNCT 69 F R y y gabapentin 1800mg, lamotrigine 200mg daily
7 SUNCT 52 M L » R y y no medication
12 SUNCT 67 M L y y carbamazepine 800mg daily, temazepam lOmg daily
42 SUNCT 43 F L y y no medication
56 SUNCT 33 M L y y paracetamol and codeine combination, sertraline 50mg daily
17 SUNCT 71 M L y y gabapentin 1200mg, carbamazepine 400mg daily
23 SUNCT 39 M R or L y y no medication
33 SUNCT 67 M R y y no medication
34 SUNCT 62 M L y y gabapentin 1200mg, tramadol as required
Also had cluster headache and a history of migraine
13 SUNCT 58 M R n y carbamazepine 800mg, lamotrigine 600mg daily
15 SUNCT 65 M L n y gabapentin 900mg, indomethacin 75mg daily
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11.3 Image Acquisition
MRI scanning was performed on a 1.5 Tesla magnetic resonance imaging (MRI) system 
(Siemens Vision). A high resolution ( l x l x l  mm voxel size) Tl- weighted structural 
MRI was acquired for each subject. In each functional imaging session a total of 170 
MRI volumes (40 axial slices per scan, slice thickness 2 mm) were acquired using a 
gradient echo echo-planar (EPI) T2* sensitive sequence (TR 3600 ms, slice time 90 ms). 
The images were oriented at an angle of -25° to the horizontal. The same scanner 
parameters and scanner hardware were used for the acquisition of all anatomical volumes.
The subject’s head was positioned in a standard head coil with foam pads and earphones 
to protect the subject’s ears from the noise of the scanner. Each patient kept their eyes 
open. The first four volumes were discarded to allow for Tl equilibration effects.
11.4 Headache Protocol
Once every 3.96 seconds during the scanning session, the patients received a pure 250Hz 
tone auditory stimulus via the headphones. On hearing this tone they were asked to rate 
the severity of their pain at that time. Ratings were delivered via a keypad with 4 buttons, 
corresponding to index finger = zero (no attack); middle finger = 1, ring finger = 2 and 
little finger = 3; which corresponded to attack present at mild, moderate or severe 
intensity respectively. The patients practised the keypresses with the auditory stimulus 
prior to being placed in the scanner. All patients had spontaneous attacks whilst in the 
scanner except Patient #17, for whom some attacks were triggered by touching the 
ipsilateral eyebrow. These attacks lasted well beyond the duration of the trigger stimulus 
and were captured during imaging.
A PC running customized software (COGENT) was used to present the auditory stimuli 
and record the patients’ ratings. It recorded the time of auditory stimuli and time of finger 
presses. The onset of each patient’s headache ‘event’ was calculated as starting at the
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time of the previous auditory stimulus. The same PC and COGENT script were used for 
all patients.
Each scan lasted 10 minutes, with 150 tones and responses in each session. Patients 
underwent between 1-5 functional scans, depending on the individual patient.
One patient (#SUNA44) had an attack of his TAC on the right side in the fifth scanning 
session, but the first 4 sessions were purely SUNA attacks.
11.5 Analysis of Images
Data were analysed on a Dell PC using Matlab 6.5 (The MathWorks Inc., Natick, MA, 
USA) and statistical parametric mapping SPM2 (www.fil.ion.ucl.ac.uk/spm/sDm2.htmD. 
The software analysis package was used to pre-process the functional images as follows:
1) realignment to correct the functional images for temporally asynchronous slice 
acquisition and head movement
2) normalisation to warp the functional images to standard space (Talairach and 
Toumoux, 1988)
3) spatial smoothing with a Gaussian filter of 4 mm FWHM (full width half 
maximum) in the x- y- and z-planes (Friston et al., 1995a; Friston et al., 1995b).
Data analysis was performed using the general linear model (GLM) and modelled the 
different trials (headache, sound, press) as delta functions convolved with a canonical 
haemodynamic response as implemented in SPM2. The design matrix was modelled as an 
event-related experiment. The headache event was modelled in the design matrix as 
lasting 3.96 seconds and the ‘sound’ and ‘press’ events were modelled as lasting 0 
seconds, in order to conform better to the haemodynamic response function.
The headache was assessed parametrically with rating, both in a binary sense (0 = no 
headache, 1 = attack of any intensity), and in a linear parametric model with a polynomial
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order of 1 (0 = no headache; and 1, 2, 3 = attack of mild, moderate or severe intensity 
respectively).
Each patient’s dataset was assessed independently. Patients underwent between 1-5 
sessions, and in cases of more than 1 session, these were analysed in a fixed-effects single 
design matrix. An example of the design matrix for one patient who underwent one 
session is shown in Figure 11.1, and for one patient who underwent four sessions in 
Figure 11.2.
Voxel-wise regression coefficients for all regressors were estimated using weighted least 
squares (WLS) within SPM2. Effects were tested with appropriate linear contrasts of the 
regression coefficients, resulting in a t statistic for each voxel. The T test was performed 
for both directions of effects, e.g. an activation or a deactivation (Josephs and Henson, 
1999). An example of a contrast for positive activation is shown in Figure 11.1, and for 
negative activation is shown in Figure 11.2.
11.6 Testing for effects at the hypothalamus
When making inferences about regional effects (e.g. activations) in SPMs, one often has 
some idea about where the activation should be. In this instance a correction for the 
entire search volume is inappropriate. However, a problem remains in the sense that one 
would like to consider activations that are 'near' the predicted location, even if they are 
not exactly coincident. There are two approaches one can adopt; (i) pre-specify a small 
search volume and make the appropriate Gaussian Random Field (GRF) correction 
(Worsley, 1996) or (ii) used the uncorrected p  value based on spatial extent of the nearest 
cluster (Friston, 1997), according to the size of the structure of interest. This probability 
is based on getting the observed number of voxels, or more, in a given cluster 
(conditional on that cluster existing).
Design matrices for individual patient analysis
Figure 11.1
contrast(s)
Figure 11.2
contrast(s)
i rm
- I _____________ L_
1 2  3 4
Design matrix
ii
5 10 15
Design matrix
Figure 11.1. The design matrix for one scanning session in one patient. Each horizontal line (numbered up to 166) represents an image volume acquisition in 
time. For each image, Column 1 represents the headache, Column 2 represents the headache as parametrically assessed with rating (0, 1, 2, 3). Column 3 
represents the auditory stimulus, and Column 4 represents the finger press. Column 5 is the error, after the General Linear Model (Friston et al., 1995b). The 
contrast vector is [0 1 0 0 0], that is a T test for positive activation for headache as parametrically assessed with rating.
Figure 11.2. The design matrix for a patient undergoing 4 scan sessions. The contrast vector is
[0-1 0 0 0 - 1  0 0 0 - 1  0 0 0  1 - 0 0 0 0 0  0], i.e. a T  test for negative activation for headache as parametrically assessed with rating.
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11.7 Locating the hypothalamus
The coordinates for the region of interest, being the hypothalamus, were determined from 
reports in published studies of hypothalamic activation on functional imaging in CH 
(May et al., 1998a; May et al., 2000; Sprenger et al., 2004a), PH (Matharu et al., 2006b), 
SUNCT (Cohen et al., 2004a; Sprenger et al., 2005), a TAC not otherwise specified but 
which is probably a longer-lasting attack of SUNCT (Sprenger et al., 2004b) and HC 
(Matharu et al., 2004c), and also from coordinates for deep brain stimulation in CH 
(Leone, 2001; Leone et al., 2004a; Schoenen et al., 2005), SUNCT (Leone et al., 2005) 
and aggression (Sano et al., 1970). These were normalized to a standard stereotactic 
Talairach space (Talairach and Toumoux, 1988).
A table of the different coordinates is presented (Table 11.2), where x, y  and z are the 
coordinates as millimetres from the anterior commissure, in a right to left, anterior to 
posterior, and superior to inferior axis respectively. As is convention, positive values for 
x, y  and z indicate right, anterior and superior respectively. T tests were applied both for 
positive and negative activation, as shown in Figures 11.1 and 11.2. Each region of 
interest was specified as a 10mm sphere with these coordinates at the centre.
It can be seen that these results are not consistent between studies, and some studies have 
reported at more anterior sites, especially in SUNCT and the atypical TAC (Cohen et al., 
2004a; Sprenger et al., 2004b; Sprenger et al., 2005). Therefore the T test was applied 
using both an anterior and a posterior region of interest, corresponding to the area of the 
hypothalamus and posterior hypothalamus, respectively.
Table 11.2 Coordinates for hypothalamic functional imaging and deep brain stimulation in previous studies
Functional imaging Diagnosis X y z
May et al Lancet 1998 CH -2 -18 -8
May et al Neurology 2000 CH -2 -18 -8
Sprenger at al Neurology 2004 CH -4 -14 -6
Matharu et al Ann Neurol 2006 PH +1-6 -16 -6
May et al Ann Neurol 1999 SUNCT Not specified
Sprenger et al Cephalalgia 2004 Atypical TAC 6 -8 0
Cohen et al Cephalalgia 2004 SUNCT +/-4 -6 -2
Sprenger et al Pain 2005 SUNCT -6 -6 -6
Matharu et al Headache 2004 HC 6 -14 -6
Stimulation Diagnosis X z
Franzini et al Neuromodulation 2004 CH stimulation +1-2 -15 -8
Leone et al Brain 2004 CH stimulation +1-2 -18 -8
Schoenen et al Brain 2005 CH stimulation +1-2 -18 -8
Leone et al NEJM 1991 CH stimulation 2 -18 -8
Leone et al Ann Neurol 2005 SUNCT stimulation 2 -15 -5
Sano et al 1970 J Neurosurg- stimulation 
No T&T coordinates given: ‘from 1mm ai 
to the midpoint (most often the midpoint i 
lateral wall of the 3rd ventricle’
Probably +1-6, -11/-14, -2/-4
'or aggression
aterior to the midpoint of the intercommissural line to 2mm posterior 
tself), 2-4mm below the intercommissural line, 2mm lateral to the
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11.8 Group Analysis
In order to assess the effects across the group of SUNCT patients, group analyses were 
performed. These included only patients with primary (idiopathic) SUNCT, and thus 
excluded the two patients with SUNA and one patient with symptomatic SUNCT.
Two group analyses were performed; a fixed- effects and a random (mixed) effects 
analysis.
Fixed-Effects analysis
The fixed-effects analysis was a first-level analysis, in which all patients’ scans were 
included in one large design matrix (Figure 11.3), and this assessed mainly intra-patient 
variability.
The patients’ normalised images were smoothed to a Gaussian smoothing kernel of 8mm 
FWHM. Intersubject statistical analysis requires a large enough smoothing kernel filter 
to compensate for the large interindividual variability.
Two patients with right sided attacks (#6 and #33) had their images flipped so that all 
patients’ attacks were assessed as coming from the same (left) side. The normalised 
images were flipped from right to left using SPM2, with the formula 
(il +jlipud(il))/2
in Image Calculation (ImCalc), and these flipped images were subsequently smoothed to 
8mm FWHM.
The contrast was performed by a T-test at ‘headache parametrically associated with pain 
rating’ at each session for each patient. T- tests were performed in two analyses, one to 
assess positive activation, and one to assess negative activation. T tests were applied to 
regions of interest as spheres of 10mm diameter at the anterior and posterior coordinates 
of the hypothalamus at both sides, as for individual patients.
180
Random-Effects analysis
The random (mixed) effects analysis was a basic model second-level analysis, in which 
the contrasts from each patient’s individual analysis were taken to the second level and 
assessed as part of a group (Worsley et al., 2002). This analysis assesses mainly inter­
patient variability, and the inferences can be generalised to the population from which the 
patients were drawn.
For each patient, four contrasts {con images) were taken, corresponding to the following 
states:
1) headache parametrically varying to pain rating (positive)
2) headache parametrically varying to pain rating (negative)
3) headache with binary variation (attack on/off) (positive)
4) headache with binary variation (attack on/off) (negative) activations
Each of these 4 con images per patient was smoothed to 8mm FWHM using SPM2. For 
the two patients with right-sided attacks, their con images were flipped in SPM2 using the 
formula 
flipud (il)
in Image Calculation (ImCalc), and then smoothed to 8mm FWHM.
A single design matrix was constructed at the second-level for each of the four contrasts: 
headache according to pain rating headache according to pain rating (negative), and 
headache with binary variation (positive), and headache with binary variation (negative). 
An example is shown in Figure 11.4.
A T -test was applied for each design matrix as shown in Figure 11.4. T-tests were 
applied to regions of interest as spheres of 10mm diameter at the anterior and posterior 
coordinates of the hypothalamus at both sides, as for individual patients.
Design matrices for group analysis 
Figure 11.3
contrast(s)
Figure 11.4
contrast(s)
40 60 80 100
Design matrix Design matrix
Figure 11.3 Fixed-effects group analysis for 9 patients. Each session for each patient is represented within the matrix (22 sessions in 
total), and the contrast set is (0 1 0 0) repeated 22 times, with 22 zeros for the error estimate.
Figure 11.4 Random-effects group analysis for 9 patients. Each patient’s contrast (for example headache parametrically assessed with 
rating) was taken to a second-level design matrix; therefore there is only one contrast and no error estimates in this model.
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11.9 Group Analysis with no a priori hypothesis
All of the previous analyses were performed on the basis of the a priori hypothesis that 
there was activation in the area of the hypothalamus during attacks of SUNCT/SUNA. 
One further analysis was performed with no a priori hypothesis to ascertain the structures 
which were generally activated during attacks of SUNCT as opposed to the painffee state. 
The same design matrix was used as for the fixed- effects analysis (Figure 11.3) for 
headache in a binary state (attack on/off), but this assessed the whole brain SPM with 
significance level set at P < 0.001 uncorrected for multiple comparisons, with no a priori 
hypothesis. The threshold for reporting activated clusters of voxels was set at P < 0.05 
corrected for the whole brain volume. Two contrasts were performed, one for positive 
and negative activation, respectively.
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Chapter 12
Results- Functional MRI in attacks of SUNCT and SUN A
12.1 Psychophysical Data
Patient #2- Symptomatic SUNCT- right sided attacks
The patient underwent 5 scanning sessions. The first one was stopped after 22 volumes 
(79.2 seconds) as the patient had defaulted on some keypresses. This scan was still used 
in the final analysis, as the patient reported that the default non-keypresses corresponded 
to the painffee state. He had spontaneous attacks as follows:
Session 1: 4 attacks (mild to severe)
Session 2: 9 attacks (mild)
Session 3: 24 attacks (mild)
Session 4: 12 attacks (mild)
Session 5: 22 attacks (mild to moderate)
Attacks lasted between 3.96 seconds (the time between consecutive auditory tones) and 
305 seconds.
Patient #SUNA44- SUN A- left sided attacks
The patient underwent 3 scanning sessions. She only had attacks in the second session, 
where she had 2 mild spontaneous attacks, of 3.96 and 15.8 seconds’ duration each. 
Scanning was terminated after the third session at the patient’s request.
Patient #SUNA40- SUNA-right sided attacks, and a TAC on the left side
The patient had right-sided SUN A attacks, but also had a separate TAC on the left side, 
with left periorbital and nasal pain with ipsilateral conjunctival injection, nasal 
congestion, and a feeling of ear fullness. There was ipsilateral photophobia and 
phonophobia, and agitation. Each attack lasted an hour. He had 2-3 attacks a week, 
sometimes triggered by alcohol. He originally had bouts of a few weeks with remissions 
of 6-8 weeks, although the remissions had reduced in length. This had been diagnosed as
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secondary chronic cluster headache. As an abortive he would have sumatriptan 6mg 
subcutaneously, and was taking verapamil 160 mg daily as a preventive, which would 
suppress the pain but he would still have occasional attacks, comprising predominantly 
autonomic symptoms. He could easily distinguish between the two types of attacks.
He underwent 5 scanning sessions. He had spontaneous attacks as follows:
Session 1: 9 mild SUNA attacks
Session 2: 10 SUNA attacks (mild to moderate)
Session 3: 4 SUNA attacks (moderate)
Session 4: 11 SUNA attacks (mild to moderate)
Session 5: spontaneous TAC; although this manifested itself as 19 episodes of mild to 
moderate pain separated by some painffee episodes.
SUNA attacks lasted 3.96-35.6 seconds each. The TAC episodes lasted 3.96-91.1 
seconds.
For the purposes of this study, the contrast vector only applied to the SUNA sessions. 
Patient #6- SUNCT- right sided attacks
The patient underwent 3 sessions. The second session was stopped after 76 volumes (273 
sec) because the stimulus PC crashed. The data was recovered for use in the analysis. She 
had spontaneous attacks as follows:
Session 1:10 attacks (mild to severe)
Session 2: 1 attack (ranged from mild to severe)
Session 3: 4 attacks (mild to moderate)
Attacks lasted between 3.96-455 seconds.
Patient #7- SUNCT- left sided attacks
This patient had left sided attacks during the scanning sessions. He can also have right­
sided attacks, but had none on this occasion. He underwent 4 sessions but had pain only 
in the first session. This was a spontaneous attack lasting 23.8 seconds (ranged from mild 
to moderate). Only this session was included in the analysis.
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Patient #12- SUNCT- left sided attacks
The patient underwent 5 scanning sessions. In the first and second sessions he had no 
attacks. He had spontaneous attacks as follows:
Session 3: 6 mild attacks
Session 4: 7 mild attacks. This session was stopped early as the patient then tried to 
trigger an attack whilst in the scanner. The first 50 scans’ worth of data (200 sec) was 
included in the analysis.
Session 5: 12 attacks
Attacks lasted between 3.96 and 7.92 seconds each. Only these sessions were included in 
the analysis.
Patient #42- SUNCT- left sided attacks
The patient underwent one scanning session. She had 5 mild attacks, lasting 19.8- 103 
seconds each.
Patient #56- SUNCT-left sided attacks
The patient underwent 4 scanning sessions. He had spontaneous attacks as follows:
Session 1: 4 mild attacks
Session 2: 4 mild attacks
Session 3: 6 mild attacks
Session 4: 13 mild attacks
Attacks lasted between 3.96 and 15.8 seconds each.
Patient #17- SUNCT- left sided attacks
The patient underwent 4 scanning sessions. There were no attacks in the first session, so 
this was excluded from the analysis. The remaining sessions were started after an attack 
was triggered by touching the ipsilateral side of the face. The attacks lasted long after the 
stimulus was removed, and were therefore captured in the scanner.
Session 1: 1 attack (mild-moderate)
186
Session 2: 1 attack (mild-moderate)
Session 3: 1 attack (mild-severe)
Attacks lasted 95-115 seconds each.
Patient #23- SUNCT- attacks on both sides
The patient underwent 4 scanning sessions. He had spontaneous attacks in the first three 
sessions, and these were included in the analysis. Spontaneous attacks occurred on either 
right or left side at random. There was no way of recording the laterality of the attacks in 
the scanner.
Session 1: 4 attacks (mild-moderate)
Session 2: 3 mild attacks 
Session 3: 2 mild attacks 
Attacks lasted 3.96-162 seconds each.
Patient #33- SUNCT- right sided attacks
The patient underwent 3 scanning sessions. He only had 2 spontaneous attacks, both in 
the third session, lasting 3.96 and 7.92 seconds, and being mild and moderate in severity 
respectively. This session was used for analysis.
Patient #34- SUNCT- left sided attacks, left sided cluster headache, and migraine
This patient had migraine, CH and SUNCT and has been the subject of a previous case 
report (Empl et al., 2003). He underwent 3 scanning sessions, during which he had a dull 
background ache on the left side which was attributable to his CH. He had spontaneous 
SUNCT attacks, all of which were distinguishable from the CH, as follows:
Session 1:18 attacks (mild-moderate)
Session 2: 14 attacks (mild-moderate)
Session 3:11 attacks (mild-severe)
Attacks lasted between 3.96 and 107 seconds.
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12.2 Individual Patient Results
Results were analysed on uncorrected whole brain statistical parametric maps with a 
threshold of P < 0.01. Activated voxels were reported at P < 0.001 uncorrected, within a 
sphere of 10mm radius corresponding to the region of interest, with centre as the 
coordinates of either anterior or posterior hypothalamus, on right or left side.
The results, including Z scores at each activated voxel, are shown in Table 12.1. In all 
figures the coloured bar represents the Z score, with different coloured clusters of voxels 
corresponding to different Z scores.
Patient #2- Symptomatic SUNCT- right sided attacks
There were no significant activations in the anterior or posterior regions on either side. 
There was positive activation in the region of the right posterior hypothalamus, both on 
parametric and binary analysis (T test at 6,-16, -6), but this did not survive the 
significance at P < 0.001.
Patient #SUNA44- SUNA- left sided attacks
There was no significant positive activation. There was significant negative activation in 
the posterior region bilaterally on binary analysis (as the patient only had mild attacks). A 
T-test at (6, -16, -6) showed an activated voxel at (2, -14, -14) (Figure 12.1) and a T-test 
at (-6, -16, -6) showed an activated voxel at (0, -14,-14).
Table 12.1 Activations for individual patients in the region o interest (anterior or posterior hypothalamic area)
Patient Diagnosis Side Activations
location polarity of 
activation
coordinates tested coordinates where 
P < 0.001
Z score 
(P< 0.001)
X y z x y z
#SUNA44 SUNA L right posterior negative 6
-6
-16
-16
-6
-6
2 -14 -14 3.02
left posterior negative 0 -14 -14 2.99
#SUNA40 SUNA R right posterior negative 6 -16 -6 6 -16 2 3.2
right anterior negative 6 -8 0 6 0 -6 3.85
left anterior negative -6 -8 0 6 -16 2 3.12
#6 SUNCT R right posterior negative 6 -16 -6 10 -6 -4 3.12
right anterior negative 6 -6 -6 8 -2 -10 3.89
#7 SUNCT L (bilateral) right posterior positive 6 -16 -6 0 -18 -12 4.39
left posterior positive -6 -16 -6 0 -18 -12 4.39
#12 SUNCT L right posterior positive 2 -18 -8 0 -14 0 3.17
left posterior positive -6 -16 -6 -4 -6 -4 3.09
left anterior positive -6 -6 -6 -4 -6 -4 3.09
#42 SUNCT L right posterior positive 6 -16 -6 8 -14 -6 3.17
right anterior negative 6 -8 0 0 -2 -2 4.08
left anterior negative -6 -8 0 -2 -2 -2 4.26
#56 SUNCT L right posterior positive 6 -16 -6 8 -20 -12 3.09
#17 SUNCT L right posterior positive 6 -16 -6 8 -10 -14 4.85
left posterior positive -2 -18 -8 -6 -16 -6 3.8
left anterior positive -6 -8 0 -4 -6 -2 3.95
right anterior positive 6 -8 0 2 -6 -2 3.59
Table 12.1 ctd
patient diagnosis side activations
location polarity of 
activation
coordinates tested coordinates where 
P< 0.001
Z score 
(P< 0.001)
X y z X y z
#23 SUNCT bilateral right posterior positive 6 -16 -6 4 -12 -14 4.1
right anterior positive 6 -6 -6 6 -8 -10 3.26
6 -8 0 8 -6 0 2.99
left posterior positive -6 -16 -6 -12 -16 -10 3.31
left anterior positive -6 -8 0 -2 -2 6 3.41
#33 SUNCT R right posterior negative 6 -16 -6 16 -14 -6 3.07
6 -16 -6 6 -4 -6 3.38
right anterior negative 6 -6 -6 6 -4 -8 2.97
6 -6 -6 6 -2 -4 3.13
#34 SUNCT L right posterior positive 6 -16 -6 2 -14 -14 3.95
6 -16 -6 2 -16 -16 5.2
right anterior positive 6 -6 -6 6 -2 -12 4.87
left anterior positive -6 -6 -6 -2 -10 -14 3.47
left posterior positive -6 -16 -6 -2 -10 -14 3.47
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Figure 12.1
Negative activation in Patient #SUNA44
Figure 12.1
Negative activation at (2, -14,-12)
Figure 12.2
Negative activation in Patient #SUNA40
Figure 12.2
Negative activation at (6, 0, -6)
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Patient #SUNA40- SUNA-right sided attacks, and a TAC on the left side
There was negative activation in both the anterior and posterior regions on the right side, 
and in the anterior region on the left side, when the analysis was set for SUNCT attacks 
only. For parametric analysis, testing at (6, -16, -6) showed an activated voxel at (6, -16,
2) and testing at (6,-8, 0) showed an activated voxel at (6, 0, -6). For binary analysis, 
testing at (6,-8, 0) showed an activated voxel at (6, 0, -6). This is shown in Figure 12.2. 
Testing at (-6, -8, 0) showed an activated voxel at (6, -16, 2).
Patient #6- SUNCT- right sided attacks
There was no significant positive activation. There was significant negative activation on 
parametric analysis in the anterior and posterior regions on the right side. Testing at (6, - 
16, -6) showed an activated voxel at (10, -6, -4) (Figure 12.3), and testing at (6, -8, 0) 
showed activated voxels at (10, -4, 0) and (10, -4, -8). Testing at (6, -6, -6) showed 
activated voxels at (8,-2,-10) (Figure 12.4), (10,-4, 0) and (12,-6,-4).
Patient #7- SUNCT- left sided attacks
There was significant positive activation in the posterior region when T -tests were 
applied to left or right sides. On parametric analysis, testing at (2, -18, -8) showed an 
activated voxel at (0, -18, -14). Testing at (6, -16, -6) and at (-6, -16, -6) showed an 
activated voxel at (0, -18,-12) (Figure 12.5). On binary analysis, testing at (2, -18, -8) 
showed an activated voxel at (0, -18,-14) and testing at (-6, -16, -6) showed an activated 
voxel at (0, -18,-12).
Patient #12- SUNCT- left sided attacks
There was significant positive activation on both sides in the posterior region, and in the 
left anterior region, on binary analysis. Testing at (2, -18, -8) showed an activated voxel 
at (0, -14, 0) (Figure 12.6), and at (-6, -16, -6) showed activated voxels at (-4, -6, -4) and 
(-12,-18, 0). Testing at (-6, -8, 0) and (-6, -6, -6) showed activated voxels at (-4, -6, -4) 
(Figure 12.7) and (-12, -18, 0).
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Figures 12.3 and 12.4
Negative activation in Patient #6
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Figure 12.3
Negative activation at (10, -6, -4)
Figure 12.4
Negative activation at (8, -2, -10)
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Figure 12.5
Positive activation in Patient #7
Figure 12.5
Positive activation at (0, -18,-12)
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Figures 12.6 and 12.7
Positive activation in Patient #12
Figure 12.6
Positive activation at (0, -14, 0)
Figure 12.7
Positive activation at (-4, -6, -4)
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Patient #42- SUNCT- left sided attacks
There was significant positive activation in the right posterior region. Testing at (2, -18, - 
8) and (6, -16, -6) showed an activated voxel at (8, -14, -6) (Figure 12.8). There was 
significant negative activation in the anterior region on both sides. Testing at (6, -8, 0) 
showed an activated voxel at (0, -2, -2), and testing at (-6, -8,0) showed an activated 
voxel at (-2, -2, -2). Testing at (6, -6, -6) and (-6, -6, -6) both showed an activated voxel 
at (-2, -2, -2) (Figure 12.9).
Patient #56- SUNCT-lefi sided attacks
There was significant positive activation in the right posterior region. On binary analysis, 
testing at (2, -18, -8) showed an activated voxel at (8, -20, -14); and testing at (6, -16, -6) 
showed activated voxels at (8, -20, -12) and (8, -20, 0) (Figure 12.10).
Patient #17- SUNCT- left sided attacks
On parametric analysis there was significant positive activation in both anterior and 
posterior regions on both left and right sides. For posterior activation, testing at (2, -18, - 
8) and (-2, -18, -8) showed activated voxels at (-6, -16, -6) (Figure 12.11). Testing at (6, - 
16, -6) showed activated voxels at (8, -10,-14) (Figure 12.12). For anterior activation, 
testing at (6, -8, 0) showed an activated voxel at (2, -6, -2) (Figure 12.13). Testing at (-6, 
-8, 0) showed activated voxels at (-6, -16, -6) and (-4, -6, -2) (Figure 12.14). Testing at 
(6, -6, -6) showed activated voxels at (6, -4, -12), (-2, -6, -2) and (8, -10,-14).
On binary analysis there was significant positive activation in both anterior and posterior 
regions on both left and right sides. For posterior activation, testing at (2, -18, -8) showed 
activated voxels at (6, -20, -14) Testing at (6, -16, -6) showed activated voxels at (8, -12, 
-14) and (2, -6, -2). For anterior activation, testing at (6, -8, 0) showed an activated voxel 
at (2, -6, -4). Testing at (-6, -8, 0) showed activated voxels at (-4, -6, -4), (2, -6,-4) and (- 
4, -2, -6). Testing at (6, -6, -6) showed activated voxels at (2, -6, -4), (-2,-2, -2) and (8,- 
10, -12). Testing at (-6, -6, -6) showed activation at (-4, -2, -6), (2, -6, -4) and (-4, -6, -4).
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Figures 12.8 and 12.9
Positive and Negative activation in Patient #42
Figure 12.8
Positive activation at (8, -14, -6)
5
4
3
2
1
0
Figure 12.9
Negative activation at (-2, -2, -2)
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Figure 12.10
Positive activation in Patient #56
Figure 12.10
Positive activation at (8, -20, 0)
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Figures 12.11 and 12.12
Positive activation bilaterally in posterior regions in Patient #17
Figure 12.11
Positive activation at (-6, -16, -6)
I
Figure 12.12
Positive activation at (8, -10,-14)
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Figures 12.13 and 12.14
Positive activation bilaterally in anterior regions in Patient #17
Figure 12.13
Positive activation at (2, -6, -2)
Figure 12.14
Positive activation at (-4, -6, -2)
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There was also negative activation on parametric analysis. Testing at (2, -18, -8) showed 
activation at (10, -12, -8), (-6, -12, -8) and (-4, -18, -16).Testing at (-2, -18, -8) showed 
activation at (-6, -12, -8) and (-4, -18,-16). Testing at (6, -8, 0) showed activation at (10, 
-12, -8). Testing at (-6, -8, 0) showed activation at (-6, -12, -8). Testing at (-6, -14, -6) 
showed activation at (-6, -12, -8), (-10, -6, -10) and (-14,-18, -6). Testing at (6, -6, -6) 
showed activation at (10, -12, -8) and testing at (-6, -6, -6) showed activation at (-6, -12, - 
8). There was no significant negative activation on binary analysis.
Patient #23- SUNCT- attacks on both sides
On binary analysis there was positive activation bilaterally in the posterior region, and in 
the right anterior region. Testing at (6, -16, -6) showed activation at (4, -12,-14) (Figure 
12.15), (6, -8, -10) and (10, -16, -2). Testing at (-6, -16, -6) showed activation at (-12, - 
16, -10) (Figure 12.16). Testing at (6, -8, 0) showed activation at (-2, -10, 0), (6, -8, -10) 
and (8, -6, 0) (Figure 12.17). Testing at (6, -6, -6) showed activation at (4, -10,-14), (6, - 
8,-10) and (8, -6, 0).
On parametric analysis there was positive activation bilaterally in both posterior and 
anterior regions. Testing at (6, -16, -6) showed activation at (4, -12,-14). Testing at (-6, - 
16, -6) showed activation at (-12,-16, -10). Testing at (6, -8, 0) showed activation at (8,- 
6,0), but testing at (-6, -8, 0) showed activation at (-2, -2, 6) (Figure 12.18). Testing at 
(6, -6, -6) showed activation at (6, -12,-14), and (8, -6, 0).
Patient #33- SUNCT- right sided attacks
There was no significant positive activation on either binary or parametric analysis. 
However there was right-sided posterior and anterior negative activation in both binary 
and parametric analysis. Testing at (6, -16, -6) showed activation at (6, -4, -6) for 
parametric and (16,-14, -6) for binary analysis. Testing at (6, -8, 0) and (6, -6, -6) 
showed the same results: activation at (6, -4, -4) for parametric analysis, and (6, -2, -4) 
and (6, -4, -8) for binary analysis (Figure 12.19).
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Figures 12.15 and 12.16
Positive activation bilaterally in the posterior region in patient #23
Figure 12.15
Positive activation at (4, -12,-14)
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Figure 12.16
Positive activation at (-12, -16, -10)
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Figures 12.17 and 12.18
Positive activation in anterior regions in Patient #23
Figure 12.19
Positive activation at (8, -6, 0)
Figure 12.18
Positive activation at (-2, -2, 6)
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Figure 12.19
Ipsilateral negative activation in patient #33
Figure 12.19
Negative activation at (6, -4, -8)
4
3
2
1
0
204
Patient #34- SUNCT- left sided attacks, left sided cluster headache, and migraine
There was significant positive activation in both anterior and posterior regions, on both 
sides. This was in both binaiy and parametric analyses. Testing at (6, -16, -6) showed 
activation at (10, -8, -12) (Figure 12.20) and (2, -14, -14). Testing at (-6, -16, -6) showed 
activation at (0, -14,-14) for both parametric and binary analysis, and also at (-2, -10, - 
14) for parametric analysis (Figure 12.21). Testing at (6, -6, -6) showed activation at 
(10,-6,-14) and (6,-2,-12) (Figure 12.22). Testing at (-6, -6, -6) showed activation at (-12, 
-6, -14) and (-4, -4,-14) for both parametric and binary analysis, and also at (-2, -10,-14) 
for parametric analysis.
205
Figures 12.20 and 12.21
Positive posterior activation in Patient #34
Figure 12.20
Positive activation at (10, -8, -12)
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Figure 12.21
Positive activation at (-2, -10, -14)
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Figure 12.22
Positive anterior activation in Patient #34
Figure 12.22
Positive activation at (6,-2,-12)
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12.3 Group Results 
Fixed effects analysis
On assessing the binary pain states (attack on/off). There was significant positive 
activation in the anterior and posterior regions of the hypothalamus bilaterally on fixed 
effects analysis. Testing at (6, -16, -6) showed activations at (6, -22, 2), (2, -12, 2) and (2, 
-8, -2). Testing at (-6, -16,-6) showed activation at (-6, -24, 0), (2, -12, 2), (-14,-18, -2) 
and (-2, -8, -2) (Figure 12.23). Testing at (6, -6, -6) showed activation at (4, -4, 2). 
Testing at (-6, -6, -6) showed activation at (0, -6, 0) (Figure 12.24). There was no 
significant negative activation.
Random effects analysis
There was positive activation in the right posterior hypothalamic region on analysing 
both the binary pain states (attack on/off), and headache parametrically analysed with 
pain severity. However this did not survive the P < 0.001 threshold for significance. 
There was no significant negative activation.
12.4 Group Analysis- no a priori hypothesis
There was positive activation in 21 clusters of voxels, all of which survived the threshold 
of P < 0.05 uncorrected for whole brain. These included bilateral primary somatosensory 
cortices, bilateral insulae (Figure 12.25), bilateral orbitofrontal cortices, the mediodorsal 
thalamic nucleus on both sides (Figure 12.26), right anterior cingulate cortex, right 
primary motor cortex incorporating left cingulate gyrus, right occipital cortex, left middle 
occipital lobe incorporating left temporal lobe, left putamen/globus pallidus, bilateral 
superior parietal cortex, and bilaterally in the cerebellum. These results are shown in 
Table 12.2.
There was no significant negative activation.
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Figures 12.23 and 12.24
Positive activation in group analysis (fixed effects)
Figure 12.23
Positive activation at (-2, -8, -2)
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Figure 12.24
Positive activation at (0, -6, 0)
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Figures 12.25 and 12.26
Activation on group analysis with no a priori hypothesis
Figure 12.25
Positive activation in the insula: 
on the right side at (52, 20, -4) and 
on the left side at (-42, 18, -6)
y
Figure 12.26 
Positive activation in the 
mediodorsal thalamic nucleus: on 
the right side at (8, -26, 2) and on 
the left side by inspection at (-8, - 
26, 2)
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Table 12.2
Activations in group analysis for whole brain with no a priori hypothesis
cluster location coordinates (mm) Z score voxel size
X y z
1 R primary somatosensory cortex 50 -32 54 5.67 334
2 L primary somatosensory cortex -36 -48 60 5.14 354
3 L primary somatosensory cortex -32 -16 64 4.84 289
4 R prefrontal cortex 52 32 20 4.76 481
incorporating R insula 52 20 -4 4.49
5 L orbitofrontal region -30 62 4 6.57 2520
incorporating left insula -42 18 -6 6.25
6 R anterior cingulate cortex 14 58 2 5.81 656
incorporating R orbitofrontal cortex 44 52 -2 5.16
7 R primary motor cortex 4 4 60 5.73 582
incorporating L cingulate gyrus -2 12 44 4.49
8 R primary motor cortex 26 2 66 4.83 264
9 R orbitofrontal cortex 16 66 20 6.01 160
10 L putamen/globus pallidus -22 -12 -4 4.9 220
11 R superior parietal cortex 16 -74 52 4.57 226
incorporating L parietal lobe -2 -66 46 3.45
12 midline posterior parietal cortex 0 -52 62 4.68 142
13 L middle occipital lobe -50 -66 2 5.52 684
incorporating L superior temporal lobe -68 -30 -8 4.19
14 R occipital cortex 8 -96 8 6.53 1836
incorporating L occipital cortex -10 -106 -8 5.55
15 R occipital lobe 32 -76 12 5.03 183
16 R occipital lobe 50 -60 -24 4.76 186
17 R occipital lobe 46 -66 6 4.46 158
Table 12.2 ctd
18 L cerebellum -26 -64 -30 4.14 289
19 R cerebellum 44 • oo
00m• 4.57 203
20 R cerebellum 24 -58 -28 4.47 195
21 R cerebellum 4 -40 -2 5.91 1580
incorporating mediodorsal thalamic nucleus 8 -26 2 5.38
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Chapter 13
Discussion: Functional MRI in attacks of SUNCT and SUNA
13.1 Results from this series
Bilateral Activation
Some patients (#7, #12, #17, and #34) had left-sided attacks but bilateral positive 
activation in the posterior region. In their cases, the bilateral activation may indicate a 
propensity for TACs on both sides but which are clinically manifest only on one side at 
present. For patient #7 this is unsurprising as he could have attacks on either left or right 
side, but had only left sided attacks during the scanner. Another patient (#34) had 
experienced some attacks on the right side in the past, but none during the scanning 
session.
Bilateral Attacks
One patient (#23) had attacks in the scanner affecting either left or right side in equal 
proportions, and had significant activation bilaterally in both anterior and posterior 
hypothalamic regions.
One patient (#7) experienced only left-sided attacks during the scanning session, but 
could experience right-sided attacks at other times. This could be that even though only 
the left sided attacks were manifest during the scanning session, there was still bilateral 
hypothalamic activation and the patient had the potential to experience right-sided attacks 
as well.
Unilateral Attacks
Two patients (#42 and #56) had left sided attacks with right-sided posterior hypothalamic 
activation.
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Patients with right-sided attacks (#6, #33) had negative right-sided activation, although 
this was more anterior in patient #33. This negative activation may represent a reciprocal 
inhibition, such that in unilateral syndromes, when one side is active, the other side has 
an opposite effect. Patient #42 also had negative anterior activation which was bilateral.
SUNA
Both SUNA patients had negative activation. Patient #SUNA40 had right-sided SUNA 
attacks. His activation was ipsilateral in the posterior region and bilateral anteriorly. In 
the second SUNA patient (#SUNA44) there was bilateral negative activation with only 
left-sided attacks.
In both patients the bilateral activation could be explained as a propensity for them to 
develop bilateral attacks. Indeed Patient #SUNA40 had a TAC on the left side which was 
not assessed in this analysis. However the striking finding is that both SUNA patients had 
only negative activation. This raises the possibility that SUNA has a different 
pathophysiological basis to SUNCT, in that the hypothalamus is activated differently in 
the two conditions (i.e. positive in SUNCT and negative in SUNA). This in turn may 
modulate the autonomic and nociceptive pathways differently between the two 
syndromes via the disinhibition of the trigeminal-autonomic reflex (Benjamin et al.,
2004) and the hypothalamic-trigeminal pathway (Bartsch et al., 2004; Malick and 
Burstein, 1998), which may account for the lack of conjunctival injection and lacrimation 
as autonomic symptoms in SUNA.
Symptomatic SUNCT
The patient with symptomatic SUNCT (#2) had no significant activation in the region of 
the anterior or posterior hypothalamus, either in binary analysis or with headaches 
assessed parametrically with pain ratings. It may therefore be fair to speculate that 
patients with symptomatic SUNCT/SUNA which are secondary to intracranial lesions 
have a different pathophysiology to those with the idiopathic disease. However there was 
some subthreshold posterior hypothalamic activation which did not survive significance. 
Moreover this is just a single case so it would be difficult to generalise to other cases,
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especially those with SUNCT/SUNA secondary to lesions elsewhere in the brain. 
Furthermore, the patient had a very abnormal structural MRI scan with an unusual 
configuration of the deep grey matter at the lateral ventricles and the upper brainstem, 
and a lacune in the left thalamus. Whereas the normalisation step in pre-processing 
should be able to warp the brain onto a standard template, even with inter-subject 
variations in structural scans (Friston et al., 1995a), this patient’s abnormalities may have 
eluded even the normalisation processes of SPM, and would therefore have given results 
of a diminished quality.
13.2 Location of the hypothalamus
The functional imaging studies done hitherto have reported activation in the area of the 
posterior hypothalamus (for example, (±6, -14, -6) (Matharu et al., 2004c) and (±2, -18, - 
8) (Leone, 2001; May et al., 1998a; May et al., 2000)), but also in the anterior region of 
the hypothalamus, especially in SUNCT and the atypical TAC (Cohen et al., 2004a; 
Sprenger et al., 2004b; Sprenger et al., 2005), as illustrated in Table 11.2. The reporting 
here of slightly different coordinates for the hypothalamus may be explained in the 
following way:
1) There may be a difference in the exact location of the hypothalamic activation 
between different syndromes. This was raised in light of the atypical TAC which 
had activation at different coordinates to CH (Sprenger et al., 2004b). However 
the argument against this would be activation of the posterior region in all TACs 
and HC, and its response to stimulation in CH and SUNCT.
2) Different scanning techniques, smoothing parameters and statistical analyses 
between authors may contribute to slightly different voxels. In this study the 
smoothing kernel was 4mm at FWHM (full width half maximum) for individual 
cases, and an 8mm sphere was used for the region of activation, although this was 
by no means standard across the studies.
3) In cases of bilateral activation, the coordinates were different for ipsilateral (jc, y, z  
= 9, -9, -6) and contralateral hypothalamus in the same patient (x, y ,z  = -6, -6, -6)
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(Sprenger et al., 2005); so the reported active voxels may vary from one side to 
another even within the same patient.
4) The coordinates for stimulation varied between studies, and even within 
stimulation series. For instance Leone et al (Leone, 2001) started with one set of 
coordinates with a good outcome, and then changed them after 2 patients when 
they realised there was a better outcome with the more anterior coordinates 
(Franzini et al., 2004). Schoenen and colleagues (Schoenen et al., 2005) used the 
older, more posterior coordinates and found more oculomotor side effects and a 
need for higher stimulation. This suggests that the area stimulated may have been 
just outside the hypothalamus.
5) A study showing correlation of functional and structural changed in patients with 
CH (via fMRI and VBM respectively), demonstrated activation at the 
hypothalamus at slightly different voxels: (-2, -18, -8) for functional imaging and 
(-4, -16,-10) for VBM changes (May et al., 1999a). This (albeit small) difference 
serves to highlight the inexact nature of pinpointing the posterior hypothalamus, 
even using different techniques within the same group of patients. Therefore an 
‘area in the region o f the posterior hypothalamus’ is implied, and the imaging data 
with a smoothing kernel of up to 10mm is accepted as such.
It is the anterior regions which are conventionally described as the hypothalamus 
(Talairach and Toumoux, 1988). However it seems to be the posterior regions that 
respond to surgical intervention, both in terms of attacks and also for the agitation 
associated with the attacks (Sano et al., 1970), which is a known feature of TACs, as 
discussed in Section 5.9. There may be a number of reasons for the discrepancy, which is 
borne out by our study:
1) There may be activation or deactivation both of the posterior and anterior regions, 
as in patients #SUNA40, 6, 12, 17, 23 and 34. This activation may have not 
survived significance testing in all patients.
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2) There may be posterior activation with reciprocal anterior hypothalamic 
deactivation such as in patient #42. It is unclear from previous studies with 
posterior positive activation whether they checked for anterior negative activation.
133 Negativity
The advantage of the T test is that directions of activation (e.g. activation or deactivation) 
can be studied (Josephs and Henson, 1999). In a number of our subjects the activation 
was negative; that is a Z score > 2.99 was obtained at P  < 0.001 uncorrected with a 
negative J-test at that voxel. Negative activation has been reported in the posterior 
cingulate cortex in PET (Coghill et al., 1994), and subthreshold negative signal changes 
in the hypothalamus in fMRI studies of pain (Becerra et al., 1999). An area of 
deactivation in the ipsilateral pons, alongside activation in the contralateral pons, has 
been reported in spontaneous migraine (Afridi et al., 2005b)The role of negativity in 
functional imaging studies remains unclear; it could be due to decreasing neural activity 
at that site or synaptic inhibition by GABAergic intemeurons (Lauritzen and Gold, 2003), 
although the release of inhibitory neurotransmitters is an energy-demanding process in 
itself which may evoke increases in rCBF (Coghill et al., 1994; Sokoloff, 1991).
In one patient (#42) there was positive activity on the right side and negative activity 
contralaterally, and in two patients with right sided attacks (#6 and 33) there was negative 
right-sided activation. This suggests a reciprocal activation and deactivation across the 
midline, in that activation associated on the side contralateral to the headache is 
accompanied by deactivation on the other side. This phenomenon has been reported in 
the pons in a PET study of migraine (Afridi et al., 2005b). In the two patients with right­
sided attacks the activation which should have been seen on the left side may not have 
survived the threshold for significance.
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13.4 Laterality
One of the prerequisites of SUNCT by definition is unilaterality. However this study 
shows eight patients with SUNCT who have either right- or left-sided attacks, and one 
with bilateral attacks, in Chapter 5.4. Three of these patients participated in the fMRI 
study. These were #7 who had exclusively left-sided attacks during the scanning session 
although he had right-sided attacks on other occasions, and #23 whose attacks were 
equally distributed between right and left. The third patient (#34) usually had left-sided 
attacks, but had very occasionally experienced SUNCT attacks on the right side. Bilateral 
attacks of SUNCT have been reported in isolated cases (Kuhn et al., 2005; Pareja and 
Sjaastad, 1997; Sabatowski et al., 2001).
A study by Afridi et al (Afridi et al., 2005c) specifically aimed at assessing lateralisation 
of activation in migraine, found ipsilateral dorsolateral pontine activity in unilateral 
attacks, but patients with bilateral migraine activated the left side of the dorsolateral pons 
predominantly, and a conjunction analysis revealed that in fact there were bilateral 
activations. The authors speculated that the activation could have spread to the 
contralateral side during the course of the attack, as is the case in cutaneous allodynia 
(Burstein et al., 2000), or that the unilateral pain could result from an asymmetric brain 
dysfunction.
Bilateral hypothalamic activity during unilateral attacks of SUNCT has been previously 
reported in 2 patients in this series (Cohen et al., 2004a), and in a third patient with 
cutaneously triggered attacks (Sprenger et al., 2005). It is noted that in all 3 patients this 
was the anterior aspect of the hypothalamus which was active. Previously hypothalamic 
action has been described as ipsilateral to the side of the pain in SUNCT (May et al., 
1999b), triggered cluster headache (May et al., 1998a; May et al., 2000), a spontaneous 
CH attack in which a hypothalamic stimulator had been implanted and then switched off 
(Sprenger et al., 2004a), but contralateral in PET studies of paroxysmal hemicrania 
(Matharu et al., 2006b) and hemicrania continua (Matharu et al., 2004c).
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The striking feature of TACs is the unilaterality of their attacks, as reinforced by 
unilateral photophobia and phonophobia in 48-80% of patients with TACs and 
hemicrania continua but only in 4-13% of migraine patients (Irimia et al., 2005).
However the functional imaging results suggest that the pathophysiology is a bilateral 
issue. Indeed, most primary headache syndromes can involve bilateral pain. For example, 
migraine, which derives its name from the term hemicrania since Galen (ADI31-201) 
(Lance, 1998), can be bilateral, and hemicrania continua can alternate sides (Marano et 
al., 1994; Matharu et al., 2006a; Newman et al., 1992; Newman et al., 2004). Cluster 
headache can also occur with side shifts between bouts, between attacks, and during 
attacks (Bahra et al., 2002), and has rarely been reported as affecting both sides at the 
same time (Kudrow, 1980; Sjaastad et al., 1985; Young and Rozen, 1999). It is known to 
recur on the opposite side to trigeminal gangliorhizotomy (Mathew and Hurt, 1988) in 
patients with a past history of attacks on that side; and in a recent series of trigeminal 
nerve section in CH, 2 patients with no history of contralateral attacks developed CH on 
the opposite side to the trigeminal root section (Jarrar et al., 2003).
In terms of deep brain stimulation, a total of sixteen CH patients with ipsilateral posterior 
hypothalamic stimulators had relief of their symptoms (Franzini et al., 2003; Leone et al., 
2004b), and a SUNCT patient had successful ipsilateral posterior hypothalamic 
stimulation (Leone et al., 2004b). Six cases of ipsilateral ventroposterior hypothalamic 
stimulation have been published with two patients painfree (Schoenen et al., 2005). In 
two patients with bilateral CH ipsilateral stimulators only provided relief in the ipsilateral 
side, and therefore had bilateral stimulators implanted with good effect (Leone et al., 
2003b; Leone et al., 2004a). One of these patients had headache recur on the opposite 
side despite destructive trigeminal surgery to that side, thus providing further evidence 
that TACs are indeed centrally generated syndromes and are not purely peripheral nerve 
phenomena.
Occipital nerve stimulation has been used in patients with bilateral chronic migraine, who 
received bilateral stimulators with a marked beneficial response (Matharu et al., 2004a). 
They have also produced a fair to excellent outcome in 2 patients with CCH, 2 with
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chronic migraine and one with hemicrania continua (Dodick et al., 2005). However 
unilateral occipital nerve stimulation in 5 patients with CCH provided no lasting relief in 
4 patients, and caused the headache to recur on the contralateral side in the fifth patient 
(Magis et al., 2005). The side switch may be explained by a bilateral predisposition to 
develop a TAC, which is manifest only on one side and remains subclinical on the 
opposite side until the first side is suppressed.
The apparent discrepancy in laterality of activity observed in this series may be due to a 
number of reasons:
1) The first is that the hypothalamus has abnormal activity on the side contralateral 
to the attacks (as in patients #42 and #56): the other side is either inhibited (as in 
patients #6 and #33), or there is activation of inhibitory neurons in order to 
compensate for the abnormal activity.
2) The second reason is that either side of the hypothalamus can generate attacks on 
either side of the face, as being a midline structure it is not generally associated 
with a lateralized hemibody function in hormonal or other functions. This may be 
the case in Patient #7, for whom analysis in both left and right posterior regions 
showed activation which straddled the midline (Figure 12.5).
3) Moreover there are bilateral projections from each side of the hypothalamus to the 
caudal trigeminal nucleus and brainstem parasympathetic nuclei, and this may 
explain why a unilateral lesion of the trigeminal sensory pathway does not 
exclude the possibility of contralateral trigeminal and parasympathetic pathways 
being recruited by a rostral diencephalic generator (Malick and Burstein, 1998).
4) Another explanation could be in the nature of SUNCT/SUNA attacks; the stab 
attacks are very short-lasting (1-600 seconds in this series), and therefore the 
switch between hypothalamic activation and deactivation may also be in this time 
frame. An activation on one side and contralateral deactivation may flip so 
quickly, especially in saw-tooth attacks (Figure 5.3), that the overall picture may 
be one of bilateral activation.
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13.5 Hypothalamic activity as a cause or consequence of trigeminal pain?
One may argue that the activations seen in the hypothalamic region may be secondary to 
the pain of the SUNCT/SUNA attacks, and not a generator of the attacks. This theory can 
be refuted by a study which applied painful electrical stimuli to the first division of the 
trigeminal nerve, and found activation in the insula, thalamus, somatosensory cortex, and 
cingulate cortex, but not in the hypothalamus (Fitzek et al., 2004). Moreover the 
hypothalamus is implicated as a generator for these attacks by virtue of the striking 
autonomic symptoms in SUNCT/SUNA, which are thought to be due to hypothalamic- 
autonomic reflexes (Goadsby et al., 2001). Moreover agitation is seen in SUNCT and 
TACs (Chapter 5.9), and is resolved by destruction or stimulation of the posterior 
hypothalamic region (Franzini et al., 2005; Sano et al., 1970). Furthermore posterior 
hypothalamic stimulation was performed on one SUNCT patient with a beneficial effect 
(Leone et al., 2005), thus suggesting that this region is a generator or modulator of the 
attacks.
13.6 Hypothalamic activity and clinical characteristics
Some patients had contralateral posterior hypothalamic activation in SUNCT (Patients # 
42, 56), some had reciprocal ipsilateral deactivation (patients # 6, 33), and some patients 
with attacks that were not strictly unilateral had bilateral positive activation (#7, 23, 34). 
Two patients (#12, #17) had bilateral activation but unilateral attacks. In SUNA, we can 
assume negative activation, which is bilateral in both cases. The only patient with no 
significant activation was one with SUNCT secondary to a brainstem lesion (#2).
The clinical characteristics o f these patients, and their responses to medications, were 
explored in the light of the fMRI findings. These are tabulated in Table 13.1.
Table 13.1
Hypothalamic activity and clinical characteristics in SUNCT and SUNA
Patient no and 
diagnosis side activations
LTG
response
TPM
response
awake/
asleep
photo/
phonophobia
migraine
biology
background
pain triggers
episodic 
or chronic disease
location polarity
2
Sympto­
matic
SUNCT
R nil + ++ both phonophobia 0 1 none chronic
SUNA44 SUNA L bilateral posterior neg - - both none 1 0 none chronic
SUNA40 SUNA and TAC R
contralateral 
posterior and 
bilateral anterior
neg - n
awake,
early
morning
ipsilateral
photophobia 1 0 none chronic
6 SUNCT R ipsilateral anterior and posterior neg ++ n awake nausea 0 0 most
secondary
chronic
7 SUNCT L (bilat) bilateral posterior pos + - both nil 0 1 few chronic
12 SUNCT L bilateral posterior and left anterior pos + - both
ipsilateral
photophobia,
bilateral
phonophobia
0 1 few chronic
42 SUNCT L
contralateral
posterior pos ++ ++ both
nausea,
ipsilateral
photophobia
1 0 equal chronic
bilateral anterior neg
56 SUNCT L contralateralposterior pos
_* ++ awake nausea 0 1 most secondarychronic
17 SUNCT L all pos ++ - both nil 1 1 equal chronic
23 SUNCT bilateral all pos ++ n awake ipsilateralphotophobia 0 0 none chronic
33 SUNCT R ipsilateral anterior and posterior neg - n
awake,
early
morning
nil 1 0 most episodic
34
SUNCT, 
migraine 
and CH
L all pos - - unsure bilateralphonophobia 1 1 none chronic
Key: all = bilateral posterior and anterior, pos = positive activation, neg = negative activation, LTG = lamotrigine, TPM = topiramate, + = moderate effect, ++ = 
good effect, - = no effect, -* = no effect at low dose which had to be stopped due to side effects, n = not tried, awake/asleep = diurnal variation of attacks 
occurring mainly during waking hours or sleep
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There was no obvious link between clinical characteristics and activation, other than the 
diagnosis of idiopathic SUNCT, symptomatic SUNCT or SUNA.
Triggering o f attacks
One patient with SUNCT (#17) whose attacks were triggered for the scanner, had 
bilateral positive activation. This would strengthen the importance of hypothalamic- 
trigeminal connections in SUNCT; given the fact that the patient’s attacks (and 
hypothalamic activation) persisted long after the stimulus was removed, it is possible that 
the hypothalamus is switched into an active state for a short while following a trigeminal 
cutaneous trigger. One could assume that attacks that were mostly triggered would have a 
different hypothalamic activation to spontaneous attacks, via the hypothalamic-trigeminal 
pathway and the hypothalamic modulation of autonomic symptoms. Therefore it might be 
speculated that SUNA with its relative paucity of Vj autonomic symptoms and relative 
lack of triggerability would explain the negative hypothalamic activation. Indeed both 
SUNA patients had attacks that were entirely spontaneous, as has been shown to be more 
common in SUNA than SUNCT (Table 5.12). However two SUNCT patients with 
entirely spontaneous attacks (#23 and #34) had bilateral positive activation as opposed to 
the negative activation found in SUNA. Therefore no correlation can be made between 
triggerability of attacks and patterns of activation.
Previous studies in SUNCT have assessed triggered attacks, and have found ipsilateral 
(Sprenger, 2004) or bilateral (Sprenger et al., 2005) hypothalamic activation, although the 
coordinates specified were rather more anterior. Ipsilateral activation was demonstrated 
in spontaneous SUNCT attacks (May et al., 1999b) in the region of the posterior 
hypothalamus. It may be, therefore, that triggered attacks are associated with anterior 
hypothalamic and spontaneous attacks with posterior hypothalamic activity. Some 
patients with equal or predominantly triggered attacks had anterior hypothalamic 
activation (#6,42, 17, 33). However there were patients with entirely spontaneous attacks 
whose activation was anterior as well (#23, 34). We would therefore conclude that both 
triggered and spontaneous attacks are associated with either anterior or posterior 
hypothalamic activation, or both.
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Diurnal variation o f  attacks and migrainous features
Given that the hypothalamus is known to regulate circadian (and seasonal) rhythms, 
through the suprachiasmatic nucleus (SCN) (Ralph et al., 1990), and that cluster headache 
has a strong diurnal variation, with attacks occurring at specific times of day or usually 
during the night (Bahra et al., 2002; Russell, 1981), it might be expected that SUNCT 
patients with a similar pattern of hypothalamic activity to CH would exhibit similar 
diurnal variation of attacks. However there was no discernible pattern in activation in 
patients whose attacks occurred with a predominantly diurnal variation, as would be 
expected in hypothalamically-driven attacks.
Migraine biology and migrainous features
Patients with migraine biology (the two SUNA patients, #42, 17, 33, 34) had no unifying 
pattern to their activation, nor did those with background interictal pain (#2, 7, 12, 56, 17, 
and 34). Interestingly, both patients with bilateral phonophobia associated with their 
attacks (#12, #34) also had bilateral positive activation. Usually TACs have unilaterality 
of symptoms such as photophobia and phonophobia (Irimia, 2005), so the presence of 
bilateral phonophobia in association with bilateral positive activation might indicate the 
propensity of these patients to develop bilateral attacks. Alternatively this may be a 
manifestation of bilateral representations of central structures such as the hypothalamus 
in unilateral attacks.
Response to treatments
It would be attractive to speculate that lamotrigine and topiramate targeted the 
hypothalamus; thus by suppressing attacks they would prevent not just the pain, but also 
the accompanying autonomic symptoms and agitation that are attributed to hypothalamic 
activation. However there were no obvious links between responses to preventives such 
as lamotrigine and topiramate, and hypothalamic activation. This could be due to the 
small number of patients in the fMRI study, and of these one patient (#56) could only 
tolerate a low dose of lamotrigine due to its side effects. Indeed the patient with 
symptomatic SUNCT (#2) with no significant hypothalamic activation demonstrated, had 
a moderate to good response to both lamotrigine and topiramate.
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13.7 Pain, verbal rating scales and linearity
The assessment of level of perceived pain is important, not only for research purposes, 
but also in order to gauge the response to treatment. Pain is a multi-dimensional 
phenomenon, including nociceptive intensity, affective components, and cognitive 
aspects related to the pain. The pain intensity or severity is the aspect most commonly 
measured in pain (Von Korff et al., 2000); usually by a continuous visual analogue scale 
(VAS) or discrete categories such as in the verbal rating scale (VRS) or numerical rating 
scale (NRS). The NRS had previously been reported as preferable for chronic pain 
syndromes (Dworkin et al., 2005), and although no one scale has proven superior in 
showing benefits associated with treatment of pain, patients tend to prefer NRS or VRS 
scales as they are easier to understand (Jensen, 2001), and a greater intra-individual 
concordance was found using VRS rather than the continuous VAS scale (Lund et al., 
2005).
The pain intensities on the VRS, by nature of being descriptive (no pain, mild, moderate 
and severe), are transferable to a linear scale (0, 1,2 and 3 respectively) but this may not 
reflect a true proportionality of the pain experience. However Lund et al (Lund et al.,
2005) found that it was particularly the VAS scale particularly did not show linearity with 
the pain intensity assessments. Linearity has been demonstrated in NRS scales, but only 
in certain conditions such as obstetric and postoperative pain, and not for postoperative 
orthopaedic patients (Hartrick, 2003). The authors concluded that the young age of the 
former group and the nature of the visceral pain may account for the differences.
In fMRI, the magnitude of the BOLD response is assumed to be linearly related to the 
magnitude of underlying neuronal activity (Josephs and Henson, 1999). It has previously 
been shown that signal changes at the ACC correlated with the intensity of the pain 
(Davis et al., 1997).
i
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Functional imaging studies o f pain have assessed pain-related activation in different 
ways. Some studies use a separate analysis each for painful and non-painful stimuli, and 
then performed a T  test between the groups at the region of interest (Becerra et al., 1999). 
Others perform separate analyses per pain intensity unit (on a verbal rating scale from 0 
to 10) in visceral pain (Dunekley et al., 2005a), and multiple regression analyses were 
used to assess the effect of different intensities of arm pain (Coghill et al., 1999). A recent 
fMRI study used a four-point scale ranging from no pain to severe pain, and modelled the 
haemodynamic response in a linear parametric conjunction analysis in order to determine 
the stimulus intensity-related effects at the anterior cingulate cortex (ACC) (Mohr et al., 
2005).
There are however a number of differences between measuring pain in SUNCT patients 
for fMRI and other scenarios. One is that outcome measures for pain clinical trials 
usually deal with conditions such as osteoarthritis and low back pain; these are constant 
or long-lasting painful episodes wherein the pain levels may vary during an episode of 
pain, as opposed to the short-lasting neuralgiform attacks of SUNCT and SUNA which 
are usually separated by pain-free periods and may in some cases be too short for a 
perceptible intra-attack change in pain rating.
The difference in functional imaging terms is that studies so far have focused on the CNS 
response to a graded painful stimulus. The hypothesis in this study is the reverse: that 
there is hypothalamic activation which causes the attacks, and that a greater activation 
may cause a greater degree o f pain in the attack. Aside from two patients whose results 
have been reported in 2004 (Cohen et al., 2004a), this aspect of differential hypothalamic 
activation in primary headache syndromes has not been explored.
k
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13.8 Shortcomings of the Study
Location o f hypothalamus
As it can be seen from the figures, (for example Figures 12.10 (Patient #56) and 12.18 
(Patient #23)), some of the activations shown are in clusters of activated voxels which do 
not correspond to the area generally regarded as the posterior aspect of the hypothalamus 
in previous imaging work (Table 11.2). Furthermore some patients have activation which 
has been reported as bilaterally positive, when the cluster of activated voxels has 
straddled the midline (Patients #7, 17, 42, SUNA44). However we have reported these as 
positive results, due to the a priori hypothesis for the study, which specified the region of 
the posterior hypothalamus as a spherical region of interest with radius 10mm. Any 
activated voxels within this region which met the threshold of P  < 0.001 (uncorrected) 
were therefore included in the analysis.
Small numbers
Some patients only had a small number of attacks (#7, #33, #SUNA44); therefore the rate 
of detection of activation may have been diminished. However the SPM package 
provides a statistically robust method, so any activation with P < 0.001 in an individual 
patient was reported.
Methodological Issues
During the scanning sessions, the patients received an auditory tone once every 3.96 
seconds, which prompted them to rate their pain via a keypad. The design matrix was 
constructed such that each headache ‘event’ was the 3.96 seconds between consecutive 
tones. Attack lengths were therefore calculated as the number of positive keypresses 
multiplied by 3.96 seconds. It is possible that an attack could be shorter than 3.96 
seconds, or could have started or terminated in the middle of one of these epochs, and this 
information would be missed according to the current paradigm. However the 
haemodynamic response function, that is the transient increase in regional cerebral blood 
flow cause by neuronal activity, has been estimated at around 5 seconds (Friston et al., 
1995b), and the BOLD signal which is roughly proportional to the concentration of
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deoxyhaemoglobin, follows the rCBF function with a delay of about 1 second (Friston,
2003), so any events taking place on a shorter timescale than this may not be accurately 
modelled by the GLM.
One problem with this design matrix is that the start of each headache event was timed to 
the onset of the auditory stimulus. As the neuronal activity associated with ‘sound’ had to 
be modelled out in the design matrix, it is possible that some information from each 
headache event was lost. In order to minimise any loss of information, the ‘sound’ and 
‘keypress’ functions were modelled as events lasting zero seconds each, and the 
‘headache’ event lasted 3.96 seconds.
Medications
Most patients were taking preventive therapies up until 24 hours prior to the scans, and in 
most cases were having a good to moderate effect in suppressing the attacks. Therefore 
any scans performed under the influence of preventive medications would be influenced 
by the reduced frequency and severity of attacks. It is also plausible that some 
preventives may have a direct influence on hypothalamic activity, particularly melatonin 
(although none of our patients were taking it at this time). It has been noted that 
amitriptyline has an effect on the hypothalamic-pituitary axis (Barden et al., 1995), and it 
is possible that the lack of significant hypothalamic activation of Patient #2 may be due to 
his amitriptyline intake, although this effect has not been replicated in clinical studies 
(Rota et al., 2005).
In any case, all 8 patients who were taking preventives had stopped them 24 hours prior 
to the scan, and they were all experiencing attacks of SUNCT/SUNA, which would imply 
that the central generator of these attacks was not suppressed. PET studies in patients 
with PH and HC who stopped their medications 24-48 hours prior to scanning still 
demonstrated hypothalamic activation (Matharu et al., 2006b; Matharu et al., 2004c), and 
bilateral hypothalamic activation was still detected in a SUNCT patient who only omitted 
his medications on the day of the scan (Sprenger et al., 2005).
228
Movement related artefact
Two patients (#12, #17) were noted to have some head movement at the time of the scan. 
Both of their statistical parametric maps included horizontal ‘bands’ of activations which 
are characteristic of movement-related artefact (Figure 13.1). In the case of #12, the 
active voxels were not in the immediate region of interest, but in the case of #17 there 
was a band of active voxels in the plane of the region of interest. This may explain the 
reason why both patients had significant activation bilaterally, in both anterior and 
posterior regions. However the regions of interest were small in comparison to the total 
brain volume (10mm spheres), so it was decided to report them as active with this one 
caveat.
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Figure 13.1
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13. 9 Group analyses
Group analyses with a priori hypothesis o f hypothalamic activity 
The original analysis was done on individual patients in order to provide a stand-alone 
statistically significant result for each case in the series. Group analyses were performed 
as an additional step, to ascertain any significant activations of the group of patients.
In random-effects analysis the activation in the right posterior hypothalamic region did 
not reach statistical significance. This is unsurprising, as contrast images from only 9 
patients were taken to the second level in this analysis; therefore the numbers were 
probably too small to achieve a significant effect.
One of the problems with studying such rare syndromes as SUNCT and SUNA is the 
small numbers of patients with these conditions, and that number diminishes even further 
for patients willing to take part in research trials, and those actually experiencing attacks 
whilst in the scanner.
The random effects analysis, which takes contrasts from the first level analysis and enters 
them into the second level analysis, is described as being more sensitive than the fixed- 
effects analysis (Worsley et al., 2002). It ensures that there is only one observation (i.e. 
contrast) per subject in the second-level analysis, and that the error variance is computed 
using the subject to subject variability of estimates from the first level (Friston, 2003). It 
makes inferences about differences in activation; however it is generally required to have 
a minimum of 10-12 subjects within each group (www.fil.ion.ucl.ac.uk/spm). In this 
group the SUNA patients and the symptomatic SUNCT were excluded, as these were 
thought to represent slightly different clinical phenotypes to idiopathic SUNCT.
Therefore there were only 9 patients in the group analysis.
In the fixed-effects analysis, there was positive activation in regions of the anterior and 
posterior hypothalamus on both sides, with no significant negative activation.
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A fixed-effects analysis estimates the error variance on a scan to scan basis, assuming 
that each scan represents an independent observation (Friston, 2003). It is likely to 
overestimate differences between patients (www.fil.ion.ucl.ac.uk/spmf Fixed effects 
analyses are used in the context o f single case studies, or when the functional anatomy of 
interest replicates from subject to subject (Worsley et al., 2002). Inferences can only be 
made to the group of patients studied, and cannot be generalised to the population from 
which they were drawn (Friston et al., 1999).
It is used for the SUNCT patients; however the SUNA patients were excluded as they 
were thought possibly to have a different (negative) activation. The analysis was reported 
for only the binary pain states (attack on/off), and not for the headache parametrically 
analysed with pain rating. This was because the pain ratings were assigned as numbers (0, 
1,2, 3) relating to no attack, mild, moderate and severe pain. On an intra-individual level 
it makes sense to assess all ‘mild’ or ‘moderate’ attacks together; however there will be 
much inter-individual difference in rating the different severities of pain, such that one 
patient’s ‘moderate’ may be different from that of the next patient. This inter-subject 
variability is borne out in functional imaging, where subjects with high sensitivity to pain 
activated the ACC significantly more than those who rated the same stimulus as less 
painful (Coghill et al., 2003). Therefore the fixed effects models was analysed only for 
the binary (attack on/off) states, and not for differential pain ratings.
The symptomatic SUNCT patient (#2) was excluded from both group studies due to no 
significant activation being found in the region of the hypothalamus for either binary or 
parametrically assessed attacks. This led to the assumption that patients with SUNCT or 
SUNA secondary to intracranial lesions may have a different pathophysiology to those 
with the idiopathic disease; and for this reason the patient was excluded from the group 
analysis.
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Group analysis with no a priori hypothesis
All the original analyses had been performed under the hypothesis that there was 
activation in the region of the hypothalamus. The purpose of this analysis was to assess 
effects over the group of 9 SUNCT patients, assessing whole brain analysis with no 
correction for region of interest, to look for other areas activated during the attacks.
The areas activated were those in the ‘pain matrix’ (Ingvar, 1999), a term coined to 
represent the group of cortical and subcortical brain regions found to be commonly 
activated in studies of nociceptive stimulation. These include the primary and secondary 
somatosensory cortices (SI and S2), insula, ACC, parietal cortex, dorsolateral preffontal 
cortex (DLPFC) and the thalamus (Apkarian et al., 1999; Casey et al., 1996; Kwan et al., 
2000; May et al., 1998b; Peyron et al., 2000; Talbot et al., 1991).
In this study there was activation in SI, insula, ACC and thalamus bilaterally. The 
thalamus was activated on both sides (Figure 12.26), although the local maximum of the 
cluster was on the right side. The activation of these structures thus confirm that the pain 
matrix is active in spontaneous attacks of pain as well as in experimentally induced 
painful states. In a case of spontaneous CH, there was activation ACC and medial 
thalamus based on small volume correction at the region of interest (Sprenger et al., 
2004a), and the pain matrix was also active during spontaneous attacks of PH (Matharu et 
al., 2006b). There was also activation in the cerebellum, which has been documented in 
pain studies (Iadarola et al., 1998; Ploghaus et al., 1999). Activation in the bilateral 
frontal and insular region, parietal region and occipital cortex has been associated with 
cognitive evaluation of pain intensity (Kong et al., 2005), with signal change in S2 and 
insula increasing linearly with pain intensity (Bomhovd et al., 2002). The putamen and 
globus pallidus have been seen in capsaicin-induced pain, and are purported to be an 
initiation of withdrawal from the pain (Iadarola et al., 1998). Bilateral cerebellar 
activation associated with contralateral primary motor cortex activation has been reported 
(Coghill et al., 2001). The activation of subcortical structures such as the putamen, red 
nucleus and cerebellum which are mainly involved in motor function and reactive 
behaviour, is thought to be linked to pain avoidance and defence (Bingel et al., 2002).
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Interestingly there was no activation in the region of the hypothalamus on this analysis. 
This may be because it used a different method to that of the a priori hypothesis. The 
previous method concentrated solely on the area of interest, and this method assessed the 
whole brain with a more stringent threshold (P < 0.001 for the whole brain, as opposed to 
P < 0.01 for the region-of-interest method). Therefore the hypothalamic activation may 
not have survived this threshold. This is discussed further in Chapter 18.
Alternatively it may be that there is no single locus of activation which is typical of all 
SUNCT patients within a fixed-effects analysis. In individual patient analyses, the results 
differed between patients, both in terms of psychophysical data (number and length of 
attacks) and in the functional imaging results. For instance, some patients had bilateral 
activation, and in some the activation was only unilateral, or even negative which was 
presumed to be a reciprocal deactivation to the activated side.
The laterality of the attacks should have been corrected by flipping all the scans so each 
patient’s attacks seemed to be on the left side. However the patients with bilateral attacks 
or a propensity for bilateral attacks (#7, #23, #34) would not have fitted neatly into this 
category. Nevertheless, each patient in the group analysis had scans with attacks on the 
left side, and thus our original assumption that there is activation in the region of the 
contralateral hypothalamus should have manifested itself in this analysis.
13.10 Summary
It is therefore speculated that the activation seen in the region of the hypothalamus in 
individual patients remains specific to each individual, and that the common locus of 
activation in all patients with SUNCT is yet to be elucidated. It may not be as clear-cut as 
in groups of CH patients, where the ipsilateral posterior hypothalamus is demonstrated in 
both functional MRI (May et al., 1998a; May et al., 2000) and VBM (May et al., 1999a). 
The varying results observed between the patients may be because some patients have the 
potential for bilateral attacks, or that the hypothalamus is bilaterally active in some cases.
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Patients with SUNA appear to have negative activation, and this may reflect the 
differences in phenotype between SUNCT and SUNA in terms of Vi cranial autonomic 
symptoms.
The lack of hypothalamic activation on group assessment, using whole brain analysis and 
no a priori hypothesis, may be due to differences in statistical methods between the two 
types of analysis. Alternatively it may indicate the concept that the hypothalamus is not 
the only cause for SUNCT and SUNA, as will be discussed in Chapter 18.
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Chapter 14
Voxel-Based Morphometry in SUNCT and SUNA 
14.1 Introduction
A fundamental tenet of primary headache syndromes is that these disorders are due to 
abnormal brain function in the setting of normal brain structure. However this axiom has 
been called into question by the advent of voxel-based morphometry (VBM), an 
automated non-biased whole brain technique which analyses changes in brain structure 
(Ashbumer and Friston, 2000). A VBM study in 27 CH patients showed a significant 
structural difference in grey matter corresponding to an increase in volume in the 
ipsilateral posterior hypothalamic grey, as compared to healthy controls (May et al., 
1999a). In another study patients with chronic tension type headache were demonstrated 
to have a decrease in volume of structures associated with pain, such as the anterior and 
posterior cingulate cortices, insulae and the cerebellum (Schmidt-Wilcke et al., 2005). 
Interestingly there was no significant change in patients with migraine (Matharu et al., 
2003b), or those with a history of migraine and analgesic overuse (Schmidt-Wilcke et al., 
2005). It could therefore be speculated that there is a structural difference in posterior 
hypothalamic grey matter in TACs, but not in migraine.
This study aimed to assess 13 patients with SUNCT and SUNA using VBM, and to 
compare them to a group of 16 healthy controls. The a priori hypothesis was that there 
was a significant change in the volume of the grey matter in the region of the posterior 
hypothalamus, in patients with SUNCT and SUNA.
14.2 Methods- Voxel-Based Morphometry
Eleven patients (ten male) were recruited from our cohort of primary SUNCT, along with 
two patients with SUNA (one male). The patients’ ages ranged from 33-72 years (mean 
54.6 years). Sixteen healthy volunteers (12 male) were recruited as control subjects. They 
all gave no personal or family history of headache. Their ages ranged from 31-79 years 
(mean 55.4 years).
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The study was approved by the National Hospital for Neurology and Neurosurgery and 
Institute of Neurology Joint Research Ethics Committee (REC Ref 97/033). The subjects 
gave their written consent for the study, and were free to withdraw from the study at any 
time.
Clinical Characteristics
Of the SUNCT patients, six had left-sided attacks. One patient (#23) had attacks affecting 
either side equally, and one (#7) had mainly left sided attacks but could occasionally get 
attacks on the right. Four patients had right-sided attacks. Of the SUNA patients, one had 
right-sided and one had left-sided attacks. One patient (#SUNA44) with left-sided attacks 
had another TAC on the right side, and one (#34) had a history of cluster headache and 
migraine (Empl et al., 2003). The clinical characteristics are displayed in Table 11.1.
143 Image Acquisition
MRI scanning was performed on a 1.5T magnetic resonance imaging (MRI) system 
(Siemens Vision). A high resolution (1 mm x 1 mm x 1 mm voxel size) Tr  weighted 
structural MRI was acquired for each subject.
Scanning parameters were as follows: TR (scan repetition time) = 12.24ms, TE (echo 
delay time)= 3.56ms, number of slices = 176, slice thickness of 1mm, giving voxels 1 
mm x 1 mm x 1 mm. The same scanner parameters and scanner hardware were used for 
the acquisition of all anatomical volumes.
14.4 Image Processing and Spatial Normalisation
Structural images were preprocessed using VBM implemented with Statistical Parametric 
Mapping software (SPM5) (www.fil.ion.ucl.ac.uk/spm/). running under Matlab 6.5 
(MathWorks, Natick, MA). Structural images were preprocessed in a single integrated 
segmentation and spatial normalisation routine. They were segmented to extract grey 
matter, and then normalised to an asymmetric Tr weighted template in Montreal 
Neurological Institute (MNI) stereotactic space. During the normalisation a modulation
step was added to ensure that the total amount of gray matter in each voxel was conserved 
before and after spatial normalisation (after Good et al (Good et al., 2001a)). This 
involves multiplying the spatially normalised gray matter by its relative volume before 
and after spatial normalisation, and allows VBM to compare the absolute volume of grey 
matter structures, as opposed to comparing the relative concentration of these structures 
in non-modulated images. The images were then smoothed with a 12-mm FWHM (full 
width at half maximum) isotropic Gaussian kernel.
14.5 VBM Statistical analysis
A voxel-wise statistical analysis was performed on the modulated smoothed data using 
SPM5 (www.fil.ion.ucl.ac.uk/spm/L running under Matlab 6.5 (MathWorks, Natick, 
MA), employing the framework of the General Linear Model (Friston et al., 1995b). A 
second-level group analysis was performed, using multiple regressions with a constant. 
This models the average grey matter value over both the patient and the control groups.
A design matrix was constructed with three variables: group (patient = 1, control = 0), 
age, and laterality of attacks (right = 0, left =1). The design matrix is shown in Figure 
14.1.
Regionally specific differences in grey matter between the groups were assessed 
statistically using a two-tailed contrast, namely testing for voxel-wise increases or 
decreases in grey matter. Tests were applied using the following variables or 
combinations of variables:
1) group -  i.e., differences between patients with SUNCT/SUNA as a group 
compared to controls
2) group and left sided attacks- i.e., differences between SUNCT/SUNA patients 
with left sided attacks as compared to controls
3) left sided attacks as a lone variable- i.e., differences between SUNCT/SUNA 
patients with left sided attacks compared to those with no left sided attacks and 
controls
w
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4) group, left sided, and age- i.e., differences between SUNCT/SUNA patients with 
left sided attacks compared to controls, allowing for changes in age.
Contrast vectors for ‘group’ and ‘group and left sided attacks’ are shown in Figure 14.1 
as an example.
Two voxel-vise parametric statistical methods were employed.
a) Whole brain analysis, using corrections for the search volume, and implicit 
multiple comparisons, which were made for a family-wise error (FWE) P- value 
of 0.05. Activations were reported for each suprathreshold voxel at this level.
b) Specific region of interest analysis, which did not involve correcting for the whole 
brain. This was specifically to evaluate the a priori hypothesis that there was a 
structural difference in the region of the posterior hypothalamus between patients 
with SUNCT/SUNA and healthy controls. The region of interest was selected as a 
10mm sphere with its centre at the region of the posterior hypothalamus (x, y  and 
z coordinates ±6, -16,-6 mm from the anterior commissure respectively) and as a 
secondary test, the region of the anterior hypothalamus (x, y  and z coordinates ±6, 
-6, -6 mm respectively). Activations were reported for P  < 0.001 at this threshold.
Both design matrices were repeated, with a reversal in the laterality; that is for the 
variable ‘right sided attacks’ right = 1 and left = 0. Logically speaking this was 
unnecessary, as the F-tests were two-tailed and would have detected either a positive or 
negative difference between left and right sides. However this was performed to account 
for Patient (#23) who had attacks on both sides, so his details were set as 1 in the 
laterality vector in both design matrices.
The entire study was repeated for patients with primary SUNCT only, and the SUNA 
patients were excluded from this analysis.
Figure 14.1
The Design Matrix for VBM
Figure 14.1a Figure 14.1b
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The design matrix in VBM for all patients. Each horizontal line represents a patient’s structural scan. Column 1 represents the group 
(controls = 0 (grey), patients = 1 (white)), Column 2 represents the age for each subjects, Column 3 represents laterality of symptoms 
(right = 0, left = 1), and the fourth column is the error term. Figure 14.1a looks at ‘group’ as the only contrast, with a contrast vector [1 
0 0 0]. Figure 14.1b assesses the effect of group and left-sided attacks as contrasts, with contrast vector [1010 ] .
Chapter 15
Results: Voxel-Based Morphometry in SUNCT and SUNA
15.1 Whole Brain Corrected
With family-wise errors at a threshold of P  < 0.05 corrected for whole brain, no 
suprathreshold voxels were found for the following contrasts:
a) SUNCT and SUNA, design matrix with left = 1:
a. group
b. left sided attacks
c. group and left sided attacks
d. group, age and left sided attacks
b) SUNCT and SUNA, design matrix with right = 1
a. group
b. right sided attacks
c. group and right sided attacks
d. group, age and right sided attacks
c) SUNCT alone, design matrix with left = 1:
a. group
b. left sided attacks
c. group and left sided attacks
d. group, age and left sided attacks
d) SUNCT alone, design matrix with right = 1
a. group
b. right sided attacks
c. group and right sided attacks
d. group, age and right sided attacks
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15.2 Region of Interest Analysis
With the whole brain uncorrected for multiple comparisons, and at a threshold of P < 
0.05, there were no voxels in the 10mm sphere in the region of the posterior 
hypothalamus (x, y  and z coordinates ±6, -16,-6 mm), or the anterior hypothalamus (x, y  
and z coordinates ±6, -6, -6 mm) on either side, which survived significance to P  < 0.001 
uncorrected. These were performed for the following contrasts:
e) SUNCT and SUNA, design matrix with left = 1:
a. group
b. left sided attacks
c. group and left sided attacks
d. group, age and left sided attacks
f) SUNCT and SUNA, design matrix with right = 1
a. group
b. right sided attacks
c. group and right sided attacks
d. group, age and right sided attacks
g) SUNCT alone, design matrix with left = 1:
a. group
b. left sided attacks
c. group and left sided attacks
d. group, age and left sided attacks
h) SUNCT alone, design matrix with right = 1
a. group
b. right sided attacks
c. group and right sided attacks
d. group, age and right sided attacks
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Chapter 16
Discussion: Voxel-Based Morphometry in SUNCT and SUNA
This study employed a sensitive, automated technique, VBM, to compare the brains of 
patients with SUNCT/SUNA with non-headache controls. The a priori hypothesis was 
that there is a change in the structure of the brain in the region of the posterior 
hypothalamic grey matter in patients with SUNCT and SUNA. This study revealed no 
such difference between patients and controls at the significance levels and thresholds set.
16.1 Methodology
Voxel-based morphometry is an unbiased automated whole-brain technique which can 
detect changes in the structure of grey or white matter which would go unnoticed in 
conventional structural imaging. Being an automated process and performing a statistical 
test at each voxel, it also reduces observer bias.
16.2 Field Strength of Scanner
The images were acquired on a 1.5 Tesla (1.5T) Siemens Scanner. It is possible that any 
structural differences between the two groups of patients were too subtle for this field 
strength of magnet, and that repeating the study on a 3T machine may yield positive 
results. However there have been positive results from studies performed in cluster 
headache operated on a 2T machine (May et al., 1999a), and in chronic tension type 
headache on a 1.5T machine (Schmidt-Wilcke et al., 2005). Still it may be useful to 
repeat this study using more powerful magnetic resonance imaging before declaring that 
there are absolutely no structural changes in SUNCT/SUNA.
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16.3 Smoothing kernel
The smoothing kernel was set at 12mm FWHM, as has been described previously in 
VBM (Wright et al., 1995). Smoothing enhances the signal-to-noise ratio of the data and 
allows intersubject averaging by blurring differences in gyral anatomy between patients 
(Turner et al., 1998). The size of the smoothing kernel should reflect the size of the 
regional differences between the groups of brains (Ashbumer and Friston, 2000). It has 
been noted using a previous version of SPM (SPM99) (www.fil.ion.ucl.ac.uk/spml that 
using a smaller smoothing kernel in patients with schizophrenia elucidated hippocampal 
changes which were not seen on a larger smoothing kernel (Kubicki et al., 2002); 
however a review of more recent SPM software suggests that most studies should use a 
smoothing kernel of 12mm (Mechelli et al., 2005).
16.4 Inclusion and exclusion of patients
Patients with SUNCT and SUNA were included in one study, which was repeated with 
only SUNCT patients. There were no positive findings in either the combined group or 
the group of SUNCT patients alone. There would be an argument in favour of assessing 
purely SUNA patients; however it was felt that a group of only 2 patients would not yield 
significant results.
A patient with SUNCT secondary to a brainstem lesion (#2) was excluded from this 
study, due to the fact that his structural MRI showed an abnormal configuration of the 
deep grey matter at the lateral ventricles and the upper brainstem, and a lacune in the left 
thalamus. The grey matter abnormalities would be problematic in segmenting the images 
into grey and white matter with SPM, as well as difficulties with normalisation onto the 
standard Talairach space, so he was excluded from the study.
A patient with abnormal white matter lesions (#7) was included in the study for two 
reasons. First, the lesions were entirely in the white matter, and would therefore not be 
included in the analysis which assessed purely segmented grey matter. Secondly, this
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patient was thought to have primary (idiopathic) SUNCT, and these lesions were not 
considered to be the cause o f his headaches.
16.5 SUNCT and SUNA
This study included both SUNCT and SUNA patients as one group. However there are 
differences noted between these two conditions in terms of phenotype (Chapter 6), their 
responses to treatment (Chapter 10), and also in functional imaging (Chapter 13); the 
latter of which showed activation during attacks of SUNCT and deactivation during 
SUNA attacks. Both SUNCT and SUNA were included in one VBM design matrix, as it 
was thought that any abnormal activation per se, be it positive or negative, would be 
associated with a structural change in the region of the hypothalamus. There were no 
positive findings in this analysis. Even taking primary SUNCT alone as an isolated 
syndrome, there were no suprathreshold voxels found.
16.6 Number of patients
Only 13 patients and 16 healthy controls were included in this study. Some VBM studies 
have used much larger groups, such as a seminal study of ageing in 465 people (Good et 
al., 2001a). The VBM study in CH assessed 25 patients and 29 controls (May et al., 
1999a), and another study compared 20 patients with chronic tension-type headache and 
20 patients with medication-overuse headache with 40 controls (Schmidt-Wilcke et al., 
2005). The SUNCT and SUNA group was smaller than this, and may be a reason why no 
statistically significant result was found. However the small number of patients cannot be 
the only reason for negative results in this group, as there have been positive findings 
recently in small groups of 9 and 13 children with high-functioning autism and 
Asperger’s syndrome respectively, compared to a group of 13 controls (Kwon et al.,
2004).
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16.7 Modulation versus non-modulation
In standard normalisation, individual images are warped to match a template, and thus 
volumetric differences are likely to be introduced. For example, if the subject’s 
hypothalamus is smaller than that o f the template, then it would be warped on to a larger 
size, voxel-for-voxel, and the information of this region would be lost. In this case, VBM 
compares the relative concentration of the structures in the spatially normalized regions. 
However this study sought to assess the relative volume of the hypothalamus; therefore a 
modulating step was added in at the normalisation level to compensate for the effect of 
spatial normalization. Analyses on modulated data appear to be more sensitive to 
regionally specific macroscopic change than analyses on unmodulated data (Good et al., 
2001b). It is possible that any change in the hypothalamus may have been a 
concentration-related change, and not a volume-related change. However the process of 
modulation has been employed in two positive studies which documented differences in 
the hypothalamus in cluster headache (May et al., 1999a) and in pain-producing 
structures in chronic tension type headache (Schmidt-Wilcke et al., 2005).
16.8 Laterality
Some patients had unilateral attacks, and some had bilateral attacks; similarly on 
functional imaging the activation was ipsilateral, contralateral or bilateral. Therefore the 
inclusion of laterality of attacks as a variable for the VBM analysis may have produced 
meaningless results. However even on using the variable ‘group’ alone, there were no 
significant differences seen between the patient and the control group.
16.9 A Negative Result
Given all of these shortcomings in the methodology, it may still be possible that there is 
no structural difference at a voxel-based level between patients with SUNCT/SUNA and 
healthy controls.
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It has been fundamental to the concept of primary headache syndromes that they were 
associated with abnormalities in neuronal function (as assessed on functional imaging) 
with completely normal brain structure (May et al., 1999a). The development of VBM as 
a technique has allowed exploration of structural changes in syndromes such as cluster 
headache (May et al., 1999a), schizophrenia (Wright et al., 1995), and indeed in normal 
ageing (Good et al., 2001a), which would be undetected on conventional MRI. However 
this study found no structural changes in SUNCT or SUNA.
It is interesting to note that no structural changes were found on VBM in migraine 
(Matharu et al., 2003b). Given the genetic basis for migraine (De Fusco et al., 2003; 
Dichgans et al., 2005; Haan et al., 2005; Ophoff et al., 1997; Ophoff et al., 1996; 
Terwindt et al., 1998), and the spectroscopic studies showing abnormal energy 
metabolism in the brains of patients with migraine (Montagna, 1995; Montagna et al., 
1994; Sandor et al., 2005b), one might expect a structural change in migraineurs on 
voxel-based morphometry. However the negative findings in VBM may be explained by 
the fact that this study assessed regional changes between migraine patients and controls; 
a mitochondriopathy or other genetic abnormality would encompass the whole brain, and 
indeed other tissues such as skeletal muscle (Lodi et al., 1997). A migraine attack may be 
generated or mediated by the brainstem and dorsal rostral pons in an already 
metabolically hypofunctioning system, but this may not necessarily require a structural 
change in these areas at a voxel-based level. The rationale that regional functional 
abnormalities can exist without structural changes can be extrapolated to SUNCT and 
SUNA.
A negative result in SUNCT/SUNA would conflict with the findings in cluster headache, 
which is the only other TAC to be studied with VBM (May et al., 1999a). Reasons for 
this may include differences between CH and SUNCT/SUNA in terms of manifestation 
of phenotypic features related to the hypothalamus. For example, CH has a strong diurnal 
variation, with ‘clock-like’ regularity, and a nocturnal propensity of attacks in around 
75% of patients (Russell, 1981). In contrast, only 7% of SUNCT and no SUNA patients 
reported attacks mainly occurring at night (Chapter 5.11). Secondly, patients with CH
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respond to melatonin (Leone et al., 1996; Peres and Rozen, 2001), whereas it has been 
rather disappointing in the few SUNCT/SUNA patients who have tried it (Chapter 
10.5.8). Lithium is also used to good effect in CH (Bussone et al., 1990; Ekbom, 1981; 
Peres and Rozen, 2001; Steiner et al., 1997b), and it is assumed to act by accumulating in 
the hypothalamus (Dodick et al., 2003) and enhancing serotonergic transmission in the 
central nervous system (Price et al., 1989). It has been tried in a limited number of our 
patients without success (Chapter 7.5.11), suggesting that hypothalamic manipulation 
may not be the effective target for therapy in these syndromes. Other differences include 
the ability to trigger SUNCT/SUNA through cutaneous stimuli, which is not the case in 
CH, and of course the difference in attack length (15-180 minutes in CH versus 5-240 
seconds in SUNCT) (Headache Classification Committee of The International Headache 
Society, 2004). Finally, the positive findings in cluster headache in one paper (May et al., 
1999a) have not yet been reproduced, so there is the possibility that it may not represent a 
sustainable theory of structural differences in primary headache syndromes.
It is therefore possible that although CH and SUNCT share some aspects of their 
phenotypes, and they both have activation in the posterior hypothalamic region in 
functional imaging studies, and also both respond to deep brain stimulation at the 
posterior hypothalamus (Franzini et al., 2003; Leone et al., 2003b; Leone et al., 2004a; 
Leone, 2004); the pathophysiology of these syndromes is different, and may be manifest 
by a structural change in the hypothalamus in CH, with no such change in 
SUNCT/SUNA.
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PART IV. DISCUSSION 
Chapter 17 
Symptomatic (secondary) SUNCT and SUNA
Primary SUNCT and SUNA, like other primary headache syndromes, are defined as 
being not attributable to another cause (Headache Classification Committee of The 
International Headache Society, 2004). However it is recognised that if a new headache 
occurs for the first time in close temporal proximity to another disorder that is a known 
cause of headache (such as an intracranial vascular event, infection and so on), then it is 
classified according to the precipitating disorder, even if it has the characteristics of a 
primary headache syndrome such as migraine, CH or any of the TACs (Headache 
Classification Committee of The International Headache Society, 2004).
The concept of post-traumatic headache requires that the headache syndrome starts within 
seven days of sustaining the trauma (Headache Classification Committee of The 
International Headache Society, 2004). In this series there are two patients (#42 and #52) 
with onset of SUNCT within one week of trauma. For other SUNCT patients the trauma 
is less acute, (Chapter 5.15 and Table 5.14), although occurring within weeks in each 
case. However it may remain that these headache syndromes were precipitated as a result 
of the trauma sustained.
Chronic headache following trauma to the head or neck is well described, with the 
duration of headache being independent of the type or severity of trauma (Warner, 2000). 
In terms of other TACs, there exist post-traumatic forms of CH (Reik, 1987; Turkewitz et 
al., 1992) and PH (Irimia et al., 2005; Matharu and Goadsby, 2001). A syndrome 
resembling SUNCT was described after a head injury, but it was diagnosed as TN 
because of a sensory deficit in V! (Putzki et al., 2005). However abnormal sensory 
examination is described in 12% of the current SUNCT series, so this may not be a 
reason for dismissing the diagnosis of SUNCT.
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A review of PH, HC and SUNCT in association with other pathologies has led to the 
suggestion of criteria to be considered in symptomatic headache syndromes, including 
close relationship in time and side of the lesion, remission on treatment of the lesion, and 
long-term follow-up (Trucco et al., 2004). It has been argued that local lesions in the 
cavernous sinus can cause syndromes resembling CH (Koenigsberg et al., 1994) and PH 
(Irimia et al., 2005), and that local lesions such as intraorbital metastatic bronchial 
carcinoid can cause SUNCT (Black et al., 2005). One could reason that the local lesions 
cause an ipsilateral syndrome of pain and autonomic symptoms; that the pituitary lesions 
could cause SUNCT via the hypothalamic-pituitary axis, and that the posterior fossa and 
brainstem lesions have a local action either on the trigeminal nerve root, or at the 
trigemino-cervical complex, or on the ascending pathways. However, there are SUNCT 
patients with intracranial lesions that anatomically may not account for the pain; Patients 
#57 and #51 who had parietal or parieto-occipital lesions, and Patient #7 with generalised 
cerebral white matter lesions, who had bilateral hypothalamic activation on fMRI. It is 
unclear as to whether these lesions were a direct cause of the SUNCT attacks, or whether 
they are incidental findings unassociated with the headache symptoms. Indeed in both 
patients #57 and #51, the pain persisted after excision of the lesions.
Classifying primary headache syndromes according to their clinical phenotype and 
secondary headaches according to the underlying cause is well-recognised, although there 
exist secondary headache syndromes which have the same clinical phenotype as the 
primary syndrome. Examples of these are SUNCT secondary to prolactinoma (Levy et 
al., 2003; Matharu et al., 2003c), and migraine caused by an angioma in the brainstem 
(Afridi and Goadsby, 2003) or migraine-like attacks after stereotactic intervention to the 
periaqueductal grey matter (Raskin et al., 1987; Veloso et al., 1998). The genetics of 
migraine are starting to be documented (De Fusco et al., 2003; Dichgans et al., 2005; 
Haan et al., 2005; Ophoff et al., 1997; Ophoff et al., 1996; Terwindt et al., 1998), so in 
patients with no previous history or family history of migraine it would be tempting to 
speculate that these migraine-like attacks resulted directly from the lesion or intervention. 
However the genetics of CH (Haan et al., 2005; Ophoff et al., 1997; Ophoff et al., 1996;
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Terwindt et al., 1998), PH (Cohen et al., 2006) and SUNCT (Gantenbein and Goadsby,
2005) are much less well-defined, so it is unclear as to whether the patients with 
supposed symptomatic SUNCT/SUNA secondary to intracranial lesions were 
predisposed to develop these syndromes, and the lesion was either incidental or by some 
mass effect or shearing force precipitated the start of the attacks; or whether indeed the 
lesion was the only cause of the headache syndrome.
Table 17.1 shows the patients with SUNCT/SUNA and intracranial lesions, and shows 
their responses to various medications. It is noted that in all SUNCT and SUN A patients, 
indomethacin had no effect and intravenous lidocaine had a beneficial effect (table 7.4), 
and in secondary SUNCT/SUNA this is no different. Oxygen generally has no effect in 
SUNCT/SUNA, although in one patient (#57) it changed the quality of her pain from a 
sharp to a burning type pain. In terms of preventives, 3 of the 4 SUNCT and the SUNA 
patient had a moderate to good effect on lamotrigine, and 3 of 7 SUNCT patients had 
some benefit on gabapentin, which reflects the figures for the total group of primary and 
symptomatic SUNCT/SUNA combined. However only one of the 4 SUNCT patients had 
a moderate benefit with topiramate, and only one in 6 had success on carbamazepine, 
which is less than that observed in the total group. It would therefore stand to reason that 
the lack of response to indomethacin and the good response to intravenous lidocaine 
would aid in the diagnosis of SUNCT or SUNA, either in its primary form or secondary 
to intracranial lesions. Intravenous lidocaine may also be useful to provide some respite 
from the pain for up to weeks or months at a time. In terms of preventives, lamotrigine 
appears to be useful both in primary and secondary SUNCT/SUNA.
In terms of treating the primary cause, two patients with pituitary lesions (#20 and #37) 
had treatment of the primary lesions, with good effect in resolution of the headaches in 
one patient (#37), and with some residual SUNCT attacks in the second patient. In both 
patients with space occupying lesions (#51 and #57) the attacks persisted after the lesions 
were removed.
Table 17.1
Secondary SUNCT/SUNA and their responses to medications
SUNCT
Patient number Oxygen Indotest iv lidocaine Lamotrigine Topiramate Carbamazepine Gabapentin
Vascular loops
46 no effect 
(low flow)
- - - - no effect minimal
13 minimal negative - good in 
combination
no effect good in 
combination
no effect
55 - negative - - moderate no effect no effect
White matter 
changes
52 - negative - moderate - no effect good
7 no effect - pain free 3 weeks moderate minimal no effect moderate
Pituitary lesions
20 - - - - - - -
25 - - - good - - moderate
37 - - - - - - -
Space occupying 
lesions
51 - - - - - - -
57 changed 
type of pain
negative reduced frequency & 
duration
no effect no effect no effect no effect
SUNA
Patient number Oxygen Indotest iv lidocaine Lamotrigine Topiramate Carbamazepine Gabapentin
White matter 
changes
SUNA4 - - - Good - - -
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The presence of an intracranial lesion may cause a mass effect, or a head injury may 
cause axonal injury and shearing effects, which are well documented after direct mild to 
moderate head injury, and physiological changes have been noted after concussion 
injuries (Saper, 2000). It is therefore plausible to speculate that, just as the dorsal raphe 
nucleus may sustain a physiological abnormality post-traumatically, and lead to chronic 
migraine (Raskin et al., 1987), there may be a physiological shift in the hypothalamus 
following trauma which may lead to the development of SUNCT or SUNA.
The functional imaging study found activation in the posterior hypothalamic region 
bilaterally in Patient #7 with generalised white matter lesions, but no significant 
activation in Patient #2 who developed SUNCT after an episode of ataxia, and who had 
an unusual configuration of the brainstem and a lacune in the thalamus. It is suggested 
that Patient #7 had primary SUNCT with incidental white matter lesions which are 
anatomically remote, and that Patient #2 had symptomatic SUNCT, secondary to his 
brainstem lesion. It would be very interesting to image patients with SUNCT secondary 
to other causes, particularly those with neurovascular compression of the trigeminal loop, 
in whom one might expect no hypothalamic activation if the syndrome was purely due to 
the local compression, but one would see hypothalamic activation if the syndrome was 
centrally generated or modulated.
Two problems arise with functional imaging in patients with intracranial lesions; the first 
is that some post-surgical patients will be unable to enter the MRI scanner if there are 
metal clips or stitches in situ; and secondly that the residual neuroanatomy may be so 
abnormal (after resection of a large tumour, or due to an abnormal configuration as in 
Patient #2), that the normalisation of the patient’s scans onto standard Talairach space 
may involve greater warping than for normal brains, with resultant loss of anatomical 
integrity or distortion of the location of the BOLD signal.
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Chapter 18
SUNCT, SUNA, TACs and the hypothalamus
18.1 Neuromodulation and a central generator for TACs
It has been argued in Chapter 10.7 that greater occipital nerve injections can modulate the 
behaviour of the trigeminal nociceptive complex in order to provide relief from the pain. 
Suboccipital electrical stimulators have had some useful effect in HC and CH (Dodick et 
al., 2003), although this effect was not replicated in a recent group of 5 patients with 
CCH (Schwedt et al., 2006). This was probably due to the short followup time (3-6 
months), during which time the stimulation parameters may not have been optimised, and 
also due to the fact that the stimulators were only implanted on the ipsilateral side and not 
bilaterally.
Occipital nerve stimulation may also cause a modulation of central pain-producing 
structures, such as the dorsal rostral pons, anterior cingulate cortex and cuneus, as seen in 
PET when turning off bilateral occipital nerve stimulators in chronic migraine (Matharu 
et al., 2004a).
Surgery to the trigeminal nerve, such as local nerve blockades, stellate ganglion block, 
supraorbital nerve block, and invasive surgery such as microvascular decompression of 
the trigeminal nerve, glycerol rhizotomy and y knife radiosurgery, have had variable or 
no beneficial effect in SUNCT, as discussed in Section 10.6. This is in contrast with TN, 
which has a good response rate to microvascular decompression (Barker et al., 1996). It 
has also been shown in this cohort that one SUNCT patient had a supraorbital nerve 
injection and one had an infraorbital nerve injection which caused numbness but the 
attacks were still triggerable. This would concur with persistence or recurrence of CH 
attacks after trigeminal root section (Leone et al., 2004a; Matharu and Goadsby, 2002a),
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in 10/17 patients undergoing trigeminal gangliorhizolysis (Mathew and Hurt, 1988), and 
in 8/10 patients undergoing y knife radiosurgery (Donnet et al., 2005).
There is however one case of SUNCT with bilateral hypothalamic activation on 
functional imaging and a blood vessel compressing the ipsilateral trigeminal nerve, with 
resolution of the attacks after decompressive surgery (Sprenger et al., 2005). However 
the followup time was only 7 months, and as the patient had a remission of 10 months in 
the previous year, this could just have been a remission period and not a true reflection of 
the outcome of the procedure.
These, along with extensive functional imaging studies in CH, other TACs and HC, 
provide strong evidence that these headache syndromes are centrally generated. The 
cranial autonomic symptoms are also believed to be centrally driven, as evidenced by HC 
and CH patients who had achieved analgesia with occipital nerve stimulation, who 
retained some autonomic features (Schwedt et al., 2006). One of the SUNCT patients 
(#57) could have autonomic features without the attacks, and one SUNA patient 
(#SUNA44) had cessation o f the painful attacks on intravenous lidocaine, but with 
continuation of the autonomic symptoms. This would suggest that even though the 
peripheral pain had been blocked or was absent, there is still a central generator for the 
attacks, likely the hypothalamus, mediating these effects via the hypothalamic-autonomic 
reflex (May and Goadsby, 1999), and that the cranial autonomic symptoms are not just a 
manifestation of the trigeminal-autonomic reflex. This putative difference in the origin of 
the autonomic symptoms may explain the difference between SUNCT and trigeminal 
neuralgia with lacrimation (Goadsby et al., 2001).
18.2 Hypothalamic activation on functional imaging
The activation of the hypothalamus in all TACs has come from functional imaging 
studies in CH (May et al., 1998a; May et al., 2000), PH (Matharu et al., 2006b) and 
SUNCT (Cohen et al., 2004a; May et al., 1999b; Sprenger et al., 2005). Deep brain 
hypothalamic stimulation has had a good effect in a series of 16 CH patients (Franzini et
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al., 2003; Leone et al., 2004b), and in a single case of SUNCT(Leone et al., 2004b); thus 
adding further evidence for the role of the hypothalamus in these syndromes. The current 
study adds to the evidence that there is activation in the area of the hypothalamus in 
SUNCT/SUNA, although with a few caveats:
1) the study set out with an a priori hypothesis that there is hypothalamic activation 
in attacks of SUNCT and SUNA. The a priori hypothesis is met on assessing the 
region of interest in individual cases and on group analysis, yet on whole brain 
analysis in the group with no a priori hypothesis there is activation of the pain 
matrix but no activation in the hypothalamic region
2) methodological issues in this study vary from other studies and so the results may 
be interpreted differently
3) the activation shown in this study is less uniform than that seen in other 
syndromes; activation is
a. ipsilateral in CH (May et al., 1998a; May et al., 2000)
b. contralateral in indomethacin-sensitive headaches (Matharu et al., 2006b; 
Matharu et al., 2004c)
c. and may be bilateral in SUNCT (Cohen et al., 2004a; Sprenger et al., 
2005)
In this study the activation is posterior or anterior, and there can be ipsilateral, 
contralateral or bilateral activation; thus calling into question the ability to generalise 
across the population of SUNCT and SUNA patients.
This serves as further evidence to link the TACs as a supergroup of headaches, but to 
separate them according to their clinical and therapeutic differences. Further differences 
between the individual TACs may be borne out by the discrepancies in laterality of 
activation.
183 Location of the hypothalamus
The location of the hypothalamus is also an issue. In functional imaging the area 
activated is the posterior hypothalamus, as is the area used in deep brain stimulation. This 
area is anatomically distinct from the suprachiasmatic nucleus which controls circadian
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rhythms. In this functional imaging study, both the anterior and the posterior areas of the 
hypothalamus were assessed, and activation in the anterior aspect of the hypothalamus 
has been reported in previous studies of SUNCT (Cohen et al., 2004a; Sprenger et al., 
2004b; Sprenger et al., 2005), which may contradict the findings that posterior 
hypothalamic deep brain stimulation is successful in SUNCT (Leone et al., 2005).
The current functional imaging study assessed a region of interest with its centre as the 
coordinates cited in previous functional imaging studies. It can be seen in certain patients 
(for example #56 and #SUNA40) that although the T test showed a statistically 
significant result, the centre of the cluster of activation was not actually at the 
hypothalamus. We have reported these as positive activations as they would refute the 
null hypothesis that there was no activation in the region of the posterior hypothalamus, 
as specified by this region of interest. However it is possible that this region of interest 
may encompass areas outside those which would physiologically function as the 
hypothalamus.
Furthermore, PH which is another TAC, and hemicrania continua which is not a TAC but 
shares some characteristics, both have activation in the posterior hypothalamus and also 
the ventral midbrain (Matharu et al., 2006b; Matharu et al., 2004c). As both of these 
syndromes respond absolutely to indomethacin, it is tempting to speculate that 
indomethacin may have an action at the ventral midbrain.
However the weakness of functional imaging techniques is that they provide regions of 
significant change on brain volumes without directional information about the ascending 
or descending nociceptive inputs from which these changes result (Jones et al., 2003). 
Hypothalamic activation has been reported in previous studies of experimental pain 
(Hsieh et al., 1996a), as well as in other pain studies (Ingvar, 1999; Jones et al., 2003; 
Kupers et al., 2000; Sanchez del Rio and Alvarez Linera, 2004). There is evidence that 
the hypothalamus is involved in nociception (Bartsch et al., 2004). The functional 
imaging results can therefore only be interpreted with reference to clinical, anatomical, 
biochemical, electrophysiological and pharmacological results derived from animal and
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human studies. With the currently available data, it remains inconclusive whether the 
posterior hypothalamic activation is the central generator of the attacks, of whether it is 
active in an anti-nociceptive role secondary to the pain, or whether it is part of a cascade 
which originates higher in the brain.
Deep brain stimulation in the posterior hypothalamic region has had a good effect in 
suppressing attacks of CH and SUNCT. Therefore it may be a good therapeutic target for 
the future in TACs, even if the hypothalamus is not the primary generator of the attacks.
18.4 Non- imaging evidence for hypothalamic involvement
Evidence for hypothalamic involvement also stems from the fact that SUNCT/SUNA are 
TACs and related to CH. For example, the hypothalamus is known to regulate circadian 
(and seasonal) rhythms, which are a striking feature of CH, with nocturnal attacks 
occurring in 75% of cases (Russell, 1981), and episodic CH occurring in seasonal bouts 
(Bahra et al., 2002), with highest bout frequency at the summer and winter solstices, 
apparently related to the length of daylight (Kudrow, 1987). These features are present in 
SUNCT but to a much smaller degree, and in fact 89% of SUNCT patients had the 
primary chronic form without seasonal bouts (Table 5.13), and only 7% of SUNCT 
patients had predominantly nocturnal attacks (Table 5.11).
The biochemical studies which demonstrated abnormal levels of serum testosterone, 
cortisol, prolactin, melatonin, and thyroptropin in CH patients, suggesting hypothalamic 
dysfunction (Leone and Bussone, 1993) have not been done in SUNCT/SUNA. There is 
one case report of SUNCT with a low serum testosterone whose attacks were reduced on 
treatment with clomiphene citrate which increases testosterone levels directly via the 
hypothalamus, but which then relapsed at the seasonal ‘change of the clocks’ (Rozen et 
al., 2005).
The apparent discrepancies between CH and SUNCT/SUNA may also be reflected in 
their responses to medications; for instance oxygen an acute abortive therapy in CH has
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been suggested to act either on abnormal mitochondrial energy metabolism (as suggested 
in Chapter 2.8), or in nocturnal CH attacks which are possibly due to hypoxia in an 
already physiologically compromised hypothalamus (Cohen and Kaube, 2005; Kudrow, 
1983; Nobre et al., 2003).
That the hypothalamus is a generator of CH attacks is further evidenced by the beneficial 
action of melatonin (Leone et al., 1996; Peres and Rozen, 2001), and the fact that 
melatonin production is reduced in CH patients, both nocturnal release and when 
measured over a 24-hour period (Chazot et al., 1984; Leone and Bussone, 1993; Leone et 
al., 1995; Waldenlind et al., 1987) and circannual melatonin (Waldenlind et al., 1994). 
Melatonin therapy is presumed to act in cluster headache by supplementing the reduced 
melatonin secretion by a malfunctioning pineal system, and has been linked to the diurnal 
hypothalamic rhythm found in CH, by preventing both the nocturnal and daytime attacks 
(Peres and Rozen, 2001). However it is also reported to be beneficial in open-label trials 
in other headache syndromes such as migraine and hemicrania continua, and has been 
suggested to have many mechanisms of action, such as an anti-inflammatory effect, free 
radical scavenging, and membrane stabilisation (Peres, 2005). Melatonin treatment has 
had a limited effect in SUNA patients (albeit in small numbers), possibly because SUNA 
patients are more refractory to treatment than SUNCT patients. Alternatively the 
pathophysiology between SUNCT and SUNA, in terms of hypothalamic involvement, 
may be different, and that in itself may be different from the hypothalamic activation in 
CH.
One of the effective preventive treatments for CH is lithium (Bussone et al., 1990; 
Ekbom, 1981; Peres and Rozen, 2001; Steiner et al., 1997b). Lithium accumulates in the 
hypothalamus (Dodick et al., 2003), and acts by increasing the absorption of tryptophan 
and promoting its transformation to 5-HT, thus enhancing serotonergic neurotransmission 
in the central nervous system (Price et al., 1989). The hypothalamic pacemaker is 
innervated by 5-HT, and lithium possibly exerts its effects on the circadian rhythms by 
slowing and altering them via this mechanism (Kafka et al., 1982; Kripke and Wybomey,
1980). Lithium has been shown to decrease REM sleep in both healthy and depressed
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people (Billiard, 1987). Moreover, both tryptophan and 5-HT are precursors for 
melatonin synthesis, and lithium has been shown to increase nocturnal melatonin levels in 
patients with CH (Chazot et al., 1987). However lithium has had no effect in the three 
SUNCT/SUNA patients who tried it (Table 7.7). Again this may be due to the small 
numbers of patients, or it may be that the pathophysiology of SUNCT and SUNA is 
different to that of CH in terms of hypothalamic activation, and thus they have different 
responses to treatment with lithium.
18.5 The role of the hypothalamus in TACs, SUNCT and SUNA
It is interesting to observe that the clinical feature that is common to the four primary 
headache syndromes in which posterior hypothalamic activation has been reported (i.e. 
PH, CH, SUNCT and HC) is prominent cranial autonomic features in association with the 
headache. It has been suggested that the pathophysiology of these syndromes revolves 
around the trigeminal-autonomic reflex (Goadsby and Lipton, 1997). There is 
considerable experimental animal literature to document that stimulation of trigeminal 
efferents can result in cranial autonomic outflow, the trigeminal-autonomic reflex (May 
and Goadsby, 1999). In fact, some degree of cranial autonomic symptomatology is a 
normal physiologic response to cranial nociceptive input (Frese et al., 2003; May et al., 
2001) and patients with other headache syndromes, such as migraine, may report these 
symptoms (Barbanti et al., 2002; Benoliel and Sharav, 1998). It has been suggested that 
the cranial autonomic symptoms may be prominent in these syndromes due to a central 
disinhibition of the trigeminal-autonomic reflex by the hypothalamus (Benjamin et al.,
2004). Indeed, there are direct hypothalamic-trigeminal connections (Malick and 
Burstein, 1998), and the hypothalamus is known to have a modulatory role on the 
nociceptive and autonomic pathways, specifically trigeminovascular nociceptive 
pathways (Bartsch et al., 2004).
The current classification of primary headache syndromes in general, and TACs in 
particular, is based largely on clinical phenotype, with response to indomethacin in PH 
and HC (Headache Classification Committee of The International Headache Society,
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2004). It is possible that HC and PH have a different pathophysiology to CH and 
SUNCT, which is why they respond to indomethacin and CH and SUNCT do not. The 
hypothalamus is suggested to be the mediator of the attacks in TACs on clinical grounds 
largely due to evidence gathered from CH, such as biochemical abnormalities and the 
diurnal and seasonal variations in CH (Cohen and Kaube, 2005). The act of including PH 
and SUNCT/SUNA as TACs from a phenotypic basis stems from the fact that they are all 
unilateral, relatively short-lasting attacks of severe orbital, retro-orbital or temporal pain, 
with ipsilateral cranial autonomic symptoms (Headache Classification Committee of The 
International Headache Society, 2004). The agitation and restlessness stated in CH has 
also been shown in this series of SUNCT patients. The differences between the 
syndromes lie not only in the duration and frequency of the attacks, but also in their 
response to medications, such that CH responds well to oxygen (Fogan, 1985; Kudrow,
1981) and sumatriptan (Diener, 2001; Ekbom et al., 1993; Hardebo, 1993); PH to 
indomethacin (Antonaci et al., 1998); and SUNCT/SUNA to intravenous lidocaine as 
shown in this series. Other differences include the ability to trigger SUNCT/SUNA 
attacks by cutaneous stimuli, which is generally not the case in other TACs.
It has been suggested in CH that although there is clear evidence that the attacks are 
centrally generated and that hypothalamic activity is key to the attacks, this activity may 
not generate an attack directly, but that an abnormality in hypothalamic function 
facilitates a cascade of metabolic and biochemical events, including deranged melatonin, 
cortisol and 5-HT metabolism, which in turn would trigger an attack (Cohen and Kaube,
2005). It is also possible in SUNCT and SUNA that the hypothalamus plays a role either 
as a generator or modulator of the attacks, but indirectly via mechanisms yet to be 
elucidated, and there may be other mechanisms for the pathophysiology of these 
syndromes that are yet unknown. This may explain the differences between SUNCT and 
other TACs in terms of the functional imaging results, phenotype and response to 
medications.
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Chapter 19
SUNCT and SUNA- a spectrum
SUNCT and SUNA can be thought of as different manifestations within a spectrum of a 
disorder, as they share many of the same characteristics of unilateral, episodic severe pain 
that occurs in stabs or jabs and is associated with ipsilateral cranial autonomic outflow. 
Both may be associated with cutaneous triggering of attacks, there is a lack of refractory 
period in both syndromes, and both respond to intravenous lidocaine and not to 
indomethacin. However there is an argument for separating out the two syndromes; and 
thus there are differences between them that are not simply the presence of Conjunctival 
Injection and Tearing that would make a diagnosis of SUNCT as opposed to SUNA.
The differences in this series of 52 patients (43 SUNCT and 9 SUNA) are as follows:
1) SUNCT affects mainly men, and SUNA affects mainly women
2) SUNCT is more likely to affect the orbital and supraorbital regions, and SUNA is 
more likely to affect the temple, V2 and V3
3) In terms of triggering of attacks, most SUNCT patients had mainly triggered 
attacks, whereas most SUNA patients had mainly spontaneous attacks (Table 
5.12)
4) Patients with SUNCT were more likely to respond to medications such as 
lamotrigine, topiramate and melatonin, and to procedures such as the GON 
injection (Table 7.7)
5) In fMRI, SUNCT patients had positive activation in the region of the posterior or 
anterior hypothalamus, either contralaterally or bilaterally, or negative activation 
on the ipsilateral side. Both SUNA patients had negative activation only
These may simply be a consequence of small group sizes, especially with only 9 SUNA 
patients in the clinical study and 2 in the functional imaging study, and these findings 
may not be significant enough to comment. However the question is asked: Is SUNA
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more refractory to treatment than SUNCT? And is this an effect of lack of conjunctival 
injection and tearing?
The presence of autonomic symptoms in V1? which are conjunctival injection and 
lacrimation, in SUNCT may be due to the trigeminal autonomic reflex (May and 
Goadsby, 1999), as pain in other headache syndromes can give rise to autonomic 
symptoms (Barbanti et al., 2002; Benoliel and Sharav, 1998), although generally to a 
lesser degree than that seen in TACs (Goadsby et al., 2001). Indeed, one patient (#59) 
specifically reported lacrimation when his pain was predominantly in V2 and nasal 
congestion when his pain was predominantly in V3, thus suggesting a topographical 
arrangement in the trigeminal-autonomic reflex. It is known from functional imaging 
work that the trigeminal nucleus shows somatotopic activation in pain according to the 
three divisions of the trigeminal nerve (DaSilva et al., 2002). As most of the SUNA 
patients in this series had V2  and V3 pain, it is plausible to suggest that this could explain 
their lack of V, autonomic symptoms in the eye.
The concept of cutaneous triggering is specific in SUNCT and SUNA as compared to the 
other TACs, although factors such as alcohol and strong smells such as paints and 
solvents, can trigger CH (Bahra et al., 2002) and PH (Cohen et al., 2006). There is a 
relative discrepancy between the two syndromes, in that most of the SUNCT patients had 
triggered attacks, and most of the SUNA patients had mostly spontaneous attacks. This 
may in turn affect their autonomic symptoms via the trigeminal-autonomic reflex, or it 
may be an effect of different hypothalamic activity between the two syndromes, in the 
central disinhibition of the trigeminal-autonomic reflex by the hypothalamus (Benjamin 
et al., 2004), the direct hypothalamic-trigeminal connections (Malick and Burstein, 1998), 
or the modulatory role of the hypothalamus on the trigeminovascular nociceptive 
pathways (Bartsch et al., 2004). This modulation may be different between SUNCT and 
SUNA, which may explain the negative activation in the fMRI study in SUNA.
As regards treatments, lamotrigine was effective in 68% of SUNCT and 25% of SUNA 
patients who tried it, and topiramate was effective in 52% SUNCT and 0% SUNA,
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although there was only one SUNA patient who took topiramate. Melatonin was 
moderately effective in one SUNCT patient, but had little to no effect in both SUNA 
patients. It is possible that these figures represent a true difference in the response to 
medications, such that SUNCT with its more prominent Vj autonomic features would 
have a more favourable outcome. Indeed animal models (Akerman and Goadsby, 2005; 
Storer and Goadsby, 2004) have shown that topiramate inhibits trigeminovascular 
activation, as measured by dura mater and superior sagittal sinus stimulation, which is 
mainly innervated by V! (Feindel et al., 1960). It may be that SUNA, with its autonomic 
symptoms in V2 and V3, has a more muted response to these medications.
The presence of a greater range or degree of autonomic symptoms could influence the 
response to medications. It is widely accepted that chronic featureless headaches such as 
new daily persistent headache are remarkably refractory to conventional therapies 
(Goadsby and Boes, 2002; Takase et al., 2004), and it could be that SUNA, being 
relatively featureless in terms of autonomic symptoms, is also relatively resistant to 
medications which are useful in SUNCT.
Both syndromes did not respond to inhaled oxygen or indomethacin, and both responded 
well to intravenous lidocaine. These results would indicate that SUNCT and SUNA are 
on the same spectrum of disorders, which are short-lasting unilateral neuralgiform 
headache attacks with a variable degree of cranial autonomic symptoms.
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Chapter 20 
Conclusions
SUNCT and SUNA are rare primary autonomic headache syndromes which have been 
poorly understood due to the small numbers of patients in previous studies. Their 
pathophysiology has been speculated to involve the posterior hypothalamus, according to 
some of their shared clinical characteristics with other TACs such as CH and PH, and 
with evidence of functional imaging studies and deep brain stimulation in the posterior 
hypothalamic region.
This project has undertaken a prospective clinical study in a large group of 52 SUNCT 
and SUNA patients. The phenotype of these two conditions has been characterised, and 
suggestions have been proposed to the current classifications by the International 
Headache Society, including: a wider variation of attack character, frequency and 
duration; the concept of attack load in minutes of pain per day; the ability to trigger 
attacks by cutaneous stimuli, and the lack of refractory period.
Clinical studies have shown that SUNCT and SUNA do not respond to inhaled oxygen or 
intramuscular indomethacin, in contrast with CH and PH respectively. Intravenous 
lidocaine, lamotrigine, topiramate and gabapentin have been shown to be useful in 
SUNCT and SUNA, although the shortcomings and methodological issues of double­
blind placebo-controlled trials have been highlighted.
Functional imaging work has shown activation in the region of the posterior 
hypothalamus or in the anterior hypothalamic region in individual cases of SUNCT and 
SUNA. The difference between patients in terms of laterality of the activation, location of 
the hypothalamic region which was activated, and polarity of the activation has been 
discussed. A voxel-based morphometric study found no difference in structure in the 
hypothalamic region compared to normal controls, and this is contrasted with the findings
i
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in CH that showed co-localisation of structural and functional changes in the posterior 
hypothalamus.
The differences between SUNCT and SUNA have been addressed with regard to clinical 
phenotypes, response to medication, and the finding of negative activation on fMRI in 
SUNA. It is speculated that SUNA and SUNCT have differing hypothalamic activation 
which may result the lack of Vi cranial autonomic symptoms in SUNA and a reduction in 
cutaneous triggerability.
A fundamental tenet of primary headache syndromes is the lack of underlying structural 
abnormality in the brain. However TACs are known to exist as a result of other disorders, 
including pituitary and posterior fossa lesions. This study presents new cases of 
symptomatic SUNCT and SUNA, and speculates the pathophysiological differences as a 
result of one case of symptomatic SUNCT with no significant hypothalamic activation.
It is possible that although all TACs share some aspects of their phenotypes, and also 
both CH and SUNCT respond to deep brain stimulation at the posterior hypothalamus, 
the pathophysiology of these syndromes is different. This may be manifest by a structural 
change in the hypothalamus in CH, with no such change in SUNCT/SUNA, and also in 
the more uniform activation of the ipsilateral posterior hypothalamic region in CH and 
PH, as compared to activations in SUNCT and SUNA over a wider area. SUNCT and 
SUNA are also phenotypically different to the other TACs in that the attacks are less 
stereotyped within the condition, with a wide range of attack duration and frequency, and 
with striking features such as triggering by cutaneous stimuli and lack of a refractory 
period between attacks. They also have a remarkable response to intravenous lidocaine, 
which can aid not just in diagnosis of these conditions, but which can also afford a 
painffee (and therefore drug-free) respite period for up to six months after cessation of 
the infusion.
The hypothesis that SUNCT and SUNA are associated with activation in the posterior 
hypothalamic region is upheld on an individual patient basis, but more evidence is needed
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that these are as strongly related to the hypothalamus as was previously thought. There is 
a need for biochemical evidence of hypothalamic derangement in these conditions, and 
from a clinical perspective a group of patients with SUNCT and SUNA should be 
followed up for deep brain hypothalamic stimulation in the long term. Preclinical studies 
to ascertain the mechanism of action of lidocaine, topiramate and lamotrigine in these 
particular syndromes are needed.
In the meantime, the suggestion is to widen the range of diagnostic criteria, and treat 
SUNCT and SUNA with intravenous lidocaine, lamotrigine, topiramate, and gabapentin 
especially in SUNA. Greater Occipital Nerve injections and Occipital Nerve Stimulators 
emerge as a new concept in treatment. Deep brain hypothalamic stimulation remains a 
possibility in the future, but with the reservation that the previously proposed 
hypothalamic activity in all TACs may not be the only mechanism for the 
pathophysiology of SUNCT and SUNA.
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Appendix 1 
International Headache Classification of Cluster Headache and other 
TACs
3.1 Cluster Headache
Diagnostic Criteria:
A: at least 5 attacks fulfilling B-D
B: severe or very severe unilateral orbital, supraorbital and/or temporal pain lasting 
150-180 minutes if untreated
C: headache is accompanied by at least one of the following:
1) ipsilateral conjunctival injection and/or lacrimation
2) ipsilateral nasal congestion and/or rhinorrhoea
3) ipsilateral eyelid oedema
4) ipsilateral forehead and facial sweating
5) ipsilateral miosis and/or ptosis
6) a sense of restlessness or agitation
D: attacks have a frequency from one every other day to 8 a day 
E: not attributed to another disorder
3.1.1 Episodic Cluster Headache 
Diagnostic Criteria:
A: attacks fulfilling criteria A-E for 3.1 Cluster Headache
B: at least two cluster periods lasting 7-365 days and separated by pain-free remission 
periods of > 1 month
3.1.2 Chronic Cluster Headache 
Diagnostic Criteria:
A: attacks fulfilling criteria A-E for 3.1 Cluster Headache
B: attacks recur over >1 year without remission periods, or with remission periods 
lasting < 1 month
3.2 Paroxysmal Hemicrania
Diagnostic Criteria:
A: at least 20 attacks fulfilling B-D
B: attacks of severe unilateral orbital, supraorbital or temporal pain lasting 2-30 
minutes
C: headache is accompanied by at least one of the following:
1) ipsilateral conjunctival injection and/or lacrimation
2) ipsilateral nasal congestion and/or rhinorrhoea
3) ipsilateral eyelid oedema
4) ipsilateral forehead and facial sweating
5) ipsilateral miosis and/or ptosis
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D: attacks have a frequency of above 5 per day for more than half the time, although 
periods with lower frequency may occur
E: Attacks are completely prevented by therapeutic doses of indomethacin 
F: not attributed to another disorder
3.3 Short lasting Unilateral Neuralgiform headache attacks with Conjunctival 
injection and Tearing (SUNCT)
Diagnostic Criteria:
A: at least 20 attacks fulfilling B-D
B: attacks of severe unilateral orbital, supraorbital or temporal stabbing or pulsating 
pain lasting 5-240 seconds
C: pain is accompanied by ipsilateral conjunctival injection and lacrimation 
D: attacks occur with a frequency of 3 to 200 per day 
E: not attributed to another disorder
* After (Headache Classification Committee of The International Headache Society, 
2004)
Headache Classification Committee of The International Headache Society.
Classification and diagnostic criteria for headache disorders, cranial neuralgias 
and facial pain (second edition). Cephalalgia 2004; 24: 1-160.
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Abstract
Chronic Paroxysmal Hemicrania (CPH) is a rare primary headache syndrome which is 
classified along with cluster headache and SUNCT (Short-lasting Unilateral 
Neuralgiform headache attacks with Conjunctival injection and Tearing) as a 
Trigeminal Autonomic Cephalalgias (TACs). CPH is exquisitely responsive to 
indomethacin so much that the response is part of the current diagnostic criteria. We 
report a patient with CPH who had significant epigastric symptoms on indomethacin 
and responded well to Topiramate 150mg daily. Cessation of Topiramate caused 
return of attacks, and the response has persisted for two years. Topiramate may be a 
treatment option in CPH.
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Chronic Paroxysmal Hemicrania (CPH) is a rare primary headache syndrome which is 
classified along with cluster headache and SUNCT (Short-lasting Unilateral 
Neuralgiform headache attacks with Conjunctival injection and Tearing) as a 
Trigeminal Autonomic Cephalalgias (TACs) (1). The International Headache Society 
(IHS) classification criteria (2) require relatively short-lasting (2-30 min) attacks of 
severe unilateral orbital, supraorbital or temporal pain accompanied by cranial 
autonomic symptoms. The attacks are prevented completely by therapeutic doses of 
indomethacin (3). The main troublesome side effect of indomethacin is gastric 
irritation in about one-quarter of patients (4), which has necessitated the withdrawal 
of indomethacin in CPH, and use of alternatives, such as cyclo-oxygenase 2 (COX-2) 
inhibitors, rofecoxib, valdecoxib and celecoxib (5-7), and calcium channel blockers 
(8).
We report a patient with CPH with a good response to indomethacin that had to be 
withdrawn due to gastric side effects, who had a subsequent good and prolonged 
response to topiramate.
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Case Report
A 42 year old man sustained an injury to the left side of the face in 2001; the next day 
he started experiencing attacks of severe pain in the left temple, lasting 2-30 minutes 
(average duration 15 minutes). They were accompanied by ipsilateral conjunctival 
injection, lacrimation, nasal blockage, and eyelid oedema. There was no nausea, 
vomiting, photophobia, phonophobia or osmophobia. He would experience 15-20 
attacks per day, which sometimes clustered during the day but could wake him from 
sleep. Movement would not make the pain worse, although he tended to keep still 
during an attack. There were no aura symptoms.
He had never had similar headache problems. He had some milder headaches in the 
past which were throbbing, beginning in the neck and radiating to the frontal region, 
with pain aggravated by movement lasting for some hours. There were no other 
features.
He had a family history of migraine in his father, who was now deceased.
There were no other medical problems. He was a non-smoker and drank no alcohol. 
Cranial nerve examination was normal, as was the rest of the neurological 
examination.
He received indomethacin 50 mg three times daily, which reduced the length of his 
attacks to 30-120 seconds, the frequency to 8-10 a day, and the severity from 8/10 to 
5/10 on a verbal rating scale. High flow oxygen (12 litres/minute) took the edge off
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the pain. Intranasal lidocaine and subcutaneous sumatriptan 6mg were not beneficial. 
A single dose of intramuscular indomethacin lOOmg abolished his attacks for several 
hours (3). His clinical picture and response to indomethacin is consistent with a 
diagnosis of CPH based on the International Classification of Headache Disorders (2).
He was discharged from hospital on Indomethacin 50 mg tds and Ranitidine. After six 
weeks he developed epigastric pains, and was switched to a proton pump inhibitor. He 
was prescribed celecoxib instead of the indomethacin, at doses up to 400 mg daily, 
with inconsistent, sometimes, useful effect on his headaches.
He was then prescribed topiramate at an increasing dose starting at 25 mg daily. At 
doses from 200 to 350 mg daily he had almost complete abolition of his attacks, but 
noticed side effects of cognitive slowing, dry mouth and weight loss. At a lower dose 
of 100 mg daily there was a moderate effect with 3-4 attacks a day of 5-10 minutes in 
duration. Thereafter an intermediate dose of 150 mg daily was achieved, with only 1- 
2 attacks per day. At two years follow-up he still has good control of his attacks. 
When he reduces the dose the attacks return.
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Discussion
This patient has post-traumatic chronic paroxysmal hemicrania (CPH), which has 
been described previously (9). Indomethacin affected a good response, but had to be 
stopped due to gastric side effects. In his case a COX-2 inhibitor had no effect, 
although they have been reported as effective in other cases of CPH (5-7), and 
hemicrania continua (10). However, the recent findings that chronic high-dose COX-2 
inhibitors are associated with an increased risk of ischemic heart disease and heart 
failure (11), plus the lack of response of some patients to COX-2 inhibitors, 
necessitates a suitable alternative preventive be identified. It is our experience that 
verapamil is not often helpful in patients with paroxysmal hemicrania in contrast to 
cluster headache.
Topiramate is a neuromodulator which is effective in the prevention of migraine, as 
shown in placebo-controlled trials (12-14), and in open-label trials in cluster headache 
(15-18) and SUNCT (19-22), although a robust response has not been seen in all 
open-label trials (23-25). There is a case report of the effectiveness of topiramate in 
paroxysmal hemicrania-tic syndrome (26).
Topiramate is also used in the treatment of other painful conditions, including painful 
diabetic neuropathy (27). It has been reported as useful in intercostal neuralgia (28), 
and in a case series of trigeminal neuralgia (29), but not in a placebo-controlled study 
(30). Topiramate has multiple mechanisms of action (31). They include modulating 
voltage-gated sodium ion channels, blocking excitatory glutamate receptors,
modulating voltage-gated calcium ion channels, inhibiting carbonic anyhdrase, and 
enhancement of inhibitory GABA-mediated chloride influx through G A B A a  receptors 
(32). Inhibition of trigeminovascular nociceptive traffic is seen with topiramate in 
experimental animals (33), and this action seems to reside outside the 
trigeminocervical complex (34). The known side effects of topiramate include 
somnolence, paraesthesia, diminished appetite, nausea, diarrhea, weight loss, 
abdominal pain and dysgeusia (35). Central nervous system adverse events included 
somnolence, insomnia, memory difficulty, language problems, concentration 
difficulty, mood problems and anxiety (35). Additionally, renal calculi and 
paraesthesia occur rarely (31), attributed to weak carbonic anhydrase inhibition by 
topiramate. It is suggested that starting at low doses, once or twice daily, and making 
small increments thereafter can minimize side effects; such was the case in a group of 
cluster headache patients (15). It is noted in our patient that the side effects were 
present only at higher doses (more than 200 mg/day), and he came to a suitable 
compromise on an intermediate dose at which there were no adverse effects, but his 
CPH attacks were adequately suppressed. Accepting the limitations of no placebo 
treatment the recrudescence of the attacks with cessation of treatment, the prolonged 
effect and natural history of CPH each argue for a real therapeutic effect in this case.
Given the success of topiramate in other primary headaches and pain syndromes, this 
report of a beneficial effect of topiramate in paroxysmal hemicrania in our patient 
highlights its usefulness in TACs, especially in cases where indomethacin and other 
preventive therapies are not viable.
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Appendix 3
Protocol For Use of Intravenous Lidocaine
Indication
Treatment of intractable headache in hospital.
Contraindications and warnings
Cardiac arrhythmias, pregnancy and lactation.
Caution: epilepsy, peptic ulceration, psychiatric disease.
Interactions: propranolol and cimetidine (reduced renal and hepatic clearance of lidocaine 
increases toxicity).
Dosage
Loading (optional) : patients may be loaded with a dose of 1 mg/kg intravenously over 15 
minutes if the clinical state indicates the need for rapid resolution of symptoms.
Infusion regime: intravenously at a dose of 1-4 mg/minute (maximum rate 3.4 mg/kg/hr). 
Total treatment period: patients should not be treated for more than seven consecutive days.
Monitoring
Patients should have a resting 12-lead electrocardiogram (ECG), liver enzymes and renal 
function tests (hypokalaemia should be corrected) performed before administration.
Patients should have continuous cardiac monitoring. After each dose escalation, pulse rate 
and blood pressure should be measured every 5 minutes for first 30 minutes, then every 15 
minutes for 4 hours, and thereafter four hourly.
Adverse effects
Cardiac arrhythmias and hypotension. Sensation of heat or cold, numbness, paraesthesia, 
nystagmus, twitching and tremor are signs of high plasma levels and treatment should be 
reviewed before continuation. Convulsions, cardiovascular collapse and respiratory arrest are 
symptoms of an overdose. Psychiatric symptoms including paranoid ideation may be 
triggered and the infusion should be stopped.
After (Matharu et al., 2003)
Matharu MS, Cohen AS, Boes CJ, Goadsby PJ. Short-lasting Unilateral Neuralgiform 
Headache with Conjunctival Injection and Tearing Syndrome: A Review. Curr 
Pain Headache Rep 2003; 7: 308-18.
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